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ABSTRACT 
 
Using a mechanism-based approach to drug discovery, efforts have been directed 
towards developing novel ATP mimics that can act as GS inhibitors. The purine-based 
systems, adenosine, adenine and allopurinol, were identified as possible scaffolds for 
potential ATP mimics, while various meta-disubstituted benzenoid compounds, 3-
aminobenzonitrile, 3-aminophenol, resorcinol, 3-aminobenzyl alcohol, 3-
hydroxybenzoic acid and 3-aminobenzoic acid have been explored as adenine 
analogues. 
 
These compounds were treated with different alkylating and acylating agents. 
Allylation of all the substrates was achieved using allyl bromide and N-9 alkylation of 
protected allopurinol was effected using a number of specially prepared Baylis-
Hillman adducts. Acylation of the benzenoid precursors with chloroacetyl chloride, 
acetoxyacetyl chloride, acryloyl chloride and specially prepared 2,3,4,5,6-
pentaacetylgluconoyl chloride afforded the corresponding mono- and /or diacylated 
products in varying yields (4-96%). Elaboration of the alkylated and acylated products 
has involved the reaction of hydroxy systems with diethyl chloro phosphate and 
chloro derivatives with triethyl phosphite in Arbuzov-type reactions to afford 
phosphorylated products.  
 
In all cases, products were fully characterized using 1- and 2-D NMR analysis and, 
where appropriate, high-resolution mass spectrometry. The application of Modgraph 
and ChemWindow NMR prediction programmes has been explored and the resulting 
data have been compared with experimental chemical shift assignments to confirm 
chemical structures and, in some cases, to establish the position of allylation or 
acylation. Experimental assignments were found to be generally comparable with the 
Modgraph data, but not always with the ChemWindow values. 
 
The docking of selected products in the ‘active-site’ of GS and their structural 
homology with ATP, both in their free and bound conformations have been studied 
using the ACCELERYS Cerius2 platform. All the selected ATP mimics exhibit some 
form of interaction with the ‘active-site’ residues, and a number of them appear to be 
promising GS ligands. 
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1. INTRODUCTION 
 
1.1 . Tuberculosis 
 
Tuberculosis (TB) is a deadly disease that has killed millions of people for a very long 
time.1,2 It primarily affects the lungs, though it does affect other parts of the body, 
being characterized by the formation of  tiny lumps otherwise referred to as tubercles 
in the affected part of the body.3  Mycobacterium tuberculosis M.tb., a tubercle 
bacillus is the organism that causes TB.4,5 Infected individuals with pulmonary TB 
transmit the disease when they cough, sneeze or talk by propelling many bacilli into 
the air. Hence, inhalation of the airborne bacilli by healthy people may lead to 
infection.3,6,7 Approximately 1.6 m illion people fell casuality to this preventable 
disease in 2005 with the highest mortality rates in the poorest parts of the world. The 
World Health Organization (WHO) TB/HIV Working Group was established to 
formulate policies directed at combating the deadly combination of TB and 
HIV/AIDS.
 
7 
1.1.1. History of tuberculosis in man                                                  
 
Archaeological evidence, art and literature strongly suggest that TB has been plaguing 
mankind from time immemorial. As a result of its widespread nature, the disease has 
been known by many different names. Some of these include: pulmonary TB, 
described as lung sickness, white plague or consumption; Lupus vulgaris, otherwise 
referred to as skin TB; and white swelling, i.e. TB of the bones. Famous people that 
have fallen prey to TB include Voltaire (philosopher), Walter Scott (poet and 
novelist), Anton Chekov (playwright), Niccolo Paganini (violinist) and George Orwell 
(writer).1,8
 
   
1.1.2 History of Tuberculosis Therapy                                                                 
 
It was not until the 16th century that tuberculosis was recognized as a contagious 
disease. The 19th century witnessed the establishment of sanatoria in different parts of 
the world to cater for TB patients. These were treatment institutions located in the 
__________________________________________________________ Introduction 
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countryside where TB patients were believed to be cured by being exposed to fresh 
air, eating a healthy diet, exercising and resting under strict supervision. However, 
there is no scientific evidence that the sanatoria reduced the menace of TB. In the 
same century, organizations around the world, such as the National Association for 
the Prevention of Consumption and other forms of TB (NAPT) in the UK and the 
National Tuberculosis Association (NTA) in the USA, were also established to curb 
the menace of the then incurable and deadly disease.1,9
         
  
In 1890, an Italian physician Forlanini invented pneumothorax (otherwise referred to 
as lung collapse) therapy. This method involved compressing the part of the diseased 
lung(s) and then filling the pleural cavities with nitrogen through a needle. An 
extreme form of the method was thoracoplasty, which involved the removal of ribs 
from one side of the thorax to accomplish a permanent collapse of the diseased part of 
the lung; an obvious side effect was shortness of breath as a result of the decreased 
lung space.1
    
   
The ability to view the tubercle bacillus in 1882, which was made possible by the 
staining technique of Robert Koch10 and the invention of X-rays by Wilhelm 
Roentgen in 1889,1 gave a boost to the fight against TB. It was then realized that TB 
is not inherited as previously believed, but that transmission occurs from diseased to 
healthy individuals through the mycobacterium and that prevention is possible.1,3 
 
    
1.1.2.1. Bacillus Calmette-Guerin BCG   
 
BCG, a potent vaccine against TB, was developed10 in 1924 by two French scientists, 
Calmette and Guérin, from an attenuated strain of mycobacterium bovis. Though not 
particularly effective in preventing infection, BCG has been administered in areas 
with high TB prevalence and incidence. It has been impossible to judge the efficacy of 
BCG because the original stocks were not kept. Scientists are working on making a 
better vaccine that can prevent TB following the successful mapping of the M.tb. 
genome in 1997.11, 12,13,14
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1.1.2.2. The antibiotic era in tuberculosis treatment                                                
 
In a method invented in 1885 b y Cantani, an Italian bacteriologist, patients inhaled 
nonpathogenic bacteria so as to reduce the level of tuberculosis bacilli in the sputum. 
It was discovered in 1888 by Babes, a Romanian scientist, that products of certain 
Gram positive and Gram negative bacteria could inhibit the growth of m.tb.15 
Sanocrysin, a double thiosulphate of gold and sodium introduced by Holger 
Mollgaard in 1925 was used as an anti TB drug in 1925, but was discontinued because 
of its high toxicity.15 Streptomycin 116,17 was first used for a human patient in 1944,1 
but by 1947, M. tb. had begun to show resistance to streptomycin. The search 
continued to find drug(s) that could treat the disease or be used together with 
streptomycin. In 1949 para-aminosalicyclic acid (PAS)18 2 became available and, in 
combination with streptomycin, afforded better treatment for TB.19
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A new d rug Isoniazid [INH]20 3 was discovered in 1951 a nd, in combination with 
PAS, proved to be more effective than the combination of streptomycin and PAS.14 
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Other drugs made to treat TB include pyrazinamide 4 (1954),21 cycloserine 5 (1955),22 
ethambuthol  6 (1962),23 and rifampicin 7 (1963).24
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1.1.3 The problem of drug resistance in TB chemotherapy 
 
Although the pathogen M.tb. does manage to evade the host-protective response in 
man’s alveolar machrophages3,25,26,27,28 to cause active TB disease in some infected 
individuals, chemotherapy has been effective in curing the disease.29 However, TB 
continues to be a major threat to life as a result of drug resistance to chemotherapy.7,30 
Drug-resistant TB, otherwise referred to as multidrug resistant TB (MDR-TB), is 
defined as resistance to INH 3 and RIF 7, whether there is resistance to other 
antitubercular drugs or not.31 Extreme drug resistant TB (XDR) is caused by a new 
strain of M.tb. and is not curable even with the current available combination therapy 
that effectively treats MDR-TB.32,33,34 Resistance to anti-TB agents is usually a 
consequence of poorly administered TB treatment.32 Mycolic acids such as compound 
835 are essential components of the cell wall of the pathogen that causes TB. INH 3 is 
believed to act by inhibiting the synthesis of mycolic acids by mimicking 
nicotinamide 9 and being incorporated instead, thereby impairing the activity of the 
enzymes that require the latter.29  
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H3C(H2C)17 (CH2)14 (CH2)17
(CH2)23CH3
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8
                                                                                                      
However, replacement of nicotinamide as the natural substrate, as a consequence of 
mutation in the katG and inhA genes of the bacteria, led to strains that are resistant to 
INH.29
 
 Similar mechanisms of resistance are encountered with other antitubercular 
drugs.                                                                    
N
ON
H
NH2
3
N
O
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1.1.4. Current TB treatment  
 
Both latent TB infection and active TB disease with the exception of XDR are curable 
with combination therapy.36 Latent TB infection can be diagnosed with the aid of the 
tuberculin skin test,29,36 while active TB, which may be drug-susceptible or drug-
resistant,29 can be diagnosed by chest X-ray, sputum smear, culture tests, polymerase 
chain reaction (PCR) and the recently developed M.tb. direct test (MTD).36
 
 The WHO 
and the International Union Against Tuberculosis and Lung disease (IUATLD) have 
formulated treatment regimens for all forms of TB plaguing society today, although 
there may be minor and major adverse reactions. 
First-line TB drugs such as isoniazid, rifampicin, pyrazinamide, ethambutol and 
streptomycin suffice for the treatment of latent TB infection and drug-susceptible TB 
disease.36,37 However, treatment of drug-susceptible TB with combination therapy 
may take up to 18 months, and resistance often develops as individuals find it difficult 
to maintain their medication for such a long time.36 The mechanism of action of INH 
is not fully understood. However, INH has been observed to be bacteriostatic as it 
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stops replication of the mycobacterium. It is also bactericidal against semi-dormant 
populations as M.tb. loses its acid-fastness after being exposed to INH, which may be 
due to the drug interfering with the cell wall of the pathogen. New research has 
suggested that38 INH is activated by the katG enzyme, which exhibits catalase-
peroxidase activity. The isonicotinoyl radical 14 or perisonicotinic acid 16  (Figure 1) 
are very reactive intermediates that may result from action of  the  katG enzyme on 
INH leading to the formation of isonicotinaldehyde 10, isonicotinic acid 11 and 
isonicotinamide 12. It has been proposed that these activated species from the 
oxidation of INH with the katG enzyme impair the activity of inhA, an enzyme that 
plays a vital role in the biosynthesis of the cell wall of M.tb.38,39,40,41,42,43
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Figure 1. Catalase-peroxidase reaction of INH when administered. 
 
Isonicotinic hydrazones 17 and isonicotinic hydrazides 18 are derivatives of INH that 
have been found to be less potent than INH.44,45 When resistance or intolerance to 
first-line TB agents occurs, second-line TB drugs are administered. These drugs, 
which are expensive, toxic and usually accompanied by severe side effects,46 include 
ethionamide 19,47 PAS 2, cycloserine 5, kanamycin 2048 and fluoroquinolones 21.49
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Ethionamide 19,47 a second line TB drug has been suggested to have a similar 
mechanism of action as INH. Ethionamide 19 is believed to be oxidized to 
ethionamide sulfoxide 22 by catalase-peroxidase, which impairs the activity of the 
inhA enoyl reductase enzyme by acylating the protein at the Cys 243 residue (Figure 
2),41,50 thus inhibiting the formation of compound 24. In addition to demonstrating 
activity against M.tb., fluoroquionolones are active against other mycobacteria such as 
M. xenopi and M. avium-intracellulare.49 Quinolones have the advantage of being 
active at low concentrations as well as having lower side effects when administered. It 
has been reported that non-fluorinated quinolones are not active against 
mycobacteria.49 However, quinolone derivatives 25, such as the piperazine analogues, 
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the pyrrolidine analogs and the 8-methoxy derivative, moxifloxacin 26, show better 
activity than the earlier quinolones.
 
51,52 
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Figure 2. Mechanism of action of ethionamide.
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It is unfortunate that XDR-TB has defied cure even by second-line TB drugs. A recent 
98% mortality was recorded within 25 da ys in patients, including those on a nti-
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retrovirals in KwaZulu-Natal, afflicted with this new strain.32 Hence, there is an 
urgent need to combat TB with a new approach, such as the target-based drug 
design.53,54
   
                                                                                                                                          
1.1.5. The synergism between HIV/AIDS and tuberculosis    
 
The HIV/AIDS pandemic is a m ajor factor in the resurgence of the global TB 
epidemic.36,53 HIV weakens the immune system permitting the progression of latent 
TB infection to active TB disease in HIV positive individuals.7,55 Hence TB is the 
leading cause of death of HIV infected people.7,36 Research has also shown that 
extrapulmonary TB and MDR-TB are more common in people with compromised 
immune systems.36 The lethal combination of HIV and TB is also complicated by the 
difficulty in diagnosing TB in HIV-positive individuals.56 However, it is interesting to 
note that the treatment and prevention of TB using standard regimens prescribed by 
the WHO and IUATLD are effective in both HIV-positive and HIV-negative patients. 
The exception is that people taking protease inhibitors for HIV should substitute 
rifabutin for rifampin.36
 
                                                 
1.1.6. WHO TB controls 
 
The WHO has adopted a practical approach to combat the TB epidemic. The Direct 
Observed Therapy (DOT) strategy seeks to ensure compliance by the patient through 
observation by a family member or health worker. The DOTS (directly observed 
therapy, short course) strategy, 57,58,59,60, which is the main strategy adopted by the 
WHO and the IUATLD for effective TB control, consists of five elements: “ 
“Government commitment to a national tuberculosis programme as a specific health-
system activity, integrated into comprehensive primary care, and supported 
technically at a national level; standardized, directly observed, short-course treatment 
prioritizing sputum smear-positive patients; case detection by means of a patient-
friendly and clinically-efficient service based primarily on smear microscopy (passive 
case-finding); an ensured supply of all essential anti-tuberculosis drugs; and effective 
monitoring.”61
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1.2. Random drug discovery and rational drug design                                                     
 
1.2.1. Random drug discovery 
                                                                                                                                                 
Traditionally, different naturally occurring substances from plants, microbes, marine 
flora and fauna, arachnids and amphibians62,63 are explored for their potency to act as 
cures for different ailments. This often random, broad-screening process involves 
looking for direct evidence of a physiological reaction in animal tests. As a 
consequence, biological, chemical and clinical practice has produced considerable 
data that has guided pharmaceutical drug research.64,65,66,67 In many cases, of course, 
examination of the constituents of materials used as traditional medicines led to the 
isolation of active principles. For example, cocaine 2768 has local anesthetic properties 
and is extracted from the leaves of Erythroxylon coca, while quinine 2868
 
 is an 
antimalarial obtained from the bark of Cinchona species.      
27
NH CO2Me
OCO.Ph
 
N
O
OH
N
H
28
 
                                                                                                                                                           
The need to reduce or eliminate side effects as well as improve the potency of natural 
drugs prompted the development of derivatives of these natural substances. 
Knowledge of synthetic chemistry, medicinal chemistry and pharmacology as well as 
imagination was needed to relate drug discovery to synthetic practice. Hence, 
medicinal chemists usually try to make active compounds (otherwise referred to as 
‘leads’) by elaborating or mimicking known potent substances to develop better 
drugs.69 Immediate examples are the hipolipidemics, Compactin 2965 and Pravastatin 
30.65 Procaine 3168 and benzocaine 3268 are drugs that were synthesized to block the 
nerve activity like cocaine, but without the side-effects that lead to the abuse of 
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cocaine. Primaquine 33 and chloroquine 34 are two quinine analogues that became 
antimalarial standards for over five decades.68
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Today, random drug discovery has been made much easier with the availability of 
high through-put screening and combinatorial chemistry using computer-controlled 
robotic systems. Hence, hundreds to thousands of compounds can be synthesized 
simultaneously and their preliminary bioassays conducted much more rapidly than in 
the past. The success of random screening depends on a good bioassay system for the 
pharmacological action of interest.69 One major criticism of random drug discovery is 
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that it is not guided by any specific biochemical theory of why some compounds work 
while others do not.66
                                                                                                                                               
  
1.2.2. Enzyme Inhibition and Rational drug design                                                                                         
 
Advances in molecular biology have afforded a better understanding of therapeutic 
targets at the molecular level.53 Hence, it is now understood that the therapeutic 
targets of many medicinal agents extracted from natural products are specific enzyme 
systems. The bark of the willow tree, for example, has been known to have analgesic 
and antipyretic capabilities; the active ingredient, salicin, a glycoside, is metabolized 
in vivo to salicylic acid 35, which inhibits the formation of the prostaglandins that 
mediate pain and fever by inhibiting the enzyme, cyclooxygenase.70 Physostigmine 
36, a substance  that is extracted from the West African Calabar bean, gives relief to 
glaucoma patients by inhibiting the enzyme, acetylcholinesterase, and, as a 
consequence, improving drainage and decreasing intra-ocular pressure.70
O
OH
OH
35
N
N
O
N O
H
36
                                                                                                            
 
The antibacterial, prontosil 37, inhibits the bacterial synthesis of folic acid 46 as a 
result of being metabolized into sulfanilamide 38 (Figure 3), a para-aminobenzoic 
acid  mimic.71 Para-aminobenzoic acid 42 is an essential metabolite in the synthesis 
of tetrahydrofolic acid which, in turn, is vital in the in vivo production of purines. The 
para-aminobenzoic acid mimic, sulfanilamide 38, selectively inhibits the bacterial 
enzyme, dihydropteroate synthase (Figure 4) production of dihydrofolic acid 45.72 
Dihydrofolic acid 45 is an important intermediate in the bacterial biosynthesis of folic 
acid (46). The rational approach to drug discovery has become more sophisticated 
with advances in molecular biology and information technology.73 Hence, modern 
drug discovery is often based on knowledge of the enzyme receptor.74,75 With a good 
understanding of the structure of a ligand and its receptor, it may be possible to 
propose molecules as lead compounds that will mimic the activity of a natural ligand. 
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Figure 3. Metabolic reduction of prontosil to sulfanilamide. 
 
The combinatorial synthesis of lead analogues,76 high through-put screening, high-
field NMR analysis, X-ray crystallography, molecular modelling,77 quantum 
mechanical calculations78 and quantitative structure activity relationship (QSAR) data 
may all contribute to the development of a rationally designed drug.65 However, it is 
important to note that drug discovery is a long and difficult process in which the 
design of an inhibitor is only the first step. The pharmacokinetic profile of the 
inhibitor, its toxicities and side effects and animal and pre-clinical studies are all 
hurdles the inhibitor has to cross before it can be entered into clinical studies as a new 
drug candidate. Ritonavir 4780,81 and saquinavir80,81 48, peptidomimetic inhibitors of 
both HIV-1 and HIV-2 proteases, as well as zanamivir 4867,82
 
 (a therapeutic for 
influenza) are examples of products of the rational approach to drug discovery. 
Perhaps rational drug design will provide a solution to the resurgence of the TB 
pandemic, especially with the evolution of XDR-TB as a r esult of resistance to the 
currently available treatment regimen for MDR-TB.        
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Figure 4.  Inhibition of bacterial folic acid biosynthesis by sulfanilamide. 
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1.3. Glutamine synthetase GS                                                                                                   
 
The survival of the M.tb. pathogen in the host to cause TB disease depends on i ts 
ability to protect itself in a kind of capsule that prevents its destruction in the 
phagocytic cells of human macrophages. Access to the cell is restricted and this 
capsule also determines what components are released into the host’s tissues. 
Research has shown that this pathogenic mycobacterium releases extracellular 
proteins that are vital for its replication and virulence in the host’s tissues.83,84,85,86 The 
enzyme, glutamine synthetase (GS), is one of these released proteins and it has been 
shown to be essential for the formation of the cell wall of M.tb.87 As well as 
catalyzing a number of other reactions, GS is an enzyme that is essential for nitrogen 
metabolism in living organisms.88,89,90 Different types of GS are present in man and 
bacteria. Man, like other eukaryotes, expresses GS II while M.tb. like other 
prokaryotes express GS I [otherwise referred to as (MTB-GS)]. The modes of 
regulation of GS I and GS II are different.88 Furthermore, pathogenic extracellular 
MTB-GS has been selectively inhibited by L-methionine-S-sulfoximine (MetSox) and 
by phosphinothricin. Hence, MTB-GS can be a therapeutic target.85
 
        
1.3.1. Structure and function of MTB-GS and GS II                                                
 
MTB-GS is a very large enzyme consisting of 12 identical subunits of two face-to-
face haxameric rings forming a dodecamer of mass 640 kDa.91 Hydrogen bonding and 
hydrophobic interactions hold the dodecamer together. The junction between each 
pair of subunit forms an active site. There are thus 12 active sites and each of them is 
in the form of a bifunnel. The top of the bifunnel is the ATP binding site, while the 
bottom is the glutamate binding site. At the neck of the bifunnel are two divalent 
cation (Mn2+ or Mg2+) binding sites (referred to as n1 and n2, respectively) separated 
by 6Å. The n1 cation is essential in glutamate binding while the n2 cation is involved 
in phosphoryl transfer. The adenylylation loop is one of several loops with different 
functional importance resulting from the structure of the enzyme (Figure 5). 92 GS II 
exists as an 8-subunit oligomer93 with a polypeptide chain of approximately 372 
residues. Although there are similar residues in the active sites of GS I and GS II, 
performing similar functions, the adenylylation loop is absent in GS I.88 Glutamine is 
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an essential source of nitrogen in the biosynthesis of many organic compounds, such 
as purines, pyrimidines and other amino acids in living systems. GS catalyzes the 
biosynthetic reaction (Scheme 1) that produces glutamine 52 as the product of the 
combination of glutamate 50 and ammonia in the presence of adenosine triphosphate 
(ATP). GS activity is dependent on the n2 cation.  The coordination of the n2 cation 
with the γ-phosphate oxygens of ATP permits phosphoryl transfer to the  γ-
carboxylate group of glutamate leading to the formation of the γ-glutamyl phosphate 
intermediate 51.88 Glutamine 52 is formed when  ammonia displaces the phosphoryl 
group as a free phosphate anion.94  
 
 
Figure 5. Trace display of reconstructed GS from Salmonella typhimurium downloaded from the PDB 
showing ADP in the ATP binding site and AMP in the adenylylation site. Downloaded at 
http://www.hort.purdue.edu/rhodcv/hort640c/ammonia/GSSt3D.htm                                                                                                                                                                                   
                                                                                                                                                 
AMP in 
adenylylation site 
ADP in ATP 
site 
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Scheme 1. Biosynthetic and transferase reactions 
 
The transferase reaction is the reverse of the biosynthetic reaction, in which glutamine 
52 is converted to γ-glutamylhydroxymate and ammonia in the presence of 
hydroxylamine.
 
88,95 
1.3.2. Regulation of MTB-GS: Feedback inhibition and covalent modification          
 
Allosteric control or feedback inhibition96,97 of MTB-GS occurs when there is 
sufficient glutamine in the system. A change in conformation at the relevant active 
site of the enzyme occurs so that other ligands, known as ‘effectors’, bind to the ATP 
and glutamate active sites.96 Crystal structures of GS have revealed allosteric 
regulation by serine, glycine and alanine at the glutamate substrate site, while GDP, 
ADP and AMP bind allosterically to the ATP site.88,98 MetSox 53 has been 
demonstrated to be a potent inhibitor of GS as it mimics glutamate and binds non-
covalently but irreversibly with ATP at the glutamate binding site forming a 
tetrahedral intermediate.88,99 
O
-
O
NH2
S
O
NH
53
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Covalent modification by adenylylation,100,101,102,103 is another means of regulating the 
catalytic activity of GS I. An ATP dependent reaction, adenylylation, inactivates GS 
when ATP binds covalently to tyr397 54 on GS I as (AMP-O-Tyr397) 55 instead of the 
n1 metal ion in response to excess nitrogen in the cell (Figure 6). Each monomer on 
MTB-GS can be adenylylated and, as more sites are adenylylated, the catalytic 
activity of GS and the amount of glutamine produced both decrease. The reverse 
process, called deadenylylation, is the phosphorolytic removal of AMP as ADP.  Both 
processes are catalyzed by adenylyl transferase (AT).104 Adenylylation does not occur 
in GS II due to the absence of the adenylylation loop.88 Consequently, this mode of 
regulation of GS I represents a therapeutic target.105
CH2
OH
CH2
O
PO O
O
NO
N
N
OHOH
N
NH2
GS MONOMER
12
12 ATP
GS MONOMER
+ 12 PP
AT
12
Tyr 397 in GS monomer
adenylylated Tyr 397 in GS monomer
54
55
 Efforts have been made to 
synthesize ATP mimics that will bind irreversibly to the relevant residues in the 
adenylylation site, preventing deadenylylation and the multiplication of 
mycobacterium in the host, which is man.                                                                                                                                            
 
 
Figure 6. Covalent modification by adenylylation as a means or regulating MTB-GS. 
 
               
Research has also shown the selective adenylylation of pathogenic MTB-GS in 
mixture of MTB-GS and nonpathogenic mycobacterium bovis (BCG) on addition of 
glutamine.80 An enzymatic mechanism detailing the role of each residue in the 
bifunnel active site of GS during the biosynthetic reaction has been proposed and is 
summarized in Table 1.88
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Table 1: A summary of the mechanism88 of the biosynthetic reaction showing the role 
of each residue. Tyr397
 
 is not in the bifunnel but lies in the adenylylation loop and is 
absent in GS II. Extracted from D. Eisenberg, H.S. Gill, G.M.U., Pfluegl, S.H. 
Rotstein, Biochimica et Biophysica Acta, 2000, 1477, 122-145. Reproduced with 
permission from D. Eisenberg.   
 
Residue Role in enzymatic mechanism Effector Reference 
Asp-50 Deprotonates ammonium substrate ion. Increases 
the affinity for ammonium binding 
ADP 78, 106, 107 
Ser-53 Increases intersubunit stability with Glu-327 ADP 78 
Asp-64 Increases intersubunit stability with Arg-344 ADP 108 
Glu-129 Coordinates the n2 ion and hydrogen bonds with 
His-271 
 78 
Glu-131 Coordinates the amino group of glutamate and 
the n1 ion 
 78 
Tyr-179 Coordinates the ammonium binding pocket  78, 106 
Glu-212 Coordinates the ammonium binding pocket and 
the n1 ion 
 78 
 
Glu 220 Coordinates the n1 ion  78 
Asn-264 Coordinates the amino group of glutamate. 
Stabilizes the Glu-327 flap upon MetSox or PPT 
binding 
Glu, Gln, Ser, 
Gly, Ala, Tl+
78, 109 
, 
PPT, MetSox 
Gly-265 Coordinates the amino group of glutamate.  78 
His-269 Coordinates the n2 ion  110, 111 
His-271 Coordinates the α-phosphate group of 
ADP/AMPPMP and Glu-129 
 108 
Arg-321 Coordinates the carboxylate of glutamate  78 
Glu-327 Stabilizes the tetrahedral adduct at the transition 
state. Accepts a proton from the adduct to form 
glutamine. Closes active site and shields 
intermediate from hydrolysis. 
Ser, Tl+ 112, 109, 78, 
106, 107 
, PPT, 
MetSox 
Arg-339 Induces intersubunit stability by interacting with 
Asp-50 
ADP 78 
Arg-344 Coordinates the β-phosphate group of 
ADP/AMPPMP 
ADP 78 
Glu-357 Coordinates the n2 ion and Arg-344 ADP, 
AMPPMP 
78 
Arg-359 Coordinates the γ-phosphate group of glutamate  78 
Tyr-397 Adenylylation site (seen in bacterial GS only)  113 
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1.4. The purine system                                                                            
 
Many systems, of which ATP is one, containing the purine114 backbone are 
biologically important. DNA and RNA, the “building blocks of life”, are made of 
purine and  pyrimidine bases.115,116 Hormones and neurotransmitters are made up of  
nucleosides and nucleotides, while energy transfers occurring in many metabolic 
systems as well as intercellular signaling are a consequence of the interconversion of 
mono-, di- and triphosphate esters of nucleosides.114 Pyrimidines 56 are six membered 
heterocycles with two nitrogen atoms while purines 57 are fused pyridine and 
imidazole heteroaromatic compounds with four nitrogen atoms.114,117,118,119
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Purine 57 can alternate between the four tautomeric forms shown in Scheme 5. It 
exists in the 7-H tautomer in the crystalline state, while the 7-H and 9-H tautomers are 
predominant in solution.120
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Scheme 2. Tautomerism in purine                                                                                                                     
                                                                                                                                                                                                                                          
Adenine 61,121 adenosine 62122 and adenosine triphosphate ATP 63123 are examples of 
aminopurines.                                                                                         
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 1.4.1. Adenine  
 
Adenine 61 is a molecule of important biological significance as it is a constituent of 
RNA and DNA114 as well as being an important component of ATP, a substance that 
is required to drive many biochemical reactions.
 
124 
1.4.1.1. Synthesis and reactions of adenine 
 
Adenine 61 has been synthesized in 43% yield by treating formamide with POCl3 at 
120 °C in a closed vessel (Scheme3).125
H N
O
H
H
N
N N
N
H
NH2
43%
POCl3, 120 
0C
64 61
  
                    
Scheme 3. Synthesis of adenine.                                                                                                                                                  
 
Alkylation and acylation can be carried out on the amino group on the pyrimidine ring 
as well as the nitrogen of the imidazole ring after deprotonation by a base. Synthesis 
of the diastereomeric acyclic nucleoside (65a and 65b) and nucleotide (74a and 74b) 
mimics have been reported according to schemes 4 and 5.126  α,β-Methylfuranoside 
67a was obtained by methylating (+)-ribose with methanol in the presence of HCl. 
Tosylation of methylated ribose with tosyl chloride in pyridine at 4°C afforded the 5-
tosylated derivative 68a in 90% yield. In the presence of NaH, compound 68a was 
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coupled to adenine under anhydrous conditions to afford compound 69a. Oxidation of 
69a with sodium periodate at 4°C for one hour afforded the dialdehyde 70a that was 
treated with aq. NaBH4 
                                                                                             
to afford the target compound 65a in 85% yield. Synthesis of 
the stereoisomeric analogue 65b in 15-30% yield was achieved with (-)-ribose using 
the same approach.            
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Scheme 4. Synthesis of adenine nucleosides 65a. Reagents and conditions: (i) 
AcCl/MeOH, rt, 16h; (ii) TsCl/Py, 4°C, 16h; (iii) Ade-/DMF, 80°C, 5 days; (iv) 
NaIO4, 4°C, 1h; (v) NaBH4
 
, 4°C, 3h. 
__________________________________________________________ Introduction 
 23 
The nucleotide 74b was made from the nucleoside 65b. Treatement of 65b with 60% 
formic acid or Dowex 50 (H+) afforded (R)-DHPA 71b. The iodomethylphosphonate 
72b was obtained in 35% yield by reacting 71b with 1.5 eq. of iodomethylphosphonic 
acid in the presence of DCC in pyridine. Intramolecular cyclisation of the 
iodomethylphosphonate to afford intermediate 73b was achieved by treating 72b with 
5 eq. of NaH in DMF. Hydrolysis did afford pure 73b; however, the nucleotide (R)-
cyclo-HPMPA 74b was isolated in 90% yield after treating crude 73b with glacial 
acetic acid for 3 h. The corresponding (S)-DHPA 71a was made from nucleoside 65a 
affording access to (S)-cyclo-HPMPA 74a.126
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Scheme 5. Synthesis of adenine nucleosides 74a and 74b. Reagents and conditions: 
(i) H+, 6h; (ii) ICH2P(O)(OH)2/DCC/Py, 16h; (iii) NaH/DMF,6h; (iv) H2
 
O, 3 h; (v) 
glacial AcOH, 3h.                    
 
1.4.2. Adenosine 
 
Adenosine is a nucleoside with a ribose sugar attached to the imidazole ring via an N-
glycosidic bond.127A molecule of great biological significance,128 adenosine exerts 
different physiological effects on the nervous, immune and cardiovascular systems by 
activating A1, A2A, A2B, and A3 receptors. Hence, heart muscles, platelets as well as 
coronary arteries depend on adenosine for their proper function. Adenosine prevents 
aggregation of platelets and modulates the immunity of the cell, through interaction 
with A2A receptors.
129,130 Research on bl ood cells has shown that adenosine and its 
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mimics may have a number of important roles, such as :  ( i) regulating  nor mal 
immune responses; (ii) acting as anti-inflammatory and endogenous anti-aggregatory  
agents and  (ii) as therapeutics.129,130 Research has also shown that adenosine, as a 
neurotransmitter, stimulates A1 receptors in the brain thereby inducing sleep. 
Interestingly, sleep time is decreased when coffee is consumed because blockage of 
the central adenosine receptors is effected by the methylxanthines in coffee.131
 
  
In the calf adenosine deamination reaction, adenosine is converted to inosine 76 
(Scheme 6) via the hemi-aminal. Enzyme-catalysed reactions such as the deamination 
reaction proceed very rapidly in the active site of the enzyme.132 However, transition-
state mimics bind more strongly to the active site of the enzyme forming structurally 
and chemically similar structures to the transition state. Such stable intermediates 
provide information on the design of better inhibitors,132,133
                                                              
 and are thus are very 
important in the mechanistic approach to drug discovery.  
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Scheme 6. The calf adenosine deamination reaction. 
  
Nucleosides such as adenosine have been synthesized by various routes.134,135,136,137 
Stemming from the therapeutic properties of natural hexopyranosyl nuclosides, the 
synthesis of ring- expanded mimics of adenosine has afforded many compounds with 
antiviral and anticancer activity. The asymmetric synthesis of the nucleoside 84 was 
recently reported138 by researchers at West Virginia University, USA (Scheme 7). The 
synthesis commenced by protecting the two hydroxyl groups on commercially 
available furfuryl alcohol in a two-step reaction to afford the Boc-protected pyranone 
77.139,140 The protected alcohol was then coupled to 6-chloropurine 78 in the presence 
of a palladium catalyst to afford the glycosylated 6-chloropurine pyranone 79 in 86% 
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yield. The alcohol 80 was obtained by exposing the pyranone 79 to NaBH4 at -78 °C. 
Conversion of the alcohol to the olefin 81 was achieved with the reagent system 
(NBSH, PPh3/DEAD, NMM). The diol 82 was obtained enantioselectively by 
dihydroxylating the olefin 81 with (OsO4
              
/NMO). Treatment of the diol 82 with 
ammonia at room temperature gave the amino derivative 83. The desired 
hexopyranosyl nucleoside 84 was finally obtained in 94% yield by deprotection of the 
diol with TBAF at room temperature. This procedure can be extended to the synthesis 
of other compounds such as adenosine.     
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Scheme 7. Synthesis of the hexopyranosyl nucleoside 84 : (i) 0.5% Pd2(dba)3.CHCl3, 
2.5%PPh3, THF, 0 °C, 86%; (ii) NaBH4, MeOH/CH2Cl2, -78 C; (iii) NBSH, PPh3, 
DEAD, NMM, -30 C; (iv) OsO4, NMO, 95%; (v) NH3
 
, MeOH, 77%; (vi) TBAF, 
THF, rt, 94%. 
1.4.3. Adenosine triphosphate ATP  
 
Adenosine triphosphate 6381,82,83,84 consists of an adenine base, a ribose sugar and a 
phosphoryl ester group (Figure 7). The adenine base in ATP is linked to the ribose 
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sugar via a glycosidic bond which, in turn, is linked to phosphate groups through a 
phosphoester linkage. The phosphate groups are linked by phosphoanhydride 
linkages.123
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63
                                                                         
 
 Figure 7. Adenosine triphosphate showing the glycosidic, phosphoester and 
phosphoanhydride linkages.          
                                                                                                                                                                                                                                                                                                                                                                                     
ATP 63 is a nucleotide formed (Scheme 8) as a result of the successive addition of 
phosphate groups to adenosine monophosphate (AMP) 85. AMP is itself the produced 
by the esterification of adenosine 62 with phosphoric acid (Scheme 8).141 
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Scheme 8. Synthesis of ATP. 
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ATP is one of the most important molecules in living systems. Referred to as “energy 
currency”, the energy released from hydrolysis of ATP is used to drive many 
biochemical reactions that are otherwise not thermodynamically feasible. ATP plays a 
very important role in mediating endergonic anabolic and exergonic catabolic 
processes as shown in Figure 8.142
 
   
ADP + Pi
ATP
Product
PrescursorWaste Product
Nutrient
catabolism anabolism
 
Figure 8. Coordination of anabolic and catabolic processes by ATP. 
 
ATP is able to drive many of these biochemical reactions because of the high negative 
free energy that accompanies its hydrolysis. Hydrolysis of ATP is a spontaneous 
reaction since ATP is less stable than the hydrolysis products, adenosine diphosphate 
(ADP) and free phosphate which exert mutual electrostatic repulsion as a result of 
both being negatively charged; the terminal phosphoryl group in ATP is not 
resonance-stabilized as effectively as the inorganic free phosphate anion (Figure 9).142
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Figure 9. Resonance stabilisation of the terminal phosphoryl group in ATP and free 
inorganic phosphate. 
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1,3,7-Trimethylxanthine (caffeine) 87 and theobromine 88 are natural stimulants 
present in coffee and chocolate respectively. Synthetically, both natural products may 
be obtained by methylating xanthine with a reagent like methyl iodide.143
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However, a more complicated methylation process is involved in vivo. Each of the 
phosphate groups and the methylene carbon of the sugar moiety in ATP can be 
attacked by hard and soft nucleophiles, respectively. A typical biochemical reaction in 
living systems is the nucleophilic attack by the amino acid methionine 89 to form S-
adenosyl methionine (SAM) 90 (Scheme 9) in an SN2 displacement
144 of the 
triphosphate moiety. SAM is a highly reactive methylating agent and, in plants, 
caffeine 88 is produced by SAM-mediated methylation of theobromine 88 (Scheme 
10).
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Scheme 9. Methylation of ATP by methionine 
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Scheme 10. Formation of caffeine via methylation of theobromine by SAM 
 
1.4.4. Other purine systems 
 
1.4.4.1. Medicinal uses of purine systems 
  
Purine systems with medicinal potential include: - (i) dideoxyinosine (DDI) 91, a 
therapeutic agent for AIDS; (ii) acyclovir 92, an antiviral agent for Herpes; and (iii) 6-
mercaptopurine 93 that is administered to cancer and leukemia patients.145
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Allopurinol 94 is used for patients afflicted with gout,146 while Sildenafil146 
(ViagraTM) 95 is an effective therapeutic for impotence. Oxanosine 96 and tubercidin 
97 are natural products, obtained from Streptomyces, and are used for treating 
cancerous and bacterial infections.146
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1.4.4.2. Synthesis of purine systems 
 
Various routes to purine derivatives have been developed. In the Traube synthesis, 8-
substituted purines 100 can be obtained from di-aminopyrimidines 98 and an 
appropriate acylating agent as shown in Scheme 11.147,148
 
 The reaction proceeds via 
the amide 99 that is isolable.                        
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Scheme 11. Synthesis of 8-substituted purines. 
 
The 8,9-dimethylated xanthine derivative 104 has been synthesized successfully from 
the 5-aminoimidazole 102 that was generated in situ as outlined in Scheme 12.149
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Scheme 12. Synthesis of dimethylated xanthine.                                                                                                                                     
 
It is also possible to synthesize purines from the corresponding pyrimidine and 
imidazole derivatives in a cycloadditon reaction as outlined in Scheme 13.150
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Scheme 13. Synthesis of purines from pyrimidines and imidazoles.   
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1.4.4.3. Synthesis of Viagra   
 
The pyrazole precursor 109 used in the synthesis of Viagra (Scheme 14) can be 
obtained by treating the ester 108 with aq. haydrazine. Methylation at the N-1 nitrogen 
followed by nitration then affords the intermediate 111 the pyrazole equivalent of 5-
aminoimidazole-4-carboxylic acid (AICA) derivatives which are the starting materials 
for the synthesis of purines from imidazole. Reduction of the nitro group in the 
intermediate amide 112 and treatment of the resulting amine 113 with an aromatic 
acid chloride affords the amide 114. Hydrolysis and cyclisation affords compound 
115, which on t reatment with chlorosulphonic acid and N-methylpiperazine affords 
Viagra 95.151
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Scheme 14. Synthesis of Viagra.                                                                                                      
 
1.4.4.4. Reactions of purine systems 
 
Alkylation of the nitrogen atoms in both the pyrimidine and imidazole moieties is 
possible. Thus the 7,9-dimethylpurinium salt 116 is the product of the reaction 
between purine 56 and iodomethane (Scheme 15).152  
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Scheme 15. Alkylation at nitrogen atoms in the imidazole ring of purine.                                                    
 
A mixture of 3,6-dimethylpurine and 6,9-dimethylpurine is obtained on methylating 
6-methylpurine with dimethyl sulfate in alcoholic KOH (Scheme 16).153
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Scheme 16. Alkylation of nitrogen atoms in the pyrimidine and imidazole rings of 
purine. 
                                                                                                                                                                                                        
Both the 7- and 9- substituted products (121 and 122 respectively) are produced in 
basic solution when 6-chloropurine is alkylated with a benzyl halide.154 However, 
substitution at N-9 (compound 123) results from the reaction of 6-chloropurine with a 
dihydrofuran-derived carbocation (Scheme 17).155
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Scheme 17. Substitution at the 7- and 9- position in 6-chloropurine.                                                                                                                                                                
 
Reductive alkylation of adenine with formaldehyde (Scheme 18)156 yields the 
monomethylated substitution product while treatment of adenine with the Mannich 
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product formed from the reaction of formaldehyde with morpholine (Scheme 19) 
affords the dimethylated derivative.157
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Scheme 18. Alkylation of adenine at the NH2
                                                                                                                                                           
 position with HCHO                                
N
N N
N
H
NH2
i  HCHO
ii Morpholine
N
O
N
N N
N
N
H
N O
61 125
                                                                                                                                                                             
Scheme 19. Alkylation of adenine at the NH2
 
 position with Mannich product from 
morpholine and HCHO. 
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1.5. Aims of this research                                                                         
 
With a detailed knowledge of the role of glutamine synthetase in pathogenic 
Mycobacterium tuberculosis,75,76,77
More specifically, the research has involved: -  
 our goal has been to prepare novel ATP mimics 
that will bind to the active site of MTB-GS, thereby inhibiting normal enzymatic 
function. In general we have focused on establishing access to a series of structural 
scaffolds and, in some cases, their elaboration to potential ATP mimics. 
(i) the synthesis and characterization of novel adenosine-, adenine- and 
allopurinol- based and truncated adenine derivatives; 
(ii) the application of C-13 NMR shift prediction programmes to confirm 
experimental assignments; and 
(iii) a study of the conformational preferences and receptor docking of 
potential ATP mimics into the MTB-GS active site using the 
ACCELERYS Cerius2 platform. 
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 2. DISCUSSION 
 
The discussion will be focused on: - the syntheses of novel adenosine derivatives 
(Section 2.1), adenine derivatives (Section 2.2), allopurinol and Baylis-Hillman 
electrophiles (Section 2.3) and truncated systems (Section 2.4) as novel ATP 
analogues; the application of NMR prediction programme to confirm experimental 
data assignments (Section 2.5); computer modelling and docking of selected 
compounds into the GS active site (Section 2.6) and conclusions (Section 2.7) 
 
ATP 63 comprises three parts: an adenine base, a ribose sugar and a phosphoryl ester 
group.158,159
 
 In our approach, each of these parts was altered in attempts to access a 
range of compounds as potential ATP mimics.                                    
Adenosine triphosphate ATP                                                                                              
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Figure 10. ATP with proposed moieties for derivatives. 
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2.1.  Novel ATP analogues from adenosine                                           
 
The method employed was to replace the primary hydroxyl hydrogen of adenosine 
with various groups through acylation and alkylation reactions (Figure 11).                                   
                                             
  
N
N
N
N
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O
OH
OH
OH
N
N
N
N
NH2
O
O
O
O
R
i.   Acetone, PTSA 
ii.  Base, 
iii. Electrophilic reagent 
62 126
       
 
Figure 11. General approach for the synthesis of adenosine derivatives.                                   
 
There are three hydroxyl groups on t he ribose ring of adenosine and, although the 
primary hydroxyl group is more susceptible to acylation and alkylation, competition 
from the two secondary hydroxyl groups cannot be ruled out. However, the 1,2-
dihydroxy groups can be selectively protected as a c yclic acetal. Acetals are not 
difficult to make, they are stable compounds and their removal does not generally 
pose any difficulty.160 Protection of the vicinal 1,2-diol was successfully achieved by 
treating adenosine with acetone in the presence of an acid catalyst161  following  
previous work in our research group by Hall.162  The method involved stirring 
adenosine 62 in dry acetone in the presence of para-toluenesulfonic acid monohydrate 
as catalyst163 at room temperature overnight to produce adenosine 3',4'-acetonide 127 
in 93% yield (Scheme 20). The structure of the acetal obtained was confirmed by 
NMR and low- resolution mass spectroscopy. The two acetonide methyl singlets were 
observed at 1.22 and 1.38 ppm respectively in the 1H NMR spectrum (Figure 12); 
while the quaternary carbon of the acetal was found to resonate at 114.0 ppm in the 
13
 
C NMR spectrum (Figure 13).  
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Scheme 20.  Protection of adenosine with acetone. 
 
 
 
Figure 12. 400 MHz 1H NMR spectrum of adenosine 3',4'-acetonide 127 in CDCl3
   
.    
2  × CH3 
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Figure 13. 100 MHz 13C NMR spectrum of adenosine 3',4'-acetonide 127 in CDCl3
 
.  
With the acetonide 127 in hand, a number of novel adenosine derivatives were 
synthesized in low to moderate yields by treating adenosine 3',4'-acetonide 127 with 
different alkylating and acylating agents164
                                                                 
 following deprotonation of the primary 
hydroxyl group using either NaH or BuLi. These reactions afforded a set of primary 
substitution products which could then be elaborated further (Figure 14). In a number 
of cases the acylating agent had to be specially prepared.                   
C(CH3)2 at 114.0 
ppm 
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Figure 14. Routes to adenosine derivatives. 
 
2.1.1. Preparation of 2-(6-aminopurin-9-yl)-3,4-dihydroxy-5-[(2,3,4,5,6–penta- 
acetoxyhexanoyloxy)methyl]tetrahydrofuran 3,4-acetonide 132                     
                            
The route to the pentaacetoxy derivative 132 is shown in Scheme 21. The required 
acylating agent, 2,3,4,5,6-pentaacetylgluconoyl chloride 131, was synthesized by 
stepwise acetylation165 of the primary and secondary hydroxyl groups in D-
gluconolactone 128. In the first step, the lactone 128 was treated with acetic anhydride 
in the presence of ZnCl2 catalyst followed by hydrolysis with ice-water to open the 
lactone ring. In the second step, 2,3,4,6-tetraacetylgluconic acid 129165 was treated 
with the same reagent and catalyst to afford 2,3,4,5,6-pentaacetylgluconic acid 130. 
Pentacetylation was confirmed by the series of signals integrating for the 15 acetyl 
protons in the 1H NMR spectrum and 5 methyl signals and 6 carbonyl carbon signals 
in the 13C NMR spectrum. An initial attempt to make the acid chloride165 131 by 
stirring 2,3,4,5,6-pentaacetylgluconic acid 130 with PCl5 in diethyl ether at room 
temperature was unsuccessful. However, 2,3,4,5,6-pentaacetylgluconoyl chloride 131 
precipitated out as a white solid in 50% yield on stirring 2,3,4,5,6-pentaacetylgluconic 
acid 130 with oxalyl chloride166 under nitrogen at room temperature for ca. 0.5 h. 
2,3,4,5,6-D-pentaacetylgluconic acid 130 melted at 142-144°C while the acid chloride 
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131 melted at 41-42°C. The adenosine acetonide 127 was treated immediately with 
the acid chloride 131, using pyridine as both  solvent and base167,168
 
 to obtain 2-(6-
aminopurin-1-yl)-3,4-dihydroxy-5-[(2,3,4,5,6-pentaacetoxyhexanoyloxy)methyl]tetra-
hydrofuran 3,4-acetonide 132 as a yellow oil in 10% yield. Evidence for the formation 
of compound 132 was largely provided by NMR, mid-IR and mass spectrometric 
data.                 
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Scheme 21. Synthesis of the acetylated derivative 132.                                                 
 
The amino nitrogen on t he adenine ring was clearly not acylated in the isolated 
product as the NH2 proton signal integrates for 2 protons at 5.88 ppm in the 
1
 
H NMR 
spectrum (Figure 15). There is also no correlation between NH and gluconoyl C=O 
(C-1'') in the HMBC spectrum (Figure 16).  
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  Figure 15. 400 MHz 1H NMR spectrum of the acetylated derivative 132 in CDCl3
 
.  
 
 
 
 
NH2 at 5.88 ppm 
C-1'' 
NH2 
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Figure 16. HMBC NMR spectrum of the acetylated derivative 132 in CDCl3 showing the 
absence of any correlation between NH2 
 
and C-1''. 
2.1.2. Preparation of 2-(6-aminopurin-1-yl)-3,4-dihydroxy-5-[(allyloxy)methyl]- 
tetrahydrofuran 3,4-acetonide 133  
           
The O-allylated derivative 133 was expected to provide access to the diol 134 and the 
bis-phosphorylated derivative 136 as outlined in Scheme 22. On treating the acetonide 
127 with NaH and allyl bromide169 in refluxing THF, the allylated derivative 133 was 
obtained in 9% yield. In the 1H NMR spectrum (Figure 17), the 1"-methylene protons 
resonate as a pa ir of doublets at ca. 4 ppm; while the vinylic methylene protons 
resonate as overlapping multiplets at ca. 5.78 ppm, each of the allylic protons 
resonates as a dd (CHa at 4.98 ppm and  CHb
                                        
 at 5.29 ppm respectively).                                    
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Scheme 22. Proposed route to the nucleotide 136. 
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Figure 17. 400 MHz 1H NMR spectrum of the allylated derivative 133 in CDCl3
 
.                                                                                                                                                          
Attempts to improve the efficiency of this reaction were made using different reaction 
conditions; the highest yield was 24% (Table 2). Unfortunately, attempts at 
dihydroxylating the allylated derivative 133 with various reagents including NaIO4 in 
the presence of RuCl3
170 catalyst, KMnO4
171,172,173 and CTAP173,174
 
 were unsuccessful. 
Table 2. Yields of the allylated derivative 134 under various reaction conditions. 
 
Conc. of 
134/[M] 
Solvent Base % Yield 
0.5 THF NaH 9.0 
0.1 THF NaH 21 
0.01 THF NaH 24 
0.5 Pyridine NaH 9.2 
0.5 THF Na 7.2 
0.5 DMF NaH 3.5 
0.03 Acetone K2CO3 0.0 
175 
 
 
CHb at 5.29 
ppm CHa at 4.98 
ppm 
2"-H at 
5.78 ppm 
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2.1.3. Preparation of 2-(6-aminopurin-9-yl)-3,4-dihydroxy-5-(7-hydroxy-2,5-di-
oxaheptyl)tetrahydrofuran 3,4-acetonide 137 and 2-(6-aminopurin-9-yl)-5[7-di-
ethylphosphoryoxy)-2,5-dioxaheptyl]-3,4-dihydroxytetrahydrofuran 3,4-
acetonide 138                          
 
The deprotonated acetonide 127 was alkylated169 with 2-(2-chloroethoxy)ethanol in 
refluxing THF to afford 2-(6-aminopurin-9-yl)-3,4-dihydroxy-5-(7-hydroxy-2,5-
dioxaheptyl)tetrahydrofuran 3,4-acetonide 137 in 72% yield (Scheme 23). In the 1H 
NMR spectrum (Figure 18), the methylene protons (7", 6", 4", 3" and 1"-Ha) resonate 
as a series of multiplets at ca. 3.6-3.8 ppm. FAB mass spectrometric analysis showed 
the presence of the M+1 peak 
                                  
at m/z 396 with an intensity of 3% relative to the base 
peak at m/z 136.                                           
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Scheme 23. Synthesis of the phosphorylated derivative 138.                                            
   
An initial attempt to phosphorylate compound 137 with tetrabutylammonium 
dihydrogen phosphate176 under reflux in an inert atmosphere of argon was not 
successful. However, 2-(6-aminopurin-9-yl)-5[7-diethylphosphoryloxy)-2,5-dioxa-
heptyl]-3,4-dihydroxy - tetrahydrofuran 3,4-acetonide 138 was successfully isolated 
pure on t reating compound 137 with BuLi and diethyl chlorophosphate.177 The 
methylene protons (7", 6", 4", 3" and 1") now resonate at slightly higher chemical 
shifts ca. 4.0-4.3 ppm (Figure 18). The 31
 
P signal is at 0.8 ppm (Figure 19) compared 
with 6.3 ppm in the diethyl chlorophosphate.                                                                                                                                                    
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Figure 18. 400 MHz 1H NMR spectra of the alkylated derivative 137 and 
phosphonate 138 in CDCl3. 
methylene 
protons 
137 
138 
methylene 
protons 
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Figure 19. 162 MHz 31P NMR spectrum of 138 in CDCl3
          
.                                            
The mid-IR absorption spectrum of 2-(6-aminopurin-9-yl)-5[7-diethylphosphoryl-
oxy)-2,5-dioxaheptyl]-3,4-dihydroxytetrahydrofuran 3,4-acetonide 138 shows a 
phosphate ester absorption band at 1028 cm-1
 
 (Figure 20).     
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Figure 20.  Mid-IR absorption spectrum of the phosphorylated derivative 138 as a 
thin film.        
0.8 ppm 
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2.1.4. Preparation of 2-(6-aminopurin-9-yl) -3,4-dihydroxy- 5-(10-hydroxy-2,5,8-
trioxadecyl)tetrahydrofuran  3,4-acetonide 139 and 2-[6-(8-hydroxy-3,6,-dioxa 
octylamino)purin-9-yl]-3,4-dihydroxy-5-(10-hydroxy-2,5,8- trioxadecyl)tetrahyd-
rofuran 3,4-acetonide 139A                                                                                          
                                                                                                                                           
On treating the acetonide 127 with NaH169 and 2-[2-(2-chloroethoxy)ethoxy]ethanol, 
in refluxing THF, the desired monoalkylated derivative 2-(6-aminopurin-9-yl)-3,4-
dihydroxy-5-(10-hydroxy-2,5,8-trioxadecyl)tetrahydrofuran 3,4-acetonide 139 was 
isolated in 2% yield as well as the competing di-alkylated product, 2-[6-(8-hydroxy-
3,6,-dioxaoctylamino)purin-9-yl]-3,4-dihydroxy-5-(10-hydroxy-2,5,8-trioxadecyl)te-
trahydrofuran 3,4-acetonide 139A, in 3% yield (Scheme 24). In the 1
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H NMR spectra 
of compound 139 and 139A (Figure 22), the methylene signals of compound 139 can 
be observed at ca. 3.58-3.96 ppm while those of the competing product 139A can be 
observed in a similar region ca. 3.51-3.81 ppm. The 2'-H methine proton of 139, 
however, resonates at 7.83 ppm while that of 139A resonates downfield at 8.50 ppm 
as a consequence of the presence of the 8-hydroxy-3,6-dioxaoctylamino substituent on 
the purine ring.        
 
Scheme 24. Synthesis of compounds 139 and 139A 
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Figure 21. Comparism of 1H NMR spectra of compound 139 and compound 139A in 
CDCl3
                                                                                                                                                
. 
                                                                                                                                                                                                              
2.1.5. Preparation of 2-(6-aminopurin-9-yl)-5-acetoxyacetyl-3,4-dihydroxytetra- 
hydrofuran  3,4-acetonide 140 and  2-[6-(acetoxyacetylamino)purin-9-yl)-5-ace-
toxyacetyl 3,4-dihydroxytetrahydrofuran 3,4-acetonide 140A                          
                                   
On treating the acetonide 127 with NaH and acetoxyacetyl chloride169,178 in refluxing 
THF, the ester 2-(6-aminopurin-9-yl)-5-acetoxyacetyl-3,4-dihydroxytetrahydrofuran 
3,4-acetonide 140 was isolated in 34% yield as well as the di-acylated product, 2-[6-
(acetoxyacetylamino)purin-9-yl)-5-acetoxyacetyl-3,4-dihydroxytetrahydrofuran 3,4-
acetonide 140A in 40% yield (Scheme 25). There is one CH3CO signal at 2.13 ppm in 
1H NMR spectrum of compound 140 while there are (2 × CH3CO) signals at 2.11 and 
2.22 ppm respectively in the 1H NMR spectrum of compound 140A (Figure 22). The 
signal of the NH2 on C-6' of the purine ring of compound 140 can be  seen at 5.71 
ppm while NH signal of compound 140A can be seen at 9.4 ppm . The methylene 
protons of the acetoxyacetyl moiety attached to the ribose sugar of both products 
resonate as singlets at ca. 4.5 ppm while the methylene protons of the amide group of 
the di-acylated product resonate as a singlet at 5.30 ppm . FAB mass spectrometric 
Methylene 
protons 
Methylene 
protons 
 
139 
139A 
2'-H 
2'-H 
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analysis of the ester 140 showed the presence of the M+1 peak at m/z 408 with an 
intensity of 96% relative to the base peak at m/z 136, while FAB mass spectrometric 
analysis of the di-acylated product showed the presence of the M+1 peak 
                                                                                              
at m/z 508 
with an intensity of 100% as the base peak. 
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Scheme 25. Synthesis of the esters mono-ester 140 and di-ester 140A.  
      
 
 
 
                                                      
 
Figure 22. Comparison of 1H NMR spectra of compounds (a) 140 and (b) 140A in 
CDCl3.  
2 × CH3C=O 
CH3C=O 
NH2 
NH 
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2.1.6. Preparation of 2-(6-aminopurin-9-yl)-5-[(2-chloroacetoxy)methyl]-3,4-di 
hydroxyltetrahydrofuran 3,4-acetonide 141 and 2-[6-(2-chloroacetamido)purin-
9-yl]- 5-[(2-chloroacetoxy)methyl]-3,4-dihydroxytetrahydrofuran 3,4-acetonide 
141A  
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Scheme 26. Synthesis of compounds 141 and 141A 
 
The ester 2-(6-aminopurin-9-yl)-5-[(2-chloroacetoxy)methyl]-3,4-dihydroxytetrahy-
drofuran 3,4-acetonide 141 was synthesized in 94% yield by stirring the acetonide 127 
with chloroacetyl chloride179 under argon at room temperature for ca. 0.5 h (Scheme 
26). In a separate reaction, on treating 127 with the same acid chloride under the same 
reaction conditions, compound 141A was obtained as well as the desired product 141. 
While each of the CH2Cl methylene signals were observed at 4.00 ppm as shown in 
Figure 23, the methylene protons next to the amide group on the purine ring of 141A 
resonate as a singlet at 4.70 ppm .  T he 8'-H methine proton of compound 141 
resonates at 7.88 ppm, while the corresponding proton in compound 141A resonates 
at 8.72 ppm. Attempts to synthesize compound 142 by refluxing compound 141 with 
triethyl phosphite (Arbuzov reaction)180
 
 were unsuccessful.                
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Figure 23. Comparison of 400MHz 1H NMR spectra of compounds 141 and 141A in 
CDCl3
 
.                      
2.1.7. Preparation of 5-[(acryloyloxy)methyl]-2-(6-aminopurin-9-yl)-3,4-dihy-
droxytetrahydrofuran 3,4-acetonide 143                                                       
 
The acrylic ester 143 was obtained as light yellow oil in 4% yield on t reating 
deprotonated 127 with acryloyl chloride under reflux (Scheme 27). 
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Scheme 27. Synthesis of the acrylic ester 143.                                                                                                                                            
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Formation of the acrylic ester 143 was confirmed by the downfield shift of the 1"-
methylene proton signals in compound 143 relative to the precursor 127 (Figure 24). 
Both methine protons on the heteroaromatic ring of the acrylic ester 143 resonate at 
about the same chemical shifts (7.84 and 8.34 ppm) as in the precursor 127  
confirming that there was no a cylation of the amino group on t he purine ring. The 
NH2 protons also integrate to approximately 2 at 5.87 ppm in the 
1
                                                                                                                                                   
H NMR spectrum 
of the acrylic ester product. The formation of the acrylic ester was further confirmed 
by the presence of the molecular ion at m/z 361.137825 with 30% abundance relative 
to the base peak at m/z 55.018601 in the high-resolution mass spectrometric analysis.                                                                           
 
 
 
 
Figure 24. 400 MHz 1H NMR spectrum of acrylic ester 143 in CDCl3
 
.   
The mid-IR spectrum of compound 143 showed an ester carbonyl absorption band at 
1714 cm-1
                                          
.   
2.1.8. Preparation of 4-bromomethyl-2,2-dimethyl[1,3]dioxolane 145      
                                                                                                          
The vicinal 1,2-diol moiety of 3-bromo-1,2-dihydroxypropane 144 was protected by 
stirring it w ith acetone in the presence of para-toluenesulfonic acid monohydrate 
NH2 
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catalyst163 to obtain 4-bromomethyl-2,2-dimethyl[1,3]dioxolane 145 in 65% yield 
(Scheme 28). The protection was confirmed by the observation of two clearly defined 
methyl singlets at 1.35 and 1.43 ppm respectively in the 1H NMR spectrum (Figure 
25) as well as six carbon signals in the 13C NMR spectrum (Figure 26). However, 
attempts at alkylating169
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 the deprotonated acetonide 127 with the dioxolane 145 was 
unsuccessful.                    
                                                                                                                                                            
Scheme 28. Proposed synthesis of the derivative 146.  
 
 
Figure 25. 400 MHz 1H NMR spectrum of the dioxolane 145 in CDCl3.                  
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Figure 26. 100 MHz 13C NMR spectrum of the dioxolane 145 in CDCl3
               
.  
2.2.  Novel ATP analogues from adenine                                            
 
The approach employed was to replace the proton on the N-9 nitrogen of adenine with 
various electrophiles after deprotonation of adenine to afford primary products 
(Figure 27) that could be elaborated further. In one case the electrophile had to be 
specially prepared.                                                 
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Figure 27. General approach for the synthesis of adenine derivatives.                                             
 
2.2.1. Preparation of 3,4,5-triacetoxy-6-acetoxymethyl-2-(6-aminopurin-9-yl)-
pyran 149    
                                                                                                
Acetylated glucose (3,4,5,6-tetraacetoxy-2-acetoxymethylpyran) 148 was synthesized 
in 87% yield by heating glucose 147 with acetic anhydride in the presence of ZnCl2 
catalyst181 (Scheme 29). 1H NMR analysis (Figure 28) indicated the presence of the 
desired product. Thus the anomeric proton (2-H) resonates as a doubl et at 6.3 ppm 
with a coupling constant of 3.7 Hz, a down-field shift of 0.1 ppm from its value in 
glucose, while the five acetoxy methyl groups resonate between 1.94 and 2.23 ppm. 
Five methyl carbons and five C=O carbons can be observed in the 13C NMR spectrum 
(Figure 29). Low-resolution mass spectrometric analysis reveals the presence of the 
molecular ion at m/z 390 with 3% abundance relative to the base peak at m/z 98, 
while mid-IR absorption at 1750 cm-1 was observed for the ester carbonyl group.   
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Scheme 29. Synthesis of the adenine derivative 149.                                                     
               
 
 
 
Figure 28.  400MHz 1H NMR spectrum of compound 148 in CDCl3
 
.       
5 × CH3CO 
6-H 
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Figure 29.  100MHz 13C NMR spectrum of the acetylated product 148 in CDCl3
  
. 
The acetylated glucose 148 was then coupled with adenine in a tin tetrachloride 
catalyzed182 glycosidation reaction using acetonitrile183 as solvent to afford of 3,4,5-
triacetoxy-6-acetoxymethyl-2-(6-aminopurin-9-yl)pyran 149 in 30% yield. In the 1H 
NMR spectrum (Figure 30), the anomeric proton (2-H) now resonates at 5.88 ppm  
with a coupling constant of 5.9 H z ca. 0.4 ppm upfield of the pentaacetylated 
precursor, while the anomeric carbon has a chemical shift of 80.3 ppm  in the 13C 
NMR spectrum (Figure 30) - an upfield shift of 8.8 ppm . Low-resolution mass 
spectrometric analysis of compound 149 showed the presence of the M-1 peak at m/z 
464 as the base peak. Mid-IR absorption at 1744 c m-1 was observed for the ester 
carbonyl groups.                                                                       
5 × CH3CO 
5 × C=O 
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Figure 30  (i) 400MHz 1H NMR spectrum of acetylated derivative 149 and (ii) 
100MHz 13C NMR spectrum of acetylated derivative 149 in CDCl3
 
.   
 
2-H 
4 × CH3CO 
4 × C=O 
C-2 
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2.2.2. Preparation of 6-(N-allylamino)purine 150 and 9-allyl-6-(N-allylamino)-
purine 150A 
 
Deprotonation of adenine in DMF followed by treatment with allyl bromide169 under 
reflux yielded the mono- and di-allylated products 150 and 150A (Scheme 30). NMR 
as well as high-resolution mass spectroscopy confirmed the formation of both 
allylated products. All protons are accounted for in the 1
N
N
N
N
NH2
H
CH2
Br
N
N
N
N
N
H
H
DMF,NaH
61 150
N
N
N
N
N
H
+
150A
H NMR spectra of both 
compounds (Figures 31 and 32). The NH proton of the mono-allylated product 
resonates as a singlet at 11.12 ppm  while its 2'-H methine proton resonates at 6.06 
ppm as a tdd. The molecular ion peak of the mono-allylated product 150 was clearly 
visible at m/z 175 as the base peak while the spectrum of the di-allylated product 
150A exhibited a molecular ion at m/z 215 with 95% abundance relative to the base 
peak at m/z 200.  
 
Scheme 30. Synthesis of the adenine derivatives 150 and 150A 
 
 
Figure 31.  400MHz 1H NMR spectrum of the adenine derivative 150 in CDCl3. 
2'-H 
NH 
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Figure 32. 400MHz 1H NMR spectrum of the adenine derivative 150A in CDCl3
 
.                                                                                                      
2.2.2. Attempted Preparations  
 
Attempts were made to couple deprotonated adenine with each of 2-
(chloroethoxy)ethanol,  acetoxyacetyl chloride and chloroacetyl chloride (Scheme 
31). Unfortunately all these acylation reactions were unsuccessful. The reason for 
these failed reactions may be the steric bulk of the purine nucleophile in the case of 
chloroacetyl chloride and acetoxyacetyl chloride. 2-(chloroethoxy)ethanol, on t he 
other hand, might have undergone intramolecular cyclisation in the presence of NaH 
(Figure 33) hence preventing its reaction with the nucleophilic deprotonated adenine.  
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Scheme 31. Attempted preparations of adenine derivatives.     
 
Cl
O
OH
NaH
Cl
O
O
-
O
O
-Cl
154 154A
 
Figure 34. Possible intramolecular cyclisation of 2-(chloroethoxy)ethanol in the 
presence of NaH.  
 
                                                                                                                                                                                    
2.3. ATP mimics from allopurinol and Baylis-Hillman electrophiles                                                                                         
                                         
The approach was to replace the hydrogen of the imidazole ring in allopurinol with 
different electrophiles, after deprotonation by a base, to afford novel ATP mimics. 
Hence, the hydroxyl group on a llopurinol was protected with dihydropyran184 
(Scheme 32) to avoid competition between the NH and OH moieties in the molecule. 
1H NMR analysis (Figure 34) showed the formation of compound 157 with all the 
protons accounted for in their expected positions, and the 2'-methine proton having 
moved upfield by 0.4 ppm relative to its position in dihydropyran. In the 13C NMR 
spectrum (Figure 35) the C-3' carbon has been shifted upfield by 71.2 ppm as a 
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consequence of being converted from an sp2 centre in dihydropyran to an sp3 
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Scheme 32. Protection of allopurinol.                                                                                                                                  
                                                      
 
 
 
Figure 34.  400MHz 1H NMR spectrum of the protected allopurinol 157 in CDCl3
  
.    
2'-H 
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Figure 35. 100MHz 13C NMR spectrum of the protected allopurinol 157 in CDCl3
 
.                 
With the protected allopurinol in hand, an attempt was made to synthesize the range 
of primary substitution products illustrated in Figure 38.                                                              
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Figure 36. General approach to allopurinol derivatives.                                                             
C-3' 
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2.3.1. Preparation of 9-allyl-4-(tetrahydropyran-2-yloxy)-1H-pyrazolo[3,4-
d]pyrimidine 161         
 
The protected allopurinol 157 was deprotonated using sodium hydride and then 
treated with allyl bromide169 (Scheme 33) under reflux and the allylated derivative 
158 was obtained in 87% yield. The 1H NMR and 13
N
N
N
N
OO
H
Br
N
N
N
N
OO
NaH, THF
157 158
C NMR (Figure 37) spectra both 
confirm the formation of the product. The 2"-methine proton resonates at 5.94 ppm as 
a multiplet due to coupling with adjacent vinylic and methylene protons, while all 13 
carbon atoms are accounted for (Figure 38). Mass spectrometric analysis shows the 
presence of the molecular ion at m/z 260 relative to the base peak at m/z 177. 
 
 Scheme 33. Preparation of the allopurinol derivative 158.                                                                                                                                         
                                                               
 
 
Figure 37.  600MHz 1H NMR spectrum of the allopurinol derivative 158 in CDCl3.        
2"-H 
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Figure 38. 100MHz 13C NMR spectrum of the allopurinol derivative 158 in CDCl3
 
.      
Attempts to acylate the pyrazole nitrogen178
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157
 of protected allopurinol with various 
acylating agents (Scheme 34) were, also unsuccessful - paralleling the difficulties 
encountered in acylating adenine at the N-9 nitrogen.  
 
Scheme 34. Attempted acylations of compound 157. 
C-2" 
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2.3.2. Preparation of tert-butyl 3-(5-bromo-2-hydroxyphenyl)-3-hydroxy-2-
methylene propanoate 165a and tert-butyl 3-hydroxy-3-(2-hydroxyphenyl)-2-
methylenepropanoate 165b 
 
In separate reactions, 5-bromo-2-hydroxybenzaldehyde 163a and salicylaldehyde 
163b were stirred with tert-butyl acrylate in the presence of DABCO as catalyst to 
obtain 165a and 165b, respectively (Scheme 35), following previous work done in the 
research group by Musa.179 Each of these Baylis-Hillman adducts was then reacted 
with deprotonated allopurinol. 1H NMR and other spectroscopic analysis confirmed 
the formation of the Baylis-Hilman products. The intramolecular cyclisation product 
166b was also obtained as side product in the reaction between salicylaldehyde and 
tert-butyl acrylate. This product arises from a conjugate addition-elimination (or SN1 
displacement) reaction affording a chromene instead of the coumarin analogue. The 
vinylic protons of compound 165b, 3"-Ha and 3"-Hb, resonate at 5.49 ppm and 6.23 
ppm, respectively (Figure 39). The 3-H methine proton singlet at 5.69 ppm and the 3-
OH and 2'-OH signals at 4.36 ppm  and 8.14 pp m disappear in the spectrum of the 
compound 166b to give way for the 2-methylene singlet (Figure 40) at 4.94 ppm as a 
consequence of the intramolecular cyclisation of 165b. The 3-H methine proton at 
5.69 ppm on a sp3 carbon in compound 165b moves downfield to 7.32 ppm (4-H in 
166b) since it now resides on a sp2
 
 carbon.                                                                                                  
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Scheme 35. General preparation of Baylis-Hilman products.                                         
 
There is also a considerable shift upfield in the position of the carbonyl carbon in the 
13C NMR spectra from 166.7 ppm in 165b (Figure 41) to 163.8 ppm in 166b (Figure 
42). High-resolution mass spectrometric analysis of compound 166b shows the 
presence of the M-1 ion at m/z 231.101945 with 30% abundance relative to the base 
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peak at m/z 57.070785, while the mid-IR spectrum shows carbonyl absorption at 1700 
cm-1
 
.                                                                                         
 
Figure 39.  400MHz 1H NMR spectrum of the B-H product 166b in CDCl3
 
  
 
Figure 40. 400MHz 1H NMR spectrum of the chromene 165b in CDCl3.  
3"-Hb 
 
3"-Ha 
2'-OH 
3-H 
3'-OH 
4-H 
CH2 
___________________________________________________________  Discussion                                                                                                                                          
 68 
 
 
 
Figure 41.100MHz 12C NMR spectrum of the Baylis-Hillman product 165b in 
CDCl3
 
.  
 
 
 
Figure 42.  100MHz 13C NMR spectrum of the Baylis-Hillman product 166b in 
CDCl3
                      
.  
C=O 
C=O 
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2.3.2. Preparation of 6-bromo-3-(chloromethyl)coumarin 167, 6-bromo-3-(ace-
toxymethyl)coumarin 168 and 6-bromo-3-(hydroxymethyl)coumarin 169                                                
 
Cyclisation of the Baylis-Hillman adduct 165a in a refluxing mixture of 
HCl/CH3COOH
185 yielded the desired 6-bromo-3-(chloromethyl)coumarin product 
167 in 31% yield together with two side-products, 6-bromo-3-(acetoxymethyl)-
coumarin 168 (1.8%) and 6-bromo-3-(hydroxymethyl)coumarin 169 (7.3%) as shown 
in Scheme 36. T he chemical structures of the side-products were confirmed by 
spectroscopic methods. The formation of the ester 168 resulted from direct 
interception by acetic acid (165a → 168) and/or the reaction of the excess acetate ion 
with the desired alkyl halide product 167, while the formation of the alcohol 169 is 
attributed to the hydrolysis of the ester 168. All the protons and carbons of the ester 
168 are accounted for as shown in Figures 43 and 44. The methyl protons resonate at 
2.16 ppm and the 1'-methylene protons resonate as a singlet at 5.06 ppm, while the 4-
H proton resonates as a singlet at 7.94 ppm . In the 13C NMR spectrum the lactone 
carbonyl and the acetyl carbonyl carbons resonate at 159.5 a nd 170.4 ppm , 
respectively. Mass spectrometric analysis of the ester 168 shows the presence of the 
molecular ion at m/z 297 with 18% abundance relative to the base peak at m/z 43. 
Mid-IR spectroscopic analysis of the compound 168 shows the lactone carbonyl 
absorption band overlapping the coumarin carbonyl band at 1720 cm-1
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Scheme 36.  Synthesis of the coumarin derivatives 167, 168 and 169. 
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Figure 43 400MHz 1H NMR spectrum of compound 168 in CDCl3
                                  
.      
 
 
 
Figure 44 100MHz 13C NMR spectrum of compound 168 in CDCl3
                                                                                           
.  
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CH2 
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Figure 45. Mid-IR absorption of compound 168.                                                          
                                                                                                                                                 
All the protons and carbons of the alcohol 169 are accounted for as shown in Figures 
46 and 47. The hydroxymethylene protons (CH2OH) signal is a multiplet at 4.36 ppm 
while the hydroxyl proton resonates as a triplet at 5.52 ppm. All the carbon signals are 
accounted for in the 13C NMR spectrum with the sp2 C-4 carbon resonating at 135.6 
ppm while the lactone carbonyl signal appears at 159.1 ppm . Mass spectrometric 
analysis of the alcohol 169 shows the presence of the molecular ion peak at m/z 255 
with 83% abundance relative to the base peak at m/z 225. Mid-IR spectroscopic 
analyses of the compound 169 show a hydroxyl absorption band at 3409 cm-1 and a 
coumarin carbonyl absorption band at 1630 cm-1
 
.                                     
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Figure 46. 400MHz 1H NMR spectrum of the alcohol 169 in DMSO-d6
 
.       
 
 
Figure 47. 100MHz 13C NMR spectrum of the alcohol 169 in DMSO-d6
 
.   
The Baylis-Hillman adducts 165a and 165b each have two electrophilic sites (Figure 
48) at which they may be susceptible to attack by a nucleophile. The 2-
CH2OH 
OH 
C=O 
C-4 
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(chloromethyl)coumarin   167, on the other hand has three different electrophilic sites, 
as shown in Figure 48, at which it may be susceptible to nucleophilic attack. 
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Figure 48. Nucleophilic sites in compounds 165a,b and compound 167 
 
2.3.2.3. Reaction of protected allopurinol 157 with 2-(chloromethyl)coumarin 167                                                                                                     
 
The 2-(chloromethyl)coumarin 167 was refluxed169,178 with deprotonated protected 
allopurinol 157 to afford the coumarin derivative 170a in 31% yield (Scheme 37). The 
structure of the coumarin derivative 170a was confirmed by spectroscopic methods. 
The significant downfield shift of the 1'-methylene protons from 4.53 ppm in the 
precursor 167 to 5.02 ppm in the product 170a (Figure 49) and the downfield shift of 
the 1'-methylene carbon signal from 40.8 ppm  in the precursor to 45.7 ppm in the 
product are clear evidence that the nucleophilic attack occurred at the 1'- centre of the 
coumarin. Furthermore there was no s ignificant change in the chemical shift of the 
carbonyl carbon [159.4 ppm in the alkyl halide compared with 160.7 ppm in the 
product derivative (Figure 50)]. All other protons and carbon signals are accounted for 
in the respective spectra (Figures 49 and 50). High-resolution mass spectrometric 
analysis of 170a shows the presence of the M-1 
 
ion at m/z 456.043762 with 19% 
abundance relative to the base peak at m/z 84.048546.                      
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Scheme 37. Synthesis of the coumarin derivative 170a.                                                 
 
 
 
 
 
Figure 49. 400MHz 1H NMR spectra in CDCl3 of compound 167 and compound 
170a in CDCl3
              
.    
1'-CH2 
CH2 
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Figure 50. 100MHz 13C NMR spectra of 167 in CDCl3 and 170a in CDCl3
                                                                                                                                                                                                                                               
 showing 
no significant change in chemical shift of the C=O signal.      
2.3.2.4. Reaction of protected allopurinol with Baylis-Hillman adducts 165a and 
165b 
 
The Baylis-Hillman adducts 165a and 165b were refluxed169,178 separately with 
deprotonated protected allopurinol to afford products 170a and 170b respectively 
(Scheme 38). In the presence of NaH, intramolecular cyclisation (Figure 51) seems to 
have occurred in both 165a and 165b before the nucleophilic SN
1 attack by the 
deprotected allopurinol to yield 170a and 170b. The chemical structure of each of 
these allopurinol derivatives was elucidated by spectroscopic methods. The only 
difference between 170a and 170b is the presence of the Br atom on C-6 of the 
coumarin moiety. Hence, a comparison of the proton NMR spectra of both 
compounds indicate the presence of 6 protons in the aromatic region of compound  
170a while compound 170b has 7 protons in the same region (Figure 52). MS analysis 
of 170a shows the presence of the molecular ion at m/z at 378.132008 w ith 35% 
C-1' 
C-1' 
 
C=O 
C=O 
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abundance relative to the base peak at m/z 84.057287, while mid-IR spectroscopic 
analysis of the compound shows carbonyl absorption at 1698 cm-1
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Scheme 38. Synthesis of allopurinol derivatives 170a and 170b.                                                                                                                                   
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Figure 51. Proposed mechanism for the formation of 170a and 170b  
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Figure 52. Comparison of 400MHz 1H NMR spectra of compounds 170a and 170b in 
CDCl3
 
. 
 
170b 
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2.4. Truncated adenine mimics                                                                                  
 
It was envisaged that benzenoid compounds with suitable meta substituents could 
serve as truncated analogues of the 6-aminopurine (adenine) nucleus. Drugs in 
chemical use often have relatively simple structures and when treated with base, 
followed by reaction with various electrophiles (as outlined in the Figure 53), it was 
hoped that such systems would provide convenient access to novel and effective ATP 
analogues.  
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Figure 53. General approach to novel truncated ATP analogoues.                                      
 
2.4.1. ATP mimics from 3-aminobenzonitrile 173 
 
3-Aminobenzonitrile was identified as a synthon for the construction of truncated 
ATP analogues (Figure 54). Deprotonation and treatment with a range of electrophiles 
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was expected to afford a number of intermediates that could be elaborated further 
(Figure 54). 
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Figure 54. Construction of truncated ATP mimics from 3-aminobenzonitrile.     
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Figure 55. Proposed preparation of derivatives of 3-aminobenzonitrile 173.                                     
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2.4.1.1. N-Allyl-3-cyanoaniline 177 and N,N-diallyl-3-cyanoaniline 177a                                                                                               
 
The alkene 177 was expected to provide access177 to the phosphorylated derivative 
180 via the dihydroxylated derivative 179 as shown in Scheme 39. Treatment of 173 
with 1 equivalent of NaH at 0°C followed by allyl bromide169 under reflux yielded the 
mono-allylated product 177 in 45% yield (Scheme 39). Using 2 equivalent of NaH 
and the same reaction conditions, both the mono-allylated derivative 177 (31%) and 
the di-allylated derivative 177a (8%) were obtained. NMR, mass spectrometric and 
mid-IR spectroscopy were employed to confirm the formation of these products. 
Figures 56 a nd 57 s how the 1H NMR spectra of compounds 177 and 177a 
respectively. The vinylic methine proton in compound 177 resonates as a multiplet at 
5.89 ppm while the two vinylic methine protons in the di-allylated product resonate as 
a multiplet at 5.81 ppm. The NH signal for the mono-allylated product 177 is evident 
as a singlet at 4.13 ppm. MS analysis of compound 177 indicates the presence of the 
molecular ion at m/z 158 as the base peak, while high-resolution MS analysis of 177a 
indicates the presence of the M+1 peak at m/z 199.119390 with 9% abundance 
relative to the base peak at m/z 41.040152. Mid-IR analysis of compound 177 (Figure 
58) showed an NH absorption band at 3391 cm-1 and the cyanide absorption band at 
2228 cm-1, while the di-allylated analogue 177a (Figure 59) show only the cyanide 
absorption band at 2228 cm-1. In attempts directed at improving the yield, the reaction 
was also carried out under various reaction conditions. The maximum yield obtained 
was 45% using 1 equivalent of NaH in THF (Scheme 39). Unfortunately, repeated 
attempts to either dihydroxylate compound 177 with CTAP,174 KMnO4
174 or NaIO4
170
 
or to make the epoxide186
                                                                                                                  
 178 were unsuccessful, precluding access to the targeted 
diphosphate 180. 
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Scheme 39. Synthesis of compounds 177 and 177a.                                                                                                                          
 
 
 
 
Figure 56. 400MHz 1H NMR spectrum of compound 177 in CDCl3
 
.                                                                             
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Figure 57. 400MHz 1H NMR spectrum of compound 177a in CDCl3
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Figure 58. Mid-IR absorption of spectrum of compound 177.                                      
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Figure 59. Mid-IR absorption of spectrum of 177a.                                       
                                                                                                                                                                                                                                                  
2.4.1.2. Preparation of 2-chloro-N-(3-cyanophenyl)acetamide 181 and diethyl [(3-
cyanophenyl)carbamoyl]methyl phosphonate 182                                                                                                
 
The chloroacetamide 181 was obtained in high yield of 95% by stirring 3-
cyanoaniline 173 with chloroacetyl chloride179 (Scheme 40). 1H NMR analysis of the 
product 181 (Figure 60) reveals the CH2Cl signal at 4.20 ppm as a singlet, while high-
resolution mass spectrometric analysis revealed the molecular ion peak at m/z 
194.02431 with 45% abundance relative to the base peak at m/z 118.05162. 
Phosphorylation of the chloroacetamide 181 with triethyl phosphite in an Arbuzov 
reaction180 afforded the phosphonate 182 in 84% yield. The protons and carbon 
signals corresponding to the CH2P methylene group are both observed to be split by 
the coupling to the 31P nucleus in the 1H and 13C NMR spectra respectively (Figures 
61 and 62). The carbonyl carbon is also observed to be split by the 31P nucleus with a 
coupling constant of 4.5 Hz. The 31P NMR spectrum (Figure 63) shows a signal at 
18.30 ppm corresponding to the phosphorous atom. The high-resolution mass 
spectrum of the phosphonate 182 shows the molecular ion at m/z 296.01963 with 65% 
abundance relative to the base peak at m/z 179.08244. Attempts to effect catalytic 
hydrogenation of the nitrile moiety in compound 182, in the presence of platinum on 
carbon catalyst, however, were unsuccessful.                                                             
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Scheme 40. Synthesis of compounds 181 and 183.   
 
                                                                           
 
 
 
Figure 60. 400 MHz 1H NMR spectrum of the chloroacetamide 181 in CDCl3
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Figure 61. 400 MHz 1H NMR spectrum of compound 182 in CDCl3
                                                                                                                                  
.    
 
 
 
 
Figure 62. 100 MHz 13C NMR spectrum of compound 182 in CDCl3, showing 
splitting of the CH2P and C=O signals by 
31
 
P.  
CH2P 
CH2P C=O 
C=O 
 
___________________________________________________________  Discussion                                                                                                                                          
 86 
 
 
 
Figure 63. 162 MHz 31
                                                                            
P NMR of the phosphonate 182.         
2.4.1.3. Preparation of 2-acetoxy-N-(3-cyanophenyl)acetamide 184                                                                                                                           
 
Treatment of deprotonated 3-aminobenzonitrile 173 with acetoxyacetyl chloride178 
afforded 2-acetoxy-N-(3-cyanophenyl)acetamide 184 in 85% yield (Scheme 41). 
Formation of the product 184 was confirmed by spectroscopic methods. The HMBC 
NMR spectrum (Figure 64) shows the correlation between the NH proton and the 
carbonyl carbon of the carbamoyl group while the mid-IR spectrum showed an amide 
C=O absorption band at 1675 cm-1 and an ester C=O absorption band at 1735 cm-1. 
Mass spectrometric analysis revealed the M+1 peak at m/z 219 with 60% abundance 
relative to the base peak at m/z 177. Attempted reduction of the nitrile group, in this 
case with lithium aluminium hydride187
NH2
CN O
O
Cl
O
173
184
NaH, THF
CN
N
O
O
O
H
N
O
O
O
H
NH2
LAH
185
 was also unsuccessful, and the difficulties 
associated with this seemingly straightforward transformation will have to be 
addressed in future studies.                      
                                                                                                                                                                                                                                  
Scheme 41. Synthesis of 2-acetoxy-N-(3-cyanophenyl)acetamide 185. 
18.3 ppm 
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Figure 64. HMBC NMR spectrum of compound 184 in CDCl3
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Figure 65. Mid-IR spectrum of compound 185 as solid deposit.  
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2.4.1.4. Preparation of 2,3,4,5,6-pentaacetyl-N-(3-cyanophenyl)-gluconamide 186                                                                                            
 
3-Aminobenzonitrile 173 was stirred with 2,3,4,5,6-pentaacetylgluconoyl 
chloride167,168
CN
NH2
173 186                                      
NaH, pyridine N
OAc
CN
H
O
OAc
OAc
OAc
OAc
Cl
OAc
O
OAc
OAc
OAc
OAc
 131 in pyridine to afford the gluconamide derivative 186 in 41% yield 
(Scheme 42), formation of which was confirmed by spectroscopic methods. The 
HMBC NMR spectrum (Figure 66) again shows the correlation between the NH 
proton and the carbonyl of the carbamoyl group. Mass spectrometric analysis of the 
gluconamide 186 shows the presence of the molecular ion at m/z 506 with 24% 
abundance relative to the base peak at m/z 505.    
 
Scheme 42. Synthesis of the acetylated derivative 187.  
                                                    
 
 
 
Figure 66. HMBC NMR spectrum of the gluconamide 186 in CDCl3. 
NHC=O 
NH 
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2.4.2. ATP mimics from resorcinol 187                                                                                
 
Deprotonation of one of the hydroxyl groups of resorcinol with 1 e quivalent of 
NaH,169 followed by treatment with different alkylating and acylating agents,169,178
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afforded a set of primary substitution products as outlined in Scheme 43.                                                                                   
                  
                                                                                                                                                
Scheme 43. ATP mimics derived from resorcinol.                                                           
 
Resorcinol 187 in dry THF was deprotonated with 1 e quivalent of NaH and then 
treated with 1 e quivalent of allyl bromide169 under reflux to afford the allylated 
derivative 188 in 28% yield (Scheme 43). However, all attempts at dihydroxylating 
188 with oxidizing agents, such as CTAP, KMnO4 and NaIO4 in the presence of 
RuCl3
  
 catalyst were unsuccessful. 
Resorcinol 187 was similarly deprotonated and boiled under reflux with 1 equivalent 
of chloroacetyl chloride.179 The reaction was repeated several times but each time the 
di-acylated product 189A was obtained instead of the desired mono-acylated product. 
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When 1 equivalent acetoxyacetyl chloride was used instead of chloroacetyl chloride, 
the di-acylated product 190A was obtained repeatedly instead of the desired mono-
acylated product.  
 
However, when resorcinol 187 was stirred with 2,3,4,5,6-pentaacetylgluconoyl 
chloride 131 in pyridine,167,168 the desired mono-ester 191 was obtained in 24% yield 
(Scheme 43). The 1
 
H NMR spectrum of compound 191 (Figure 68) shows the 
expected acetyl and methine protons, while MS analysis revealed the molecular ion 
peak at m/z 498.  
Resorcinol was again deprotonated with 1 equivalent of NaH and then treated with 1 
equivalent of acryloyl chloride169 (Scheme 43). In this case however, both the mono-
acrylic and di-acrylic esters were obtained in very low yields. Attempts to improve the 
yield of the monoester by using 1 equivalent of KOH in ethanol as base appeared to 
result in the di-acrylic ester alone. Spectroscopic analysis confirmed the formation of 
both products. 1
 
H NMR spectra of both esters are shown in Figures 69 and 70 and it is 
clearly evident from integration data that both products have been isolated. Mass 
spectrometric analysis of the mono-ester 192 shows the presence of the molecular ion 
at m/z 164 in 97% abundance relative to the base peak at m/z 27, while the mass 
spectrum of the di-ester 192A shows the presence of the molecular ion at m/z 218 with 
80% abundance relative to a base peak at m/z 27. 
Generally the desired mono-acylation proved difficult to achieve, except in the case of 
gluconoylation. Acylation of one of the resorcinol hydroxyl groups would increase the 
acidity of the remaining hydroxyl group relative to resorcinol itself thus favouring 
further deprotonation and formation of the di-acylated product (Figure 67). Formation 
of the mono-gluconoyl derivative can be argued to be due to steric hindrance by the 
first gluconoyl moiety on the molecule making the now more acidic second hydroxyl 
group less accessible to acylation.     
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Figure 67. Explanation for di-acylation in resorcinol derivatives. 
                                                                                                                                                  
 
 
 
 
Figure 68. 400 MHz 1H NMR spectrum of compound 191 in CDCl3
                                                                                                                                                
.     
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Figure 69. 400 MHz 1H NMR spectrum of the mono-acrylic ester 192 in CDCl3
  
.   
 
 
 
 Figure 70. 400 MHz 1H NMR spectrum the of di-acrylic ester 192A in CDCl3
 
.         
2.4.3. ATP mimics from 3-aminophenol  
                                                                    
Deprotonation of the amino substituent on 3 -aminophenol 193 with NaH and 
treatment with different alkylating and acylating agents was expected to afford a set of 
primary substitution products (Figure 71). While regioselectivity might have been 
expected to be a major problem, the use of one equivalent of NaH169 for deprotonation 
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of the substrate worked very well in achieving mono-alkylation and mono-acylations 
at the amino nitrogen.                                                                                                               
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Figure 71. General approach to 3-aminophenol derivatives.    
                                                                                                                                            
2.4.3.1. Preparation of N-allyl-3-hydroxyaniline 194, N-allyl-3-allyloxyaniline 194A 
and N,N-diallyl-3-hydroxyaniline 194B  
 
Treatment of 3-aminophenol 193 with NaH and allyl bromide169
                                                                                                                                                   
 afforded 194, the 
desired allylated intermediate with two other allylated products 194A and 194B.                                                                               
OH
NH2
OH
N
H
Br
THF,NaH
194
193
OH
NN
O
H
194A 194B
+ +
 
                                                                                                                          
Scheme 44. Synthesis of compounds 194, 194A and 194B. 
                                                                                                                                                                                                                                                                                       
In the comparative 1H NMR spectra (Figure 72) of N-allyl-3-hydroxyaniline 194, N-
allyl-3-allyloxyaniline 194A and N,N-diallyl-3-hydroxyaniline 194B, the 1'-methylene 
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protons have similar chemical shift values (ca. 3.8 ppm), while the methyleneoxy 
protons in the O-allylated moiety 194A resonate downfield at 4.51 ppm because of the 
greater de-shielding effect of the oxygen atom. It is also observed that the 2'-H (5.97 
ppm) and 2"-H (6.07 ppm) vinylic methine protons in the N,O-di-allylated product 
194A resonate as multiplets at slightly different chemical shifts, while the 
corresponding methine protons in the N,N-di-allylated  product 194B resonate as a 
multiplet at 5.58 ppm  being in the same chemical environment. The C-3' vinylic 
carbons in the N-allylated systems 194 and 194A (Figure 73) resonate at similar 
chemical shift values (ca. 116 ppm), while the corresponding nuclei in the N,O-di-
allylated system resonate at different chemical shift values. MS analysis of the 
products gave the following results: compound 194 showed the presence of the 
molecular ion at m/z 149 as the base peak, compound 194A showed the presence of 
the molecular ion at m/z 189 with 95% abundance relative to the base peak at m/z 121, 
while 194B showed the presence of the molecular ion at m/z 189 as the base peak.                                                                                  
                                                                                                                                                                                         
 
 
 
 
 
Figure 72. Comparative 400 1H NMR spectra of 194, 194A and 194B, in CDCl3.                                                                                                                                                   
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Figure73. Comparative partial 100 MHz 13C NMR spectra of compounds 194, 194A 
and 194B in CDCl3
 
.  
Attempts to di-hydroxylate the mono-allylated product 194 with different agents such 
as CTAP, KMnO4 and NaIO4 
               
were unsuccessful - a pattern observed with earlier 
systems.                                                                                                         
2.4.3.2. Preparation of 2-chloro-N-(3-hydroxyphenyl)acetamide 195 and diethyl 
{[(3-hydroxy-phenyl)carbamoyl)methyl}phosphonate 196                                              
 
2-Chloro-N-(3-hydroxyphenyl)acetamide 195 was obtained in 76% yield by treating 
3-aminophenol in dry THF under nitrogen with NaH followed by chloroacetyl 
chloride179
 
 under reflux (Scheme 45). The correlation between the NH proton and the 
carbonyl carbon can be observed in the HMBC spectrum of compound 195, 
confirming that the substitution had occurred at the amino group and not the hydroxyl 
group (Figure 74).  
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C-3' and C-3" 
194 
 
194A 
 
194B 
 
___________________________________________________________  Discussion                                                                                                                                          
 96 
OH
NH2
Cl
O
OH
NH
P
O
N
O
OO
H
OH
193
195
196
O
Cl
Cl P(OEt)3
THF, NaH
 
Scheme 45. Route to the phosphonate ester 197.    
    
 
 
          
                                                                                                                                                                         
Figure 74. HMBC NMR spectrum of 195 in DMSO-d6
                                                                                                                                                      
.                                                                                                                                                  
Phosphorylation of 195 with triethyl phosphite (Arbuzov reaction)180 afforded the 
diethyl phosphonate ester 196 in 48% yield. The protons and carbon of the CH2P 
group both resonate as doublets due to coupling to the 31P nucleus in the 1H and 13C 
NMR spectra, respectively (Figure 75). The C=O is also observed to be split by the 
31P with a coupling constant of 4.1Hz 31P. The phosphorous 31
 
P signal is at 24.2 ppm.                                                                                          
NHCO 
NH 
Corr. between 
NH and C=O 
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Figure 75. Coupling of 31P to (a) CH2 and (b) CH2
                                                                                              
 and C=O in compound 196. 
 Interestingly, the phosphonate ester 196 was found to inhibit the DOX-P 
reductoisomerase enzyme of the malaria parasite Plasmodium faciparum (PfDXR) 
CH2P 
CH2P 
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both in vitro (in Biochemistry Department at Rhodes) and from Saturation Transfer 
Difference (STD)188,189
     
 NMR spectroscopy experiments (in Chemistry). The protein-
ligand interaction was confirmed by the presence of ligand proton signals in the 
PfDXR protein spectrum (Figure 76). The implication of this observation is that 
although, the phosphonate ester 196 was made to inhibit the Mycobacterium 
tuberculosis enzyme glutamine synthetase, it is to be explored in our group as a 
potential therapeutic for malaria, and analogues are currently being made!               
 
 
 
 
          
Figure 76. 600 MHz 1
 
H STD NMR spectrum of 196 and PfDXR showing interaction 
between protein and ligand.                                                                                           
2.4.3.3. Preparation of 2-acetoxy-N-(3-hydroxyphenyl)acetamide 197  
 
2-Acetoxy-N-(3-hydroxyphenyl)acetamide 197 was isolated pure on treating 
deprotonated 3-aminophenol 193 with acetoxyactyl chloride178 (Scheme 46). All the 
proton and carbons are accounted for in the 1H NMR and 13C NMR spectra, 
respectively. The methyl signal is visible at 2.11 ppm while the methylene carbon 
resonates at 62.5 ppm The OH and NH protons resonate at 9.39 ppm and 9.92 ppm, 
respectively, while the amide and ester carbonyls resonate at 165.2 ppm  and 169.9 
ppm, respectively, as determined from the correlations between corresponding proton 
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and carbon signals in the HMBC spectrum (Figure 77). High-resolution mass 
spectroscopic analysis shows the presence of the molecular ion at m/z 209.068446 
with 40% abundance relative to the base peak at m/z 109.053492.                                                      
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Scheme 46. Route to the ester 197.        
                                                                                                                                     
 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
 
Figure 77. HMBC NMR spectrum of compound 197 in DMSO-d6
   
.  
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2.4.3.4. Preparation of 2,3,4,5,6-pentaacetyl-N-(3-hydroxyphenyl)gluconamide 198 
 
2,3,4,5,6-Pentaacetyl-N-(3-hydroxyphenyl)gluconamide 198 was isolated successfully 
from the reaction between 3-aminophenol 193 and acid chloride178 131 (Scheme 47). 
The five acetoxymethyl groups are accounted for by the fifteen protons corresponding 
to the series of singlets that resonate between 2.24 and 2.01 ppm in the 1H NMR 
spectrum (Figure 78). In the 13
                            
C NMR spectrum, the presence of only four carbon 
signals corresponding to five methyl carbons is attributed to the coincidence of two of 
the signals. Mass spectrometric analysis confirmed the formation of 198 as the 
molecular ion is prominent at m/z 497.450192 as the base peak.                
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Scheme 47. Route to the acetylated derivative 198. 
 
 
                                                                                                                                              
Figure 78. 400 MHz 1H NMR spectrum of compound 198 in CDCl3.  
5 × CH3 
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Figure 79. 100 MHz 13C NMR spectrum of compound 198 in CDCl3
  
. 
2.4.3.5. Reaction of 3-aminophenol with acryloyl chloride                                                            
 
Treatment of 3-aminophenol 193 in dry THF with 1 e quivalent of NaH at 0°C, 
followed by 1 equivalent of acryloyl chloride,169
 
 afforded both the mono-acylated and 
di-acylated products 199 and 199A. The products were separated and fully 
characterized but the yield of the acrylamide 199 was too small for the reaction to be 
carried further.                                                                                                                               
5 × CH3 
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Scheme 48. Route to acrylic amide 199 and acrylic ester 199A                    
   
2.4.4. ATP mimics from 3-aminobenzyl alcohol                                                             
 
Deprotonation of the amino substituent of 3-aminobenzyl alcohol 199 with NaH and 
treatment with different alkylating and acylating agents was expected to afford a 
further set of primary substitution products as scaffolds for elaboration to ATP 
mimics (Figure 80). 
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Figure 80. General approach to 3-aminobenzyl alcohol derivatives.                                                                                                                                                                                                                                                                                                                               
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2.4.4.1. Reaction of 3-aminobenzylalcohol with allyl bromide  
 
Treatment of 3-aminobenzyl alcohol 200 with NaH and allyl bromide169 afforded the 
desired product N-allyl-3-(hydroxymethyl)aniline 201 in 10% yield together with  N-
allyl-3-(allyloxymethyl)aniline 201A, N,N-diallyl-3-(hydroxymethyl)aniline 201B and 
3-(allyloxymethyl)aniline 201C (Scheme 49). The structures of all four products were 
confirmed by spectroscopic methods, the assignments being based largely on a 
comparison of the allyl group signals in each compound. Thus, from the inspection of 
the spectra of all four products (Figure 81), it is apparent that the N-allyl methylene 
protons resonate at ca. 3.8 ppm, the O-allyl methylenes at ca. 4.0 ppm and the 
hydroxymethylene protons at ca. 4.6 ppm. The structural assignments are consistent 
with the 13C, DEPT135, HSQC and HMBC data and are supported by the 13
                                                                                                                                                                                                                                 
C NMR 
predicted values (Section 2.5).  
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Scheme 49. Allylation of 3-aminobenzylalcohol 200.                                               
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Figure 81. Comparison of 400 MHz 1H NMR spectra of compounds 201, 201A, 201B 
and 201C in CDCl3
 
.   
 2.4.4.2. Reaction of 3-aminobenzyl alcohol with chloroacetyl chloride and acryloyl 
chloride  
 
The N,O-bis-chloroacetylated product 202A was obtained in 95% yield on stirring 3-
aminobenzyl alcohol 200 with chloroacetyl chloride179 under nitrogen. In another 
reaction a mixture of both the amide 202 and the bis-chloroacetylated product 202A 
were obtained on refluxing deprotected (using NaH) 3-aminobenzyl alcohol 200 with 
1 equivalent of chloroacetyl chloride (Scheme 50). In the HMBC spectrum of the 
amide 202 (Figure 82), the chloromethylene protons were observed to correlate with 
the carbonyl carbon only, while hydroxymethylene protons correlate with aromatic 
carbons. The hydroxymethylene protons resonate as a singlet at 4.50 ppm while the 
chloromethylene proton singlet is at 4.42 ppm . The two pairs of chloromethylene 
protons in the bis-acylated product 202A may be differentiated by examining the 
HMBC spectrum (Figure 83). The carbonyl carbon signal at 167.1 ppm  correlates 
with the 1'-methyleneoxy signal at δ 5.19 ppm as well as with the 4'-chloromethylene 
signal at 4.01 ppm , making it possible to distinguish between the amide and ester 
methylene signals as well as the corresponding carbonyl carbon signals. The Mid-IR 
spectrum of compound 202A shows both an ester C=O absorption band at 1747 cm-1 
NCH2 
CH2OH CH2OH 
2 ×  NCH2 
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and an amide C=O absorption band at 1664 cm-1
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 (Figure 84). MS analysis showed the 
presence of the molecular at m/z 199 in 10% abundance relative to the base peak at 
m/z 198 for compound 202, while the molecular ion for compound 202A was 
observed at m/z 276 as the base peak.                                                                                                                                  
 
 
Scheme 50. Routes to the Arbuzov product 203, and acryloyl chloride derivatives 204 
and 204A.   
 
Phosphorylation of the mono-acylated product 202 (Scheme 50) with triethyl 
phosphite (Arbuzov reaction)180 afforded the expected phosphonate ester 203 in 37% 
yield. The protons and carbon signals for the CH2P moiety are both split due to 
coupling with the 31P nucleus (Figures 85 and 86), while the C=O signal exhibits a 
doublet with a coupling constant of 129.9 H z due to coupling with 31P. The 
phosphorous 31P signal is observed at 23.5 ppm. High-resolution MS analysis of 203 
showed the presence of the molecular at m/z 301.275911 as the base peak.                    
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Figure 82. HMBC spectrum of the mono-acylated product 202 in CDCl3
 
.  
Reaction of 3-aminobenzyl alcohol 200 in dry THF with 1 e quivalent NaH at 0°C, 
followed by 1 equivalent acryloyl chloride, afforded a mixture of both the acrylamide 
204 and the acrylate ester 204A (Scheme 50). The products were separated and 
characterized spectroscopically, but the yields were too low for the reactions to be 
carried further in the available time.               
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Figure 83. Partial HMBC spectrum of the di-acylated product 202A in CDCl3
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Figure 84. Mid-IR spectrum of 202A as solid deposit. 
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Figure 85. 400MHz 1H NMR of compound 203 in CDCl3
 
.  
 
 
 
Figure 86. 100 MHz 13C NMR spectrum of compound 203 in CDCl3
 
.    
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2.4.4.3. Reaction of 3-aminobenzyl alcohol with acetoxyacetyl chloride and 
2,3,4,5,6-pentaacetylgluconoyl chloride      
 
2-Acetoxy-N-[(3-hydroxymethyl)phenyl]acetamide 205 was isolated pure on treating 
deprotonated 3-aminobenzyl alcohol 200 with acetoxyacetyl chloride179
 
 (Scheme 51). 
In the HMBC spectrum (Figure 87), correlation is obtained between the methyl signal 
at 2.19 ppm and the ester carbonyl signal at 169.6 ppm, while the amide C=O carbon 
resonating  a t 165.3 ppm correlates with the 2-methylene signal at 4.63 ppm. High-
resolution mass spectrometric analysis shows the presence of the molecular ion at m/z 
223.08369 as the base peak.  
The 2,3,4,5,6-pentaacetyl-N-(3-hydroxyphenyl)gluconamide derivative 206 was also 
isolated successfully from the reaction between 3-aminobenzyl alcohol 200 and the 
gluconoyl chloride167,168 131 (Scheme 51). The five acetoxymethyl groups are 
accounted for by the fifteen protons resonating as a series of singlets between 2.02 
and 2.24 ppm in the 1H NMR spectrum (Figure 88); the overlapping carbon-13 signals 
at ca. 20 ppm correspond to the five methyl groups in the 13
                                                      
C NMR spectrum of 206, 
but six discrete signals are evident in the carbonyl carbon region at ca. 163-171 ppm 
(Figure 89). MS analysis confirmed the formation of compound 206 with the 
molecular ion appearing at m/z 511.16685 as the base peak.                
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Scheme 51. Routes to amide ester 205 and acetylated derivative 206          
___________________________________________________________  Discussion                                                                                                                                          
 110 
 
 
 
Figure 87. Partial HMBC spectrum of compound 205 in CDCl3
 
.  
 
 
Figure 88.  400 MHz 1H NMR spectrum of compound 206. 
5 × CH3 
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___________________________________________________________  Discussion                                                                                                                                          
 111 
 
 
 
 
 
Figure 89.  100 MHz 13
 
C NMR spectrum of compound 206. 
2.4.5. ATP mimics from 3-hydroxy- and 3-aminobenzoic acid                     
 
Issues of regioselectivity also arose in the reaction of 3-hydroxy- and 3-aminobenzoic 
acid with allyl bromide.169 Treatment of both substrates with 1 e quivalent NaH, 
followed by allyl bromide yielded the mono-allylated products 208 and 210 
respectively, while use of 2 equivalents of NaH yielded the di-allylated products 208A 
and 210A, respectively, (Scheme 52). The position of the methylene proton signals in 
the 1H NMR spectra of all these allylated compounds as well as comparisons of 
experimental and predicted 13C NMR data were used to confirm their structures. In 
the 1H NMR spectra of compounds 208 and 210, the 1'-methylene protons resonate at 
4.81 ppm and 3.74, respectively, (Figure 90), confirming that these methylene groups 
are in different chemical environments in the mono-allylated compounds.                       
5 × CH3 
 
6 × C=O 
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Scheme 52. Synthesis of compounds 208, 208A, 210 and 210A.                                                              
 
These values are very similar to the predictions by the Modgraph NMR predict 
programme (Section 2.5) which indicate their chemical shifts to be 4.92 ppm and 3.73 
ppm, respectively, confirming that the amino group was mono-allylated in compound 
210 while the carboxylic acid group was allylated in the mono-allylated product 208.  
In the di-allylated compound 210A, the 2'- (at δ 5.94 ppm)  and 2"- (at δ 6.02 ppm) 
methine protons are clearly observed as separate multiplets confirming that there is no 
di-substitution on the amine nitrogen (Figure 91). Unfortunately, attempts at 
dihydroxylating these alkenes were again unsuccessful.  
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Figure 90. Comparison of 400 MHz 1
 
H NMR spectra of mono-allylated derivatives 
208 and 210. 
 
 
 
 
         
 
1'-CH2 
1'-CH2 
208 
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Figure 91. 400 MHz 1H NMR spectra of di-allylated derivative 210A in CDCl3
 
.       
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2.5. Application of NMR chemical shift prediction programmes   
         
The Modgraph NMRPredict programme (version 3.2.2) was used to verify chemical 
shift assignments of selected systems. This programme can be used to predict both 1H 
and 13C chemical shifts. The Hierarchical Organization of Spherical Environments 
(HOSE) code and the Neural Network (Nnet) algorithm are the two approaches used 
for prediction. The HOSE code looks at a carbon atom relative to its spherical 
environments and uses this information based on the NMR spectral data base of 
thousands of compounds it contains as references. The draw-back of this approach is 
that if the query compound is not well represented in the data base, the prediction is 
not reliable as the programme can only make a prediction to a maximum of two 
spheres. Another disadvantage of this method is that it uses the contents of the data 
base and, hence, it is prone to inherent errors or bias. The Nnet is a general and more 
reliable approach as it is much more error tolerant and more accurate in predicting the 
chemical shifts of atoms not encountered before.190  The Modgraph data presented in 
this section is a combination of both the HOSE and Nnet approaches. For comparative 
purposes, use was also made of the ChemWindow C-13 prediction module. The 
relevant 13
 
C data is tabulated on the following pages and, while comment is generally 
limited to particular assignments, significant discrepancies between experimental and 
predicted data are highlighted in the various tables.   
2.5.1. NMR chemical shift prediction for adenosine analogues  
 
2-(6-Aminopurin-9-yl)-5[7-diethylphosphoryloxy)-2-5-dioxaheptyl]-3,4-dihydroxy-
tetrahydrofuran 3,4-acetonide 138                                          
 
The experimental chemical shifts assigned for compound 138 were compared with 
shift values provided by both NMR predict programmes, Modgraph and 
ChemWindow. Generally the Modgraph data is more comparable to the experimental 
data than the ChemWindow data. The CH3CH2OP protons resonate as superimposed 
triplets at 1.38 ppm in the experimental spectrum while Modgraph predicts them to be 
at 1.29 ppm. The 13C signals for the polyoxyalkyl centres, C-1", C-3", C-4", C-6" and 
C-7", are present in the 13C NMR spectrum between 66.6 and 66.7 ppm, while both 
ChemWindow and Modgraph predict them to be between 66.5 and 71.2 ppm (Table 
3). However, the ChemWindow predictions tend to vary significantly from the 
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experimentally established values, over-estimating certain aromatic carbons by as 
much as 9 ppm  and under-estimating alkyl carbons by as much as 13 ppm  (data 
highlighted in yellow).             
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Table 3. Experimental and predicted 13
                      
C NMR data for compound 138   
13 a C nuclei b c 
CH3 16.02 P 15.8 14.3 
CH3 16.09 P 15.8 14.3 
C.(CH3) 25.3 2 25.9 28.6 
C.(CH3) 27.1 2 25.9 28.6 
CH2 64.08 P 63.8 58.6 
CH2 64.10 P 63.8 58.6 
1",3",4”,6"and 
7" 
66.6-
66.7 
66.3-
71.4 
66.5-
71.2 
5 81.8 86.2 71.6 
3 84.4 85.2 78.1 
4 85.4 81.7 72.7 
2 91.0 91.1 83.1 
C.(CH3) 114.7 2 114.1 101.6 
5' 119.9 119.7 113.7 
8' 140.2 139.4 147.9 
4' 149.0 149.0 157.2 
2' 150.8 152.4 151.1 
6' 154.4 156.0 156.1 
 
a = Experimental values, b = Modgraph predict, c = ChemWindow predict                    
 
 
 
 
 
 
 
 
 
138 
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2-(6-Aminopurin-9-yl)-5-[(2-chloroacetoxy)methyl]-3,4-dihydroxytetrahydrofuran 
3,4-acetonide 141 and 2-[6-(2-chloroacetamido)purin-9-yl]-5-[(2-chloroacetoxy)-
methyl]-3,4-dihydroxytetrahydrofuran 3,4-acetonide 141A                
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Table 4. Experimental and predicted 13
 
C NMR data for compounds 141 and 141A  
                             142            142A   
13 a C nuclei b c         13 a C  
nuclei 
b c 
C.CH 25.3 3 25.9 28.6  C.CH 25.3 3 25.9 28.6 
C.CH 27.1 3 25.9 28.6  C.CH 27.1 3 25.9 28.6 
CH2 44.5 Cl 40.6 48.3  3" 40.5 40.6 48.3 
1" 65.4 64.0 65.1  2''' 44.6 43.8 48.6 
5 81.5 83.8 70.5  1" 65.3 64.0 65.1 
3 84.1 83.2 77.8  5 81.3 83.8 70.5 
4 84.6 80.9 72.6  3 84.1 83.2 77.8 
2 90.9 91.9 82.8  4 84.6 80.9 72.6 
C.(CH3) 114.7 2 114.1 101.6  2 91.1 91.1 82.8 
 5' 120.3 119.7 113.7  C.(CH3) 115.0 2 114.1 101.6 
8' 139.8 139.4 147.9  5' 122.5 122.6 119.6 
4' 149.1 149.0 157.2  8' 142.8 142.2 147.9 
2' 153.1 152.4 151.1  4' 148.5 150.2 157.6 
6' 155.7 156.0 156.1  2' 152.4 151.9 149.7 
C=O 166.8 167.5 166.4  6' 166.0 155.1 147.5 
     1'''-C=O 166.8 166.9 163.2 
     1-C=O 166.83 167.5 166.4 
 
a = Experimental values, b = Modgraph predict, c = ChemWindow predict                    
 
In the 1H NMR spectrum of compound 141 the 3"-CH2 protons and 2'-H aromatic 
proton resonate as singlets at 4.00 ppm and 8.32 ppm, respectively in the experimental 
spectrum while Modgraph predicts them to be at 4.34 ppm and 8.58 ppm. The signals 
for the C-8' and carbonyl 13C signals observed at 139.4 ppm  and 166.8 ppm are 
predicted to be at 139.4 a nd 167.5 ppm  by Modgraph and at 147.9 and 166.4 ppm  
respectively by ChemWindow. The ChemWindow 13C value for C-8' is clearly not 
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comparable with the Modgraph and experimental data values. The ChemWindow 
values for the tetrahydrofuran carbons, C-2, C-3, C-4 and C-5, similarly exhibit large 
discrepancies from the experimental values. In compound 141A, the di-acylated 
derivative, the 3"-H and 2'''-H protons resonate at 4.01 ppm and 4.68 ppm respectively 
and are predicted by Modgraph to be resonate at 4.34 ppm and 3.63 ppm respectively. 
The C-3" carbon signal at 40.5 ppm is predicted to resonate at 40.6 ppm and 48.3 ppm 
by Modgraph and ChemWindow respectively while the C-2''' signal at 44.6 ppm is 
predicted by Modgraph and ChemWindow to resonate at 43.8 ppm and 48.6 ppm. In 
fact, going down Table 4, the discrepancies between the ChemWindow values, on one 
hand, and the Modgraph and experimental values, on t he other, continue to be 
significant; in some cases, the ChemWindow values are over-estimated by up to 9 
ppm or under-estimated by up to 14 ppm.  
 
 
2 -(6-Aminopurin-9-yl)-5-acetoxyacetyl-3,4-dihydroxytetrahydrofuran 3,4-acetonide 
140  and 2-[6-(acetoxyacetylamino)purin-9-yl)-5-acetoxyacetyl-3,4-dihydroxytetra-
hydrofuran 3,4-acetonide 140A 
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There is a generally good corellation between the experimental assignments and the 
Modgraph 13
 
C predict values for compounds 140 and 140A (Table 5). ChemWindow 
values however show considerable differences from the other two values in some 
instances as indicated by the highlighted data. Again the discrepancies are far greater 
for the ChemWindow data which over-estimates by as much as 8 ppm  and under-
estimates by as much as 13 ppm.         
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Table 5. Experimental and predicted 13
  
C NMR data for compounds 140and 140A 
140 140A    
13 a C 
nuclei 
b c  13 a C 
nuclei 
b c 
7" 20.4 20.7 17.0  7" 20.4 20.7 17.0 
C.CH 25.3 3 26.6 28.6  5''' 20.6 20.7 16.6 
C.CH 27.1 3 26.6 28.6  C.CH 25.3 3 26.6 28.6 
4" 60.5 63.0 69.7  C.CH 27.1 3 26.6 28.6 
1" 64.6 63.0 65.6  4" 60.4 63.0 69.7 
5 81.6 85.2 70.5  1" 64.4 63.0 65.6 
3 84.1 84.5 77.8  2''' 64.6 61.6 70.0 
4 84.7 82.3 72.6  5 81.4 85.2 70.5 
2 90.9 90.6 82.8  3 84.1 84.5 77.8 
C.(CH3) 114.7 2 112.0 101.6  4 84.7 82.3 72.6 
5' 120.4 119.5 113.7  2 91.1 90.6 82.8 
8' 139.8 140.9 147.9  C.(CH3) 114.9 2 112.0 101.6 
4' 149.2 151.1 157.2  5' 122.0 121.8 119.6 
2' 153.2 152.4 151.1  8' 142.7 141.8 147.9 
6' 155.5 154.5 156.1  4' 148.7 150.0 157.6 
3" 167.4 169.3 171.0  2' 150.7 151.0 149.7 
6" 170.3 171.3 171.0  6' 152.3 154.7 147.5 
     1''' 167.3 167.9 168.2 
     3" 167.3 169.3 171.0 
     4''' 170.3 171.3 171.0 
     6" 170.3 171.3 171.0 
 
a = Experimental values, b = Modgraph predict, c = ChemWindow predict  
 
2.5.2 NMR chemical shift prediction for adenine analogues  
 
6-(N-Allylamino)purine 150 and 1-allyl-[6-amino(N-allylamino)]purine 150A                        
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The chemical shift predictions for the 1'-methylene carbons in compound 150 are 
quite different; Modgraph under-estimates by 4 ppm  and ChemWindow over-
estimates by 9 ppm. The predictions for the C-3' carbon compare well with each other 
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(ca. 114 ppm) but both under-estimate the experimental value by 5 ppm. The 
experimental assignments for the pyrimidine carbons are observed to correlate well 
with the Modgraph prediction values (Table 6). The predictions for the C-3' and the 
C-3" methylene carbons in compound 150A correlate reasonably with experimental 
values but, generally, the ChemWindow values tend to be considerably less accurate.  
 
Table 6. Experimental and predicted 13
                           150        150A      
C NMR data for compounds 150 and 150A     
13 a C 
nuclei 
b c  13 a C 
nuclei 
b c 
1' 46.1 42.0 54.8  1' 45.7 42.0 54.8 
3' 119.6 114.8 114.9  1" 45.7 45.5 55.6 
5 120.4 126.2 113.7  3' 116.4 114.8 114.9 
2' 131.2 136.0 134.3  3" 118.9 117.4 114.9 
8 144.2 144.2 147.9  5 119.6 126.2 113.7 
4 149.3 151.9 157.2  2" 131.9 133.7 134.3 
6 151.9 152.3 156.1  2' 134.3 136.0 134.3 
2 152.5 150.0 151.1  8 139.7 141.1 147.9 
     4 152.5 151.1 157.2 
     2 153.0 152.4 151.1 
     6 154.7 158.1 156.1 
 
a = Experimental values, b = Modgraph predict, c = ChemWindow predict    
 
 
 
2.5.3 NMR chemical shift prediction for truncated adenine analogues 
 
While the discussion in Sections 2.5.1 and 2.5.2 has focused on an assessment of the 
relative accuracy of the two prediction approaches, Sections 2.5.3 – 2.5.5 will 
illustrate their application in supporting structural assignments. 
 
 
 
 
 
___________________________________________________________  Discussion                                                                                                                                          
 121 
3-Hydroxyphenyl acrylate 192 and 3-(acryloyloxy)phenyl acrylate 192A     
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Table 7. Experimental and predicted 13
                192                               192A         
C NMR data for compounds 192 and 192A  
13 a C 
nuclei 
b c  13 a C 
nuclei 
b c 
2 109.1 106.2 108.6  2 115.4 113.5 114.3 
6 113.2 112.3 114.0  4 119.0 117.7 118.2 
4 113.5 114.0 112.5  6 119.0 117.7 118.2 
2' 127.8 127.9 130.4  2' 127.6 127.9 130.4 
5 130.1 131.1 130.3  2" 127.6 127.9 130.4 
3' 133.0 130.9 128.8  5 129.7 131.0 129.3 
1 151.3 154.3 154.5  3' 132.9 130.9 128.8 
3 156.6 158.4 157.7  3" 132.9 130.9 128.8 
C=O 164.0 164.8 162.0  1 150.9 152.5 153.5 
     3 150.9 152.5 153.5 
     1'-C=O 164.1 164.8 162.0 
     1"C=O 164.1 164.8 162.0 
a = Experimental values, b = Modgraph predict, c = ChemWindow predict     
 
There is a generally good correlation between the experimental assignment, the 
Modgraph predict values and the ChemWindow 13
 
C values for compound 192, with 
the C-1 quartenary and C-2' methine carbons experimental assignments varying from 
prediction values by ca. 3 ppm (Table 7). Similar patterns are observed for compound 
192A, with the C-1 and C-3 quartenary carbons being indistinguishable and, hence, 
having the same chemical shifts and confirming formation of the di-substituted 
product. 
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N-Allyl-3-hydroxyaniline 194, N-allyl-3-allyloxyaniline 194A and N,N-diallyl-3-
hydroxyaniline 194B     
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Comparison of the 1'- and 1"- methylene assignments was used to establish the 
position of allylation in compounds 194, 194A and 194B. In all the compounds the 
experimental 1'-methylene carbon shifts compare very favourably with the Modgraph 
values (Tables 8 and 9); ChemWindow, however, over-estimates the chemical shifts 
by ca. 8 ppm. In compound 194A, the 1"-methylene carbon resonates at the higher 
chemical shift value of 68.6 ppm (Modgraph 69.0 ppm), consistent with acylation of 
the phenolic group. The aromatic carbon predictions for these compounds generally 
show good correlation with the experimental assignments as indicated in the Tables. 
 
 
 
 
 
 
 
 
 
 
194B 
194 
194A 
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Table 8. Experimental and predicted 13
     
C NMR data for compounds 194 and 194A  
        195        195A    
13 a C 
nuclei 
b c  13 a C 
nuclei 
b c 
1' 46.6 46.2 54.8  1' 46.5 46.2 54.8 
2 100.3 102.8 99.5  1'' 68.6 69.0 75.5 
6 105.0 105.3 104.9  2 99.7 101.7 98.0 
4 106.2 113.0 104.1  4 103.4 104.8 103.9 
3' 116.4 116.4 114.9  6 106.3 107.6 102.6 
5 130.1 130.9 130.7  3' 116.1 116.4 114.9 
2' 135.1 134.6 134.3  3" 117.3 117.7 115.1 
1 149.4 150.2 144.9  5 129.8 129.7 129.9 
3 156.6 159.0 158.1  2" 133.5 133.2 137.5 
     2' 135.3 134.6 134.3 
     3  149.4 150.6 144.1 
     1 159.8 159.8 159.6 
 
a = Experimental values, b = Modgraph predict, c = ChemWindow predict  
 
Table 9. Experimental and predicted 13
 
C NMR data for compound 194B  
13 a C 
nuclei 
b c 
1'-CH 52.7 2 51.4 59.6 
1"-CH 52.7 2 51.4 59.6 
2 99.6 151.1 100.3 
6 103.5 107.3 105.7 
4 105.3 113.0 105.2 
3' 116.0 117.8 114.9 
3" 116.0 117.8 114.9 
5 129.9 131.7 130.8 
2' 133.8 133.3 134.3 
2" 133.8 133.3 134.3 
1 150.2 151.1 145.9 
3 156.4 160.2 158.2 
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a = Experimental values, b = Modgraph predict, c = ChemWindow predict  
N-Allyl-3-(hydroxymethyl)aniline 201, N-allyl-3-[(allyloxy)methyl]aniline 201A,      
N,N-di-allyl-3-(hydroxymethyl)aniline 201B and 3-[(allyloxy)methyl]aniline 201C 
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Table 10. Experimental and predicted 13
             201             201A                                            
C NMR data for compounds 201 and 201A  
13 a C 
nuclei 
b c  13 a C 
nuclei 
b c 
1’-CH 46.5 2 46.2 54.8  1' 46.5 46.2 54.8 
CH2 65.6 OH 64.3 68.5  1" 71.0 71.0 73.0 
2 111.4 113.1 111.1  7-
CH
72.3 
2 
73.7 75.8 
6 112.2 117.2 111.2  2 112.15 114.13 111.4 
4 116.0 118.5 115.7  6 112.20 117.1 111.4 
3’ 116.2 116.4 114.9  3' 116.2 116.4 114.9 
5 129.4 129.6 129.5  3" 116.91 116.9 114.5 
2’ 135.3 134.6 134.3  4 116.93 118.7 116.0 
1 142.1 146.5 143.7  5 129.2 129.5 129.2 
3 148.3 143.5 141.7  2" 134.8 135.6 135.6 
     2' 135.3 134.6 134.3 
     3 139.4 142.2 138.0 
201B 
201 
201A 
201C 
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     1 148.2 147.1 143.4 
a = Experimental values, b = Modgraph predict, c = ChemWindow predict 
Table 11. Experimental and predicted 13
 
C NMR data for compounds 202B and 202C   
                             201B                           201C        
13 a C 
nuclei 
b c  13 a C 
nuclei 
b c 
1'-CH 52.7 2 51.4 59.6  1'-CH 71.0 2 71.0 73.0 
1"-CH 52.7 2 51.4 59.6  7 72.1 73.7 75.8 
CH 65.9 2 64.3 68.5  2 114.2 114.0 114.2 
2 110.8 115.1 111.9  6 117.0 114.7 114.2 
6 111.7 119.3 112.0  4 117.9 118.7 117.6 
4 114.9 119.2 116.8  5 129.2 129.4 129.2 
3' 116.0 117.8 114.9  2' 134.8 135.6 135.6 
3" 116.0 117.8 114.9  3 139.5 139.3 138.0 
5 129.3 130.6 129.6  1 146.5 146.5 146.6 
2' 133.8 133.3 134.3 
2" 133.8 133.3 134.3 
3 141.9 144.1 141.8 
1 148.9 147.4 144.7 
 
a = Experimental values, b = Modgraph predict, c = ChemWindow predict 
 
Comparison of the experimental and predicted 1'- and 1"- methylene 13
 
C chemical 
shifts was also used to establish the position of allylation in compounds 201, 201A 
201B and 201C (Tables 10 a nd 11). The Modgraph predicted values, in particular, 
correlate closely with the assignment of experimental data. Thus in compound 201, 
the signals at 46.5 a nd 65.6 ppm correspond to the N-allyl- and hydroxymethylene 
carbons, respectively. Allylation of the hydroxyl group (compound 201A) results in a 
downfield shift of the latter carbon signal to 72.3 ppm. In the N,N-di-allylated product 
201B, both N-allyl carbons resonate at 52.7 ppm – a signal which is absent resonate in 
the spectrum of the O-allylated product 201C.  
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2.5.4 NMR chemical shift prediction for allopurinol-derived Baylis-Hillman 
analogues 
 
1-(6-Bromo-3-methyl-2H-chromen-2-one)-4-(tetrahydropyran-2-yloxy)pyrazolo[3,4-
d]- pyrimidine 170A  
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Table 12. Experimental and predicted 13
 
C NMR data for compound 170A         
13 a C 
nuclei 
b c 
5" 22.7 25.6 28.0 
4" 24.8 19.7 21.0 
3" 29.3 30.6 32.7 
NCH 45.7 2 46.9 57.1 
6" 68.3 65.1 65.6 
2" 82.8 100.2 103.0 
3 106.1 127.8 130.4 
6 117.4 121.1 119.8 
8 118.3 120.0 123.5 
5' 120.2 110.8 99.9 
10 123.0 120.8 130.0 
5 130.7 129.7 129.9 
7 135.0 134.3 131.4 
2' 135.6 158.1 155.5 
7' 143.2 131.6 154.7 
4 150.0 134.6 132.9 
6' 151.7 166.8 174.5 
9 152.4 153.5 149.8 
4' 157.3 154.0 170.8 
C=O 160.7 162.4 162.0 
170A 
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   a = Experimental values, b = Modgraph predict, c = ChemWindow predict. 
 
Comparison of the experimental and Modgraph predicted data for the N-methylene 
carbon was used to confirm the formation of the coumarin 170A. If the chromene had 
been formed, the methylene carbon would have been in the lactone ring and resonated 
at a higher chemical shift (> 65 ppm ; Modgraph prediction: 68.7 ppm). There is a 
good correlation between the experimental assignment and the Modgraph predicted 
values for most of the pyran carbons except for the C-2" carbon. Some of the purine 
and coumarin ring predictions, however, show significant differences from the 
experimental data due, perhaps, to mutual shielding or deshielding of the linked, 
magnetically anisotropic aromatic systems.  
 
2.5.5. NMR chemcial shift prediction for 3-amino- and 3-hydroxybenzoic acid 
derivatives 208, 208A, 210 and 210A 
N
OHO
H
1
2
34
5
6
1'
2'
3'
N
O
O
H
1
23
4
5
6
1''
2''
3''
1'
2'3'
OH
O
O
1
23
4
5
6 1'
2'
3'
O
O
O
1'
2'
3'
1
2
3
4
5
6
1''
2''
3''
 
Tables 13 and 14 show the agreement between the 13C NMR experimental 
assignments and the predictions for the 1'-CH2 and 1"-CH2 carbons as well as other 
carbon atoms in each of the mono- and di-allylated products 208, 208A, 210 and 
210A. The data also confirms the structures proposed for the respective compounds. 
The argument is similar to that for compounds 194, 194A and 194B, a critical point 
being the resonance of the 1'-CH2
 
 group at ca. 65 ppm and the ester carbonyl carbon 
at ca. 166 ppm in each of the allyl esters 208, 208A and 210A.     
208 
208A 
210 
210A 
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Table 13. Experimental and predicted 13
           208           210      
C NMR data for compounds 208 and 210   
13 a C 
nuclei 
b c  13 a C 
nuclei 
b c 
1'-CH 65.8 2 65.6 69.5  1' 46.0 44.3 54.8 
2 116.4 115.5 116.9  3' 116.9 114.9 114.9 
3' 118.4 117.4 114.5  3 112.9 143.4 149.5 
4 120.4 122.2 120.0  4 115.0 117.8 117.5 
6 122.0 120.1 122.3  6 116.8 119.0 118.5 
5 129.7 129.5 129.8  2 117.3 117.0 113.9 
2' 131.4 134.1 135.6  1 119.4 133.2 131.4 
1 131.9 131.1 131.9  6 120.8 119.0 117.5 
3 155.9 155.5 157.2  5 129.8 128.9 129.2 
C=O 166.4 168.1 167.0  2' 134.2 136.0 134.3 
     C=O 148.2 167.8 172.0 
 
 a = Experimental assignment, b = Modgraph prediction, c = ChemWindow prediction 
 
Table 14. Experimental and predicted 13
   208A       210A 
C NMR data for compounds 208A and 210A.  
13 a C 
nuclei 
b c  13 a C 
nuclei 
b c 
1" 65.6 70.0 75.5  1' 46.4 44.3 54.8 
1' 69.0 65.6 69.5  1" 65.4 65.6 69.5 
2 115.1 115.7 115.4  2 113.6 114.8 113.5 
3" 117.9 117.5 115.4  3' 116.5 114.8 114.9 
3' 118.2 117.4 114.5  4 117.8 120.0 116.6 
4 120.2 121.6 118.5  3" 118.0 117.4 114.5 
6 122.2 120.8 121.3  6 118.7 118.6 118.1 
5 129.4 128.6 129.0  5 129.1 128.9 129.2 
1 131.5 131.4 131.1  1 131.0 132.5 131.3 
2" 132.2 134.5 137.5  2" 132.3 134.1 135.6 
2' 132.9 134.1 135.6  2' 134.9 136.0 134.3 
3 158.6 158.4 158.7  3 150.0 147.0 143.4 
C=O 166.1 168.1 167.0  C=O 166.0 168.1 167.6 
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a = Experimental assignment, b = Modgraph prediction, c = ChemWindow prediction 
 
 
2.6. Computer Modelling of ATP Mimics     
 
A vital tool in rational drug design is the use of computer modelling to explore 
enzyme-receptor interactions. A number of successes have been recorded in this 
rational approach to drug discovery in finding therapeutic agents such ritonavir and its 
analogues that are administered to AIDS patients191 and relenza192 for treating flu. 
Computer modelling at the molecular mechanics level has been used to explore the 
GS receptor-binding potential of compounds prepared in this study. The first step was 
to find the global minima of selected deprotected ATP analogues by subjecting each 
to a molecular dynamics routine, the assumption being that, in vivo, accessible ester 
moieties would be hydrolysed prior to binding. The most stable conformation, in each 
case, was subjected to various docking options in the receptor cavity of glutamine 
synthetase in silico, each option involving a different orientation and/or 
conformational change in the ligand. The crystal structure data for 1F52, the 
glutamine synthetase of Salmonella typhimurium co-crystallized with ADP reported 
by Eisenberg and co-workers (Figure 92)193,194,195
 
 was used for this study. The 
relevant residues with their catalytic roles both in the biosynthetic reaction as well as 
the allosteric control of the enzyme by adenylylation, as identified by Eisenberg, have 
been confirmed, in silico and are summarized below.   
2.6.1. Docking of ATP and ATP mimics into the MTB-GS receptor site                        
 
The computer modelling studies of the selected, synthesized ATP mimics were 
conducted on the ACCELERYS Cerius2 platform. The OFF METHODS and OFF 
SET UP modules were used for the conformational search while the LIGANDFIT 
module was used for receptor-docking. A reconstructed model of the crystal structure 
of MTB-GS determined by Eisenberg and co-workers was used and attention was 
focused on the ‘active site’ which is a region defined by amino acid residues within 
5Å of the ATP ligand site on G S. The divalent metal ions (Mg2+ or Mn2+) were 
adequately taken into consideration because of the vital role they play in phosphoryl 
transfer during nitrogen biosynthesis. Particular attention was given to residues which 
might interact with ATP, and we used the B-subunit (in light brown colour) of the 
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1F52 Salmonella GS, which contains one ATP binding site (Figure 93). The 
conformational homology and ‘active-site’ docking of ATP and selected mimics will 
be illustrated in the following sub-sections.    
                                       
 
Figure 92. Crystal structure of 1F52, the glutamine synthetase of Salmonella 
typhimurium co-crystallized with ADP. The structure is made up of 25 chains 
containing 9180 residues. Downloaded from the pdb site at 
http://www.rcsb.org/pdb/explore.do?structureId=1F52 . 
 
 
The following interactions were observed between ADP and amino acid residues in 
the ATP site in the B-subunit (Figure 94).  
i. Ser 273 acting as donor in hydrogen-bonding to the amino group on adenine; 
ii. Glu 129 interacting with ribose of ADP via donor hydrogen-bonding;  
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Figure 93. Reconstructed 1F52 Salmonella typhimurium GS with A-subunit (in light 
blue), B-subunit (in light brown), G-subunit (in yellow) and H-subunit (in light-
green), showing ADP molecules in the ATP sites and AMP molecules in the 
adenylylation sites.              
       
 
iii. Thr 223 interacting with ribose hydroxyl group via donor hydrogen-bonding;  
iv. Arg 355 acting as an acceptor via hydrogen-bonding with an oxygen of the  β-
phosphate group and the pyrimidine ring of ADP; 
v. His 271, Arg 344, His 210 and Glu 220 interacting with the phosphate groups 
of ADP via acceptor hydrogen-bonding. 
                   
A-subunit B-subunit 
G-subunit 
H-subunit 
AMP in 
adenylylation 
site 
ADP 
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Figure 94. ADP interaction with ‘active-site’ residues in GS, showing potential 
hydrogen-bonds in yellow, dashed lines.                          
 
2.6.1.1. Modelling of ATP in the GS active site                                          
 
ATP plays a vital role in biosynthesis and also in the covalent modification of GS by 
adenylylation, and it is important to explore its interaction with the active site in silico 
since no X-ray structure is available of ATP-bound GS. Hence, the global minimum 
of ATP was found by conducting a molecular dynamics conformational search at 
600K. ATP was then docked into the ‘B-sub-unit’ active site of GS (Figure 93) and its 
interaction with active-site residues and its binding potential were analyzed. The non-
bonded intermolecular interaction between the ligand and protein is measured in terms 
of the ‘Dock score’. The ‘Ligscore’ is a m easure of the protein-ligand interaction, 
Mn 469 
Mn 470 
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while ‘vdW’ is the Leonard-Jones soft potential. Table 15 s hows the scores for the 
best twenty, bound c onformations of ATP in descending order of the ‘dock score’. 
There are few differences between the interactions of ATP with active-site amino acid 
residues compared with ADP, but it was observed that ATP interacts with Lys 354 via 
acceptor hydrogen-bonding and with Arg 354 via donor hydrogen-bonding – 
interactions not exhibited by ADP. Figure 95 s hows the interaction of ATP with 
active site residues. 
 
 
 
Figure 95. ATP interaction with amino acid residues within 3Å in the ‘active-site’ of 
GS, showing potential hydrogen-bonds in yellow, dashed lines.  
  
 
 
 
Mn 469 
Mn 470 
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Table 15. Summary of scores of the docking of ATP into the ‘B-subunit’ GS active- 
site. 
 
Conformer Dock score 
(kcal/mol) 
Ligscore 
(kcal/mol) 
vdW 
energy 
(kcal/mol) 
1 87.41 -3.06 58.10 
2 64.10 -3.43 65.93 
3 40.16 -8.15 166.83 
4 31.93 -3.51 67.68 
5 30.31 -1.10 16.12 
6 26.05 -4.46 88.01 
7 18.49 -4.50 88.75 
8 14.83 -6.10 122.96 
9 7.89 -4.93 97.91 
10 0.06 -3.61 69.73 
11 -0.77 -14.96 312.73 
12 -12.56 -3.02 57.20 
13 -13.14 -6.27 126.75 
14 -25.75 -5.60 112.40 
15 -33.01 -0.58 4.88 
16 -35.02 -6.87 139.42 
17 -36.75 -9.38 193.18 
18 -38.32 -7.90 161.60 
19 -44.18 -2.09 37.18 
20 -47.15 -5.33 106.60 
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2.6.1.2. Computer modelling of adenosine, adenine and allopurinol derivatives in 
the GS active site                        
 
The homology of selected synthetic ATP mimics and their interaction with active-site 
residues were explored. A ‘target model’ alignment of each of the mimics with ATP 
was conducted using the DRUG DISCOVERY module in Cerius2
 
. The global 
minimum conformation of each of the analogues was aligned with ATP to check their 
in vacuo similarities with ATP. Docking of the energy-minimized mimics into the 
active-site of the enzyme in vacuo was undertaken and docking scores were examined 
to assess binding with the amino acid residues in the GS ‘active-site’ (Table 16).  
Table 16. Scores for the best binding conformations of ATP and selected adenosine, 
adenine and allopurinol derivatives. 
 
Compound Dock score  
(kcal/mol) 
Ligscore 
(kcal/mol) 
vdW 
(kcal/mol) 
ATP 87.41 -3.06 58.10 
132 -43.83 -12.29 255.55 
138 91.09 -2.56 47.25 
140 11.86 0.55 -19.33 
149 -52.76 -3.28 62.72 
170 44.61 1.64 -42.50 
 
The ‘target model’ alignment of compound 132 with ATP (in yellow) shown in Figure 
96 illustrates good structural homology and the ligand 132 was found to have 
common interactions with amino acid residues in common with those exhibited by 
ADP and ATP  (Figure 98).  In addition, the following interactions were observed. 
 
i. Lys 352 interacts with the 6-amino group via donor hydrogen-bonding; 
ii. Asn 280 and Arg 354  interacts with the 6-amino group via acceptor hydrogen-
bonding; 
iii. Mn 469 was found to be at a distance of 2.64Å to the terminal acetyl group of 
ligand 132. 
Figure 97 shows the alignment of the binding conformation of ATP with the binding 
conformation of ligand 132. While compound 132 exhibits good homology with ATP 
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when comparing both global minima (Figure 96) and fair homology when comparing 
binding conformations (Figure 97), it has a very low ‘dock score’. 
           
 
Figure 96. ‘Target model’ alignment of ATP (in yellow) with ligand 132. 
 
 
Figure 97. ‘Binding conformation’ alignment of ATP with ligand 132 (in yellow).  
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Figure 98. Interaction of ligand 132 with active-site-residues within 3Å in the active-
site of GS, showing potential hydrogen-bonds in yellow, dashed lines.   
 
On the other hand, although the global minimum and bound c onformations of 
compound 138 show poor structural homology with ATP (Figures 99 a nd 100), the 
ligand appears to bind very well to the active-site of the protein! Its dock score of 
91.09 kcal/mole is better than the value for ATP and is an indication of high affinity 
for the GS active site. Compound 138 appears to interact (Figure 101) with almost all 
the amino acid residues that ATP interacts with and exhibits the following additional 
interactions: - (i) acceptor hydrogen-bond interaction via one of the amino hydrogens 
Mn 469 
 
Mn 470 
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on adenine with Lys 352; (ii) a donor hydrogen-bond interaction between Gly 127 and 
the ribose moiety; and (iii) the side-chain that contains the alkyl phosphate group 
interacts with Ile 345 via an acceptor hydrogen-bond. The metal atoms, however, are 
too far off in this case to have any significant interaction with the ligand.  
 
 
 
Figure 99. ‘Target model’ alignment of ATP with ligand 138 (in yellow).  
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Figure 100. ‘Binding conformation’ alignment of ATP with ligand 138 (in yellow). 
  
 
 
Figure 101. Interaction of ligand 138 with active-site-residues within 3Å in the 
active-site of GS, showing potential hydrogen-bonds in yellow, dashed lines.   
    
                                                
2.6.1.3. Computer modelling of truncated adenine derivatives in the active site of 
GS          
 
Molecular dynamics to find the global minimum conformation was conducted for 
each of the truncated mimics listed in Table 17 and their alignment with ATP 
explored. While the global minimum conformations of the truncated systems exhibit 
fair to poor structural homology with ATP, several appear to interact with the GS 
active-site residues via both acceptor and donor hydrogen-bonds, indicating their 
Mn 469 
 
Mn 470 
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binding potential. Figures 102 and 103 illustrate the ‘target model alignment’ and the 
‘binding conformation’ alignment of compound 203 and ATP, while Figure 104 
summarises the interaction of the ligand 203 with active-site residues. It is interesting 
to note the significant conformational differences between the global-minimum 
(Figure 102) and bound conformations (Figure 103) of the ligand 203. 
 
Table 17. Comparison of the ligands scores of truncated adenine mimics with ATP                  
                                 
Compound Dock 
score 
(kcal/mol) 
Ligscore 
(kcal/mol) 
vdW 
(kcal/mol) 
ATP 87.41 -3.06 58.10 
186 -2.48 -0.61 5.49 
191 4.90 0.39 -15.91 
196 20.83 0.81 -24.83 
198 1.93 0.05 -8.65 
203 28.87 1.10 -30.95 
206 9.07 0.66 -21.60 
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Figure 102. ‘Target model’ alignment of ATP with ligand 203 (in yellow).  
 
 
 
Figure 103. ‘Binding conformation’ alignment of ATP with ligand 203 (in yellow).  
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Figure 104. Interaction of ligand 203 with active-site-residues within 3Å in the 
active-site of GS, showing potential hydrogen-bonds in yellow, dashed lines.   
 
Figures 105 and 106 illustrate the ‘target model’ alignment and the ‘binding 
conformation’ alignment of compound 196 with ATP, while Figure 107 summarises 
the interaction of the ligand 196 with active-site residues. While the global minimum 
conformations (Figure 105) exhibit poor structural homology, the alignment of the 
binding conformations (Figure 106) is clearly much better.  
                                                                             
 
Mn 469 
 
Mn 470 
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Figure 105. ‘Target model’ alignment of ATP with ligand 196 (in yellow).                   
 
 
 
Figure 106. ‘Binding conformation’ alignment of ATP with ligand 196 (in yellow).  
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Figure 107. Interaction of ligand 196 with active-site-residues within 3Å in the 
active-site of GS, showing potential hydrogen-bonds in yellow, dashed lines.   
 
The in silico data obtained thus far suggest a m easure of complementarity between 
various synthetic ligands and the GS-ATP active-site and some degree of 
conformational homology with ATP. Issues of enzyme inhibition and selectivity, 
aqueous solubility, and free energies of solvation/desolvation and binding have yet to 
be explored. However, on the basis of modelling data, it seems that a number of the 
ATP mimics have potential as GS inhibitors and will be investigated further. 
  
 
 
 
 
 
Mn 470 
 
Mn 469 
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2.7. Conclusions 
 
This research has formed part of a col laborative programme aimed at developing 
glutamine synthetase inhibitors as potential therapeutics for TB – a disease for which 
drug resistance to current treatment regimens makes it an even greater threat to life.  
 
A mechanism-based approach to drug discovery has been pursued in attempts to 
discover better drugs. Hence, attention has been focused on synthesizing novel ATP 
mimics that can act as inhibitors of bacterial glutamine synthetase – an enzyme that is 
essential for the virulence of Mycobacterium tuberculosis, the organism that causes 
tuberculosis. Consideration has been given to issues of structural homology in 
designing potential ATP mimics. Initially various purine derivatives were identified as 
scaffolds for the construction of novel ATP analogues and a range of adenosine, 
adenine and allopurinol derivatives have been prepared as primary targets via 
alkylation and acylation reactions. Attention was then turned to developing 
“truncated” ATP analogues and a range of 3-aminobenzonitrile, 3-aminophenol, 
resorcinol, 3-aminobenzyl alcohol, 3-hydroxybenzoic acid and 3-aminobenzoic acid 
derivatives have been successfully prepared. A number of alkylating and acylating 
agents have also been prepared and then reacted, with mixed success, with the purine 
substrates and the truncated analogues. 
 
Allylation of the hydroxyl, amino or N-9 centres of the various substrates was 
achieved readily in low to high yield (10-87%). Mono- and di-substituted derivatives 
were isolated in almost all of these allylation reactions, but attempted dihydroxylation 
of the resulting terminal alkenes of the mono-allylated derivatives with CTAP, 
KMnO4 and NaIO4 in the presence of RuCl3
 
 were frustratingly unsuccessful; in one 
case, attempted epoxidation with meta-chloroperbenzoic was also unsuccessful.  
Alkylations of the N-9 nitrogen of protected allopurinol with specially prepared 
Baylis-Hillman products, tert-butyl 3-(5-bromo-2-hydroxyphenyl)-3-hydroxy-2-
methylenepropanoate, tert-butyl 3-hydroxy-3-(2-hydroxyphenyl)-2-methylenepropan-
oate and 6-bromo-3-(chloromethyl)chromen-2-one were successful and provided 
access to interesting products.   
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Acylations were generally successful with substrates having free hydroxyl and/or 
amino groups but not at the N-9 nitrogen of adenine or protected allopurinol. Mono- 
and di-acylations were recorded in almost all cases except with 2,3,4,5,6-
pentaacetylgluconoyl chloride probably because of steric hindrance in the mono-
acylated product. Mono-acylation of resorcinol however, proved difficult as the 
second hydroxyl group becomes more susceptible to acylation as a result of increased 
acidity. While tin tetrachloride-catalyzed glycosylation of adenine with acetylated 
glucose in an inert atmosphere of argon was successfully achieved, the corresponding 
reaction with 3-aminobenzonitrile as substrate was, surprisingly, unsuccessful. 
Phosphorylation of a number of hydroxy and chloro derivatives was effected using 
diethyl chlorophosphate and triethyl phosphite, respectively. 
 
One- and two-dimensional NMR spectroscopic methods were used extensively to 
confirm the chemical structures of synthesized compounds. Experimental chemical 
shift data were compared with predicted values using NMR prediction progammes 
and this approach proved useful in assigning structures in cases of competing reaction 
centres as well with isomeric di-substituted products. 
  
Molecular modelling with the ACCELERYS Cerius2
 
 platform was used to conduct in 
silico receptor-ligand docking in the ‘active site’ of bacterial glutamine synthetase in 
order to identify potential glutamine synthetase inhibitors. The modelling results 
certainly indicate the binding potential of certain ligands, in silico at least.  
The results of this study have provided a basis for future research and for addressing 
challenges such as: -  
i. facilitating N-9 allylation and acylation in purine systems; 
ii. effective perhydroxylation of various α,β-unsaturated carbonyl derivatives; 
and 
iii. achieving better regio-control in reactions of bifunctional substrates. 
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3. EXPERIMENTAL                          
 
Reagents were supplied by manufacturers. Solvents such as DMF, THF, actonitrile, 
pyridine, etc were redistilled by literature methods before use. Dry reactions were 
carried out in an inert atmosphere either under argon or nitrogen. Plastic TLC plates 
as supplied by Merck – (precoated with silica gel 60 F254) were used for thin layer 
chromatography and visualization effected under UV light. Silica gel 60 (particle size 
0.040-0.063 nm) was employed as stationary phase for flash column chromatography 
while silica gel 60 PF254 was employed as stationary phase for radial chromatography. 
For normal phase HPLC a Whatman Partisil10
 
 semi-preparative column was used, 
while a Phenomenex C-18 LUNA semi-preparative column was used for reverse 
phase HPLC. 
1H, 13C and 31P NMR experiments were conducted on Bruker AVANCE 400 M Hz 
and 600 MHz spectrometers. Chemical shifts were reported relative to the solvent 
peaks i.e. δH : 7.25 ppm for CDCl3, 4.81 for D2O, 3.30 f or CD3OD, 2.50 ppm for 
DMSO-d6, and 20.5 pp m for (CD3)2C=O; δC : 77.0 ppm for CDCl3, 49.0 ppm for 
CD3OD, 39.4 ppm for DMSO-d6  and 30.8 ppm for (CD3)2
 
C=O. 
Low resolution mass spectra recorded on a Finnigan-MAT GCQ mass spectrometer 
while high resolution mass spectrometric data was obtained by Martin Brits using 
APCI (Atmospheric Pressure Chemical Ionization) and Tommie van de Walt 
(University of Witwatersrand Mass Spectrometry Unit). 
 
Mid-IR spectra recorded on Perkin-Elmer spectrum 2000FT-IR spectrometer as thin 
films and solid deposits between CsI discs. 
 
Melting points were determined on a Reichert hot-stage apparatus and Gallenkamp 
melting point apparatus and are not corrected.  
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Adenosine 3',4'-acetonide 127            
    
N
N
NH2
N
N
O
O
O
OH
1'2'
3'
4'
5'
9
8
7
5
4
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A solution of adenosine 62 (51 mg, 0.19 mmol) and p-toluenesulphonic acid (150 mg, 
0.79 mmol) in acetone (20 mL) was stirred at room temperature overnight. The 
reaction was quenched with aqueous Na2CO3 (10%, 7 mL). The solvent was removed 
in vacuo and the aqueous residue extracted with CH2Cl2 (3 × 10 mL). The combined 
organic extracts were dried (anhydr. MgSO4) and evaporated in vacuo to afford 
adenosine 3',4'-acetonide 127 as a white powder, (55 mg, 93%), m.p. 215-216°C, 
(Found: [M+1]+, 308.14706. C 13H17N5O4 requires: M
+, 307.30518); νmax (solid 
deposit/cm-1)  3256 (OH), 3095 (NH2); δH/ppm (400MHz; CDCl3) 1.36 and 1.64 (6H, 
2 × s, 2 × CH3), 3.78 (1H, dd, J = 12.8 and 1.9 Hz, CHaOH), 3.96 (1H, dd, J = 12.8 
and 1.4 Hz, CHbOH), 4.53 (1H, d, J = 1.1 Hz, 4'-H), 5.10 (1H, dd, J = 5.9 and 0.9 
Hz, 5'-H), 5.19 (1H, t, J = 5.4 Hz, 3'-H), 5.85 (1H, d, J = 4.9 Hz, 2'-H), 5.94 (2H, s, 
NH2), 7.84 (1H, s, 8-H) and 8.30 (1H, s, 2-H); δC/ppm (100MHz; CDCl3) 25.2 and 
27.6 (2 × CH3), 63.4 (CH2), 81.7 (C-5'), 83.0 (C-3'), 86.2 (C-4'), 94.3 (C-2'), 114.0 
[C.(CH3)2
 
], 121.0 (C-5), 140.4 (C-8), 148.4 (C-4), 152.2 (C-2) and 155.7 (C-6).   
2,3,4,6-Tetraacetylgluconic acid 129  
 
OH
AcO
OH
OAc
OAc
OAc
O
1
2
34
5
6
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Crushed zinc chloride (8.2 g, 0.060 mol) was dissolved in acetic anhydride (100 mL). 
The temperature of this solution was reduced to 0ºC, and D-glucono-D-lactone (20 g, 
0.11 mol) was added slowly with stirring. The reaction mixture was stirred at 0 ºC for 
1 h, and  then at room temperature for 24 h, before adding water (400 mL) and stirring 
for a further 1 h. The product which crystallized out on standing at 0 ºC for 24 h was 
2,3,4,6-tetraacetyl-gluconic acid 129 as white crystals (8.2 g, 20%), m.p. 84-88ºC 
(lit.165 113-117°C); νmax (solid deposit/cm
-1) 3409 (OH) and 1735 (C=O); δH/ppm 
[600 MHz; (CD3)2C=O] 2.00 (3H, s, 6-CH3), 2.03 (3H, 2 × s, 3-CH3 and 4-CH3), 
2.10 (3H, s, 2-CH3), 3.98 (1H, dd, J = 12.0 and 4.8 Hz, 5-H), 4.08 (2H, d, J = 4.9 Hz, 
6-H), 4.72 (1H, d, J = 0.5 Hz, 5-OH), 5.28 (1H, dd, J = 7.6 and 5.0 Hz, 4-H), 5.33 
(1H, d, J = 3.6 Hz, 2-H) and 5.78 (1H, dd, J = 4.9 and 3.7 Hz, 3-H); δC/ppm [150 
MHz; (CD3)2C=O]  21.4 ( 6-OCO.CH3), 21.5 and 21.7 (3-OCO.CH3 and 4-
OCO.CH3), 21.8 (2-CH3
 
), 66.7 (C-6), 69.7 (C-5), 71.4 (C-2), 72.8 (C-3), 73.0 (C-4), 
169.5 (C=O), 171.0 (2-C=O), 171.17 (3-C=O), 171.20 (4-C=O) and 171.9 (6-C=O). 
2,3,4,5,6-Pentaacetylgluconic acid 130  
 
OH
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OAc
OAc
OAc
OAc
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6
 
 
2,3,4,6-Tetraacetyl-gluconic acid (3.0 g, 9.6 m mol) was slowly added to a chilled 
solution (0ºC) of zinc chloride (1.3 g, 9.5 m mol) in acetic anhydride (13 mL, 0.14 
mol) in a 50 mL three necked round bottomed flask equipped with a condenser and a 
CaCl2 guard tube. The reaction mixture was kept at 0ºC for 1 h a nd then stirred at 
room temperature for 24 h. T he reaction was quenched with water (70 mL). The 
aqueous reaction mixture was extracted with CHCl3 (4 × 25 mL). Toluene (75 mL) 
was added to the combined extract and the volume reduced to 75 mL in vacuo. More 
toluene (75 mL) was added and the volume reduced to 12 mL. Pure 2,3,4,5,6-
Pentaacetylgluconic acid 130 crystallized out at 0ºC as white crystals (3.0 g, 77%), 
m.p. 108-112 ºC (lit.165 110-111°C); νmax (solid deposit/cm
-1) 3445 ( OH) and 1747 
(C=O); δH/ppm (400MHz; CDCl3) 2.05 (12H, m, 4 × OAc), 2.18 (3H, s, 6-OAc), 4.11 
(1H, dd, J = 12.2 and 5.5 Hz, 6–Ha), 4.29 (1H, dd, J = 12.3 and 4.0 Hz, 6–Hb), 5.06 
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(1H, dd, J = 10.3 and 5.6 Hz, 5–H), 5.29 (1H, d, J = 3.8 Hz, 2–H), 5.49 (1H, m, 4–H), 
5.61 (1H, m, 3–H), and 6.58 (1H, b, OH); δC/ppm (100MHz; CDCl3) 20.3, 20.4, 20.6, 
20.65 and 20.7 (5 × OAc), 61.4 (C–6), 68.49 (C–3), 68.51 (C–5), 69.3 (C–4), 70.1 
(C–2), 169.76 (C–1), 169.83 (C–5'), 169.91 (C–4'), 169.94 (C–3'), 170.4 (C–2') and 
170.7 (C–6'); m/z =  406 (M+
 
, 0.52%) and 43 (100%). 
2,3,4,5,6-pentaacetylgluconoyl chloride 131  
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To a solution of 2,3,4,5,6-pentaacetylgluconic acid 130 (1.0 g, 2.5 mmol) in a dry 50 
mL round bottomed flask under nitrogen was added oxalyl chloride (0.55 mL, 6.3 
mmol) through a septum. There was immediate effervescence and the product 
precipitated out within 30 minutes. Excess oxalyl chloride was evaporated in vacuo to 
afford 2,3,4,5,6-pentaacetylgluconoyl chloride 131  as a w hite precipitate (0.52 g, 
50%), m.p. 42-44ºC (lit. 68-71°C); νmax (solid deposit/cm
-1) 1748 (C=O); δH/ppm 
(400MHz; CDCl3) 2.02-2.10 (12H, overlapping singlets, 4 ×  CH3), 2.19 ( 3H, s, 6-
OAc), 4.12 (1H, dd, J = 12.2 and 5.5 Hz, 6-Ha), 4.30 (1H, dd, J = 12.3 and 4.1 Hz,  
6-Hb), 5.06 (1H, dt, J = 5.6 and 4.2 Hz, 5-H), 5.31 (1H, d, J = 3.9 Hz, 2-H), 5.50 (1H, 
dd, J = 6.4 and 5.0 Hz,  4-H) and 5.62 (1H, dd, J = 4.9 and 3.9 Hz, 3-H); δC/ppm 
(100MHz; CDCl3) 20.3, 20.4, 20.6, 20.66 and 20.7 (5 × CH3), 61.5 (C-6), 68.5 (C-3), 
68.55 (C-5), 69.3 ( C-4), 70.0 ( C-2), 169.7 ( C-1), 169.76 ( 5-O.C=O), 169.8 ( 4-
O.C=O), 169.86 (3-O.C=O), 170.1 (2-O.C=O) and 170.6 (6-O.C=O); m/z =  424 (M+
 
, 
0.08%) and 361 (100%). 
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2-(6-Aminopurin-9-yl)-3,4-dihydroxy-5-[(2,3,4,5,6-pentaacetoxy-hexanoyloxy)-
methyl]tetrahydrofuran-3,4-acetonide 132   
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A solution of adenosine 3',4'-acetonide (0.14 g, 0.47 m mol) and 2,3,4,5,6-
pentaacetyhlgluconoyl chloride (0.20 g, 0.47 mmol) in pyridine (4 mL) was stirred for 
36 h. The solvent was evaporated in vacuo and the residue dissolved in CHCl3 (30 
mL). The solution was washed with 5% aq. NaHCO3 (2 × 30 mL), water (2 × 30 mL) 
and brine (2 × 30 mL). The organic layer was then dried (anhydr. MgSO4) and the 
solvent  was evaporated in vacuo and the yellow residue was chromatographed [radial 
chromatography; elution with EtOAc] to afford 2-(6-aminopurin-9-yl)-3,4-dihydroxy-
5-[(2,3,4,5,6-pentaacetoxyhexanoyloxy)methyl]tetrahydrofuran-3,4-acetonide 132 as 
a yellow oil (46 mg, 14%), νmax (thin film/cm
-1) 3345 (NH2), 1749 (C=O) and 1598 
(aromatic C=N) and 1216 (C–N); δH/ppm (400MHz; CDCl3) 1.38 and 1.60 (6H, 2 × 
s, 2 × CH3, 2.03 (12H, series of singlets, 4 × CH3), 2.15 (3H, s, 6-CH3), 4.10 (1H, dd, 
J = 12.3 and 5.6 Hz, 6"-Ha), 4.28 (2H, m, 6-Hb and CH2a), 4.38 (1H, dd, J = 11.6 and 
6.1 Hz, CH2a), 4.45 (1H, m, 4-H), 5.05 (2H, m, 5"-H and 5-H), 5.18 (1H, d, J = 3.6 
Hz, 2"-H), 5.45 (2H, m, 3-H and 4"-H), 5.54 (1H, dd, J = 4.8 and 3.7 Hz, 3"-H), 5.93 
(2H, s, NH2), 6.10 (1H, d, J = 2.1 Hz, 2-H), 7.94 (1H, s, 8'-H) and 8.34 (1H, s, 2'-H); 
δC/ppm (100MHz; CDCl3) 20.3, 20.34, 20.56, 20.6 and 20.7 (5 × CH3), 27.1 and 29.7 
(2 × CH3), 61.5 (C-6"), 65.1 (CH2), 68.4 (C-3"), 68.6 (C-5"), 69.3 (C-4") , 70.8 ( C-
2") , 81.6 ( C-5), 84.2 (C-3), 84.8 (C-4), 90.8 (C-2), 114.6 [C.(CH3)2], 120.2 (C-5'), 
140.0 (C-8'), 149.2 (C-4'), 152.7 (C-2'), 155.3 (C-6'), 166.4 (C=O), 169.5 (5-O.C=O), 
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169.6 (4-O.C=O), 169.67 (3-O.C=O), 169.9 (2-O.C=O) and 170.5 (6-O.C=O); m/z = 
696 ([M+1]+
 
, 16%) and (694, 100%). 
2-(6-Aminopurin-9-yl)-3,4-dihydroxy-5-[(allyloxy)methyl]tetrahydrofuran-3,4-
acetonide 133         
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To a stirred solution of adenosine 3',4'-acetonide 127 (0.50 g, . 1.6 mmol) in THF (5 
mL) under nitrogen was added NaH (60% dispersion in mineral oil;  42 mg, 1.8 
mmol) in small portions to permit controlled evolution of hydrogen. Allyl bromide 
(0.20 mL, 1.8 m mol) was added through a septum and the resulting solution was 
refluxed for ca. 6h. The reaction was quenched by the addition of water (10 mL). The 
solvent was evaporated in vacuo and the aqueous residue was extracted with CH2Cl2 
(2 × 20 mL). The organic extract was washed sequentially with water (2 × 40 mL) and 
brine (2 × 40 m L). The aqueous washings were extracted with CH2Cl2 and the 
organic layers combined and dried (anhydr. MgSO4). Evaporation of the solvent in 
vacuo to afforded a yellow residue, chromatography of which [radial chromatography; 
elution with 100% EtOAc] afforded 2-(6-aminopurin-9-yl)-3,4-dihydroxy-5-
[(allyloxy)methyl]-tetrahydrofuran 3,4-acetonide 133 as a yellow oil (51 mg, 9%). 
(Found [M+1]+, 348.16276, C16H21N5O4 requires 347.36904)  νmax (thin film/cm
-1) 
3388 (NH2); δH/ppm (400MHz; CDCl3) 1.38 and 1.62 (6H, 2 ×  s, 2 × CH3),  3.59 
(1H, dd, J = 10.5 and 4.4 Hz, 1"-CHa), 3.66 (1H, dd, J = 10.5 and 3.5 Hz, 1"-CHb), 
3.94 (1H, dd, J = 4.6 and 1.2 Hz, 3"-H), 4.50 (1H, dd, J = 6.6 and 3.7 Hz, 4'-H), 4.98 
(1H, dd, J = 6.1 and 2.5 Hz, 5"-Ha), 5.17 (2H, m, 5'-H and 8'-H,), 5.29 (1H, dd, J = 
6.1 and 2.4 Hz, 5'-Hb), 5.78 (1H, tdd, J = 16.2, 10.4 and 5.8 Hz, 4"-H), 5.98 (2H, s, 
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NH2), 6.19 (1H, d, J = 2.4 Hz, 2-H), 8.06 (1H, s, 8'-H) and 8.35 (1H, s, 2'-H); δC/ppm 
(100MHz; CDCl3) 25.4 and 27.4 (2 × CH3), 70.2 (C-1"), 72.4 (C-3"), 81.8 (C-5), 85.0 
(C-3), 86.0 (C-4), 91.4 (C-2), 114.2 [C.(CH3)2
 
], 117.8 (C-5"), 119.9 (C-5') 133.8 (C-
4"), 139.6 (C-8'), 149.5 (C-4'), 152.4 (C-2') and 155.1 (C-6').  
2-(6-Aminopurin-9-yl)-3,4-dihydroxy-5-(7-hydroxy-2,5-
dioxaheptyl)tetrahydrofuran 3,4-acetonide 137             
 
N
N
N
N
NH2
O
O
O
O
O OH
7''
6''4''
3''
4
3
2
1
5
1''
9'
8'
7'
5'
6'
6'
1'
2'
3'
5''
2''
 
 
To a stirred solution of  adenosine 3',4'-acetonide 127 (0.50 g, 1.6 mmol) in THF (33 
mL) under nitrogen was added NaH (60% dispersion in mineral oil; 0.043 g, 1.8 
mmol) in small portions to permit controlled evolution of hydrogen. 2-(2-
chloroethoxy)ethanol (0.20 mL, 1.8 m mol) was added through a septum and the 
resulting solution was refluxed for ca. 6h. The reaction was quenched by the addition 
of water (40 mL). The solvent was evaporated in vacuo and the aqueous residue was 
extracted with CH2Cl2 (2 × 40 mL). The organic extract was washed sequentially 
with water (2 × 80 mL) and brine (2 × 80 mL). The aqueous washings were extracted 
with CH2Cl2 and the organic layers combined and dried (anhydr. MgSO4). 
Evaporation of the solvent in vacuo afforded 2-(6-aminopurin-9-yl) 3,4-dihydroxy-5-
(7-hydroxy-2,5-dioxaheptyl)tetrahydrofuran - 3,4- acetonide 137 as a white powder 
(0.46 g, 72%), m.p. 174-176°C. νmax (solid deposit/cm
-1) 3219 (NH2) and 3112 (OH); 
δH/ppm (400MHz; CDCl3) 1.38 and 1.60 (6H, 2 × s, 2 × CH3),  2.03-2.64 (1H, br s, 
OH), 3.63 (4H, dd, J = 10.4 and 5.3 Hz, 6"-H and 4"-H), 3.76 (5H,  m, 1"–Ha, 7"-H 
and 3"-H), 3.96 (1H, dd, J = 12.8 and 1.4 Hz, 1"-Hb), 4.53 (1H, d, J = 1.1 Hz, 4-H), 
5.10 (1H, dd, J = 5.9 and 0.9 Hz, 5-H), 5.19 (1H, t, J = 5.4 Hz, 3-H), 5.85 (1H, d, J = 
4.9 Hz, 2-H), 5.94 (2H, s, NH2), 7.84 (1H, s, 8'-H) and 8.30 (1H, s, 2'-H); δC/ppm 
(100MHz; CDCl3) 25.2 and 27.6 ( 2 × CH3), 42.9 (C-6"), 61.6 ( C-7"), 63.4 (C-1"), 
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71.1 (C-3"), 72.4 (C-4"), 81.7 ( C-8'), 83.0 ( C-3), 86.1 ( C-4), 94.3 ( C-2), 114.0 
[C.(CH3)2], 121.0 (C-5'), 140.3 (C-8'), 148.4 (C-4'), 152.3 (C-2') and 155.8 (C-6'); m/z 
=  395 (M+
 
, 0.39%) and 218 (100%).  
2-(6-Aminopurin-9-yl)-5[7-diethylphosphoryoxy)-2-5-dioxaheptyl]-3,4-dihydr-
oxytetrahydrofuran 3,4-acetonide 138          
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A solution of 2-(6-aminopurin-9-yl)-3,4-dihydroxy-5-(7-hydroxy-2,5-dioxaheptyl)-
tetrahydrofuran 3,4-acetonide 137 (260 mg, 0.67 mmol) in THF (10 mL) at room 
temperature was cooled (-1 ºC). Buthyllithium (300 µL, 0.74 mmol) was added and 
after stirring for 2 h diethyl chlorophosphate (110 µL, 0.72 mmol) was added and the 
resulting mixture stirred at room temperature for 24 h. The reaction was quenched by 
the addition of satd. aq. NH4Cl solution (10 mL). The THF was evaporated in vacuo 
and the aqueous residue extracted with CH2Cl2 (2 × 15 mL). The organic extract was 
washed with aq. NH4Cl (2 × 60 mL), water (2 × 60 mL) and brine (2 × 60 mL). The 
aqueous fractions were extracted with CH2Cl2 and the organic layers combined and 
dried (anhydr. MgSO4). The brown oil obtained after evaporation of the solvent in 
vacuo was washed with hexane (3 × 15 m L) to afford 2-(6-aminopurin-9-yl)-5[7-
diethylphosphoryoxy)-2-5-dioxaheptyl]-3,4-dihydroxyltetrahydrofuran 3,4-acetonide 
138 as a yellow oil, (130 mg, 37%). νmax (solid deposit/cm
-1) 3337 (NH2) and 1028 
(P=O); δH/ppm (400MHz; CDCl3) 1.28 (6H, td, JP–H = 16.5 and 7.1 Hz, 2 × CH3), 
1.38 and 1.61 (6H, 2 ×  s, 2 ×  CH3), 4.06 (5H,  m, 2 ×  CH2 and 1"-Ha), 4.21 (9H, 
series of multiplets, 1"-Hb, 7"-H, 6"-H, 4"-H and  3"-H), 4.48 (1H, m, 4-H), 5.06 (1H, 
dd, J = 6.2 and 2.9 Hz, 5-H), 5.35 (1H, dd, J = 6.2 and 2.3 Hz, 3-H), 6.14 (1H, d,  J = 
4.9 Hz, 2-H), 6.76 (2H, s, NH2), 8.05 (1H, s, 2'-H) and 8.32 (1H, s, 8'-H); δC/ppm 
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(100MHz; CDCl3) 16.05 (d, JP–C = 6.5 Hz, 2 × CH3),  25.3 and 27.1 (2 × CH3), 64.1 
(dd, JP–C = 5.8 and 2.1 Hz, 2 × CH2), 66.6  and 66.7 (5C, series of singlets, C-1", C-
3",C-4",C-6" and C-7"), 81.3 ( C-5'), 84.4 ( C-3'), 85.4 ( C-4),  91.0 ( C-2), 114.7 
[C.(CH3)2], 119.9 ( C-5'), 140.2 ( C-8'), 149.0 ( C-4'), 150.8 (C-2') and 154.4 (C-6'); 
δP/ppm  (162 MHz; CDCl3) 0.8 (P=O); m/z 532.31 (M+
 
+1,3%) and 444.25 (100%).  
2-(6-Aminopurin-9-yl)-3,4- dihydroxy-5-(10-hydroxy-2,5,8 - trioxadecyl)tetra-
hydrofuran 3,4-acetonide 139 and 2-[6-(8-hydroxy-3,6,-dioxaoctylamino)-purin-
9-yl]-3,4-dihydroxy-5-(10-hydroxy-2,5,8- trioxadecyl)tetrahydrofuran 3,4-
acetonide 139A 
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To a stirred solution of adenosine 3',4'-acetonide 127 (0.50 g, 1.6 mmol) in THF (33 
mL) under nitrogen was added NaH (60% dispersion in mineral oil; 43 mg, 1.8 mmol) 
in small portions to permit controlled evolution of hydrogen. 2-[2-(2-
chloroethoxy)ethoxy]ethanol (0.30 mL, 1.8 mmol) was then added through a septum 
and the resulting solution refluxed for ca. 5h. The reaction was quenched by the 
addition of water (40 mL). The solvent was taken off in vacuo and the aqueous 
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residue extracted with CH2Cl2 (2 × 40 mL). The organic extract was washed 
sequentially with satd. NaHCO3 (2 × 80 mL), water (2 × 80 mL) and brine (2 × 80 
mL). The aqueous washings were extracted with CH2Cl2 and the organic layers 
combined and dried (anhydr. MgSO4). Evaporation of the solvent in vacuo afforded a 
yellow residue that was chromatographed [column chromatography; elution with 
EtOH:CHCl3
 (i) 2-(6-Aminopurin-9-yl)-3,4-dihydroxy-5-(10-hydroxy-2,5,8-trioxadecy)tetrahydro-
furan  3,4-acetonide 139 as yellow oil (23 mg, 3%). ν
:hexane = 1:2:2] to afford two products:  
max (thin film/cm
-1) 3414 (NH2 
and OH); δH/ppm (600MHz; CDCl3) 1.37 and 1.64 (6H, 2 × s, 2 × CH3), 3.58-3.82 
(13H, series of multiplets, 1"-CHa, 3"-H, 4"-H, 6"-H, 7"-H, 9"-H and 10"-H), 3.96 
(1H, d, J = 13.0 Hz, 1"-CHb), 4.53 (1H, s, 4-H), 5.10 (1H, d, J = 5.9 Hz, 5-H),  5.19 
(1H, t, J =  5.4 Hz, 3-H),  5.74 (2H, d, J = 0.9 Hz, NH2), 5.84 (1H, d, J = 4.9 Hz, 2-
H), 7.83 (1H, s, 8'-H) and 8.31 (1H, s, 2'-H); δC/ppm (150MHz; CDCl3) 25.2 and 27.7 
(2 × CH3), 63.4 (1"-CH2), 61.5-72.8 (C-3", C-4", C-5", C-6", C-7", C-9" and C-10"), 
81.7 (C-5), 82.9 (C-3), 86.1 (C-4), 94.4 (C-2), 114.0 [C.(CH3)2
 
], 121.1 (C-5'), 140.3 
(C-8'), 148.4 (C-4'), 152.7 (C-2') and 155.9 (C-6').  
ii. 2-[6-(8-hydroxy-3,6-dioxaoctylamino)-purin-9-yl]-3,4-dihydroxy-5-(10-hydroxy  -
2,5,8 -trioxadecy tetrahydrofuran 3,4-acetonide 139A as a pale yellow oil  (43 mg, 
5%). νmax (thin film/cm
-1) 3393 (NH and OH); δH/ppm (400MHz; CDCl3) 1.38 and 
1.64 (6H, 2 × s, 2 × CH3), 3.51-3.81 (26H, series of multiplets, 1"-CH2, 3-H, 4-H, 6-
H, 7-H, 9-H, 10-H, 1'''-H, 2'''-H, 4'''-H, 5'''H, 6'''-H, 7'''-H and 8'''-H), 4.52 (1H, d, J = 
2.1 Hz, 4-H), 4.94 (1H, dd, J = 5.8 and 1.6 Hz, 5-H), 5.08 (1H, dd, J = 5.8 and 3.3 
Hz, 3-H), 6.29 (1H, b, NH), 6.31 (1H, d, J = 3.3 Hz, 2-H), 8.34 (1H, s, 2'-H) and 8.50 
(1H, s, 8'-H); δC/ppm (100MHz; CDCl3) 25.4 and 27.4 (2 × CH3), 61.2-73.1 (1"-CH2, 
C-3",C-4", C-6", C-7", C-9", C-10", C-1''', C-2''', C-4''', C-5''', C-7''' and C-8'''), 81.7 
(C-5), 84.9 (C-3), 85.4 (C-4), 90.6 (C-2), 114.0 [C.(CH3)2
 
], 118.8 (C-5'), 139.5 (C-8'), 
149.8 (C-4'), 153.2 (C-2') and 155.3 (C-6').  
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2 - (6-Aminopurin-9-yl)-5-acetoxyacetyl-3,4-dihydroxytetrahydrofuran 3,4-
acetonide 140 and 2-[6-(acetoxyacetylamino)purin-9-yl)-5-acetoxyacetyl 3,4-
dihydroxytetrahydrofuran 3,4-acetonide 140A 
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NaH (60% dispersion in mineral oil; 43 mg, 1.8 mmol)  was added in small portions 
to a stirred solution of adenosine 3',4'-acetonide 127 (0.50 g, 1.6 mmol) in THF (33 
mL) under nitrogen. Acetoxyacetyl chloride (0.20 mL, 1.8 m mol) was then added 
through a septum and the resulting solution was refluxed for ca. 5 h. The reaction was 
quenched by the addition of water (50 mL). The solvent was evaporated in vacuo and 
the aqueous residue extracted with CH2Cl2 (2 × 50 m L). The combined organic 
extract was washed sequentially with satd. aq.  NaHCO3 (2 × 100 mL), water (2 × 100 
mL) and brine (2 × 100 mL). The aqueous washings were extracted with CH2Cl2 and 
the organic layers combined and dried (anhydr. MgSO4
 
). Evaporation of the solvent 
in vacuo afforded a brownish white residue that was chromatographed [radial 
chromatography; elution with EtOAc] to afford two products: 
 i. 2-(6-aminopurin-9-yl)-5-acetoxyacetyl-3,4-dihydroxy-tetrahydrofuran 3,4-
acetonide 140, light yellow oil (230 mg, 35%). νmax (thin film/cm-1)  3326 ( NH2), 
1750 (CH3C=O) and 1644 (aromatic C=N ); δH/ppm (400MHz; CDCl3) 1.39 a nd 
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1.61 (6H, 2 × s, 2 × CH3), 2.13 (3H, s, 7"-H), 4.32 (1H, m, 1"-Ha), 4.46 (2H, m, 1"-
Hb and 4-H), 4.55 (2H, s, 4"-H), 5.07 (2H, dd, J = 6.3 and 3.3 Hz, 5-H), 5.46 (1H, dd, 
J = 6.3 and 2.0 Hz, 3-H), 5.71 (2H, s, NH2), 6.08 (1H, d, J = 2.0 Hz, 2-H), 7.88 (1H, 
s, 8'-H) and 8.34 (1H, s, 2'-H); δC/ppm (100MHz; CDCl3) 20.4 (C-7"), 25.3 and 27.1 
(2 × CH3), 60.5 (C-4"), 64.6 (C-1"),  81.6 (C-5), 84.1 (C-3), 84.7 (C-4), 90.9 (C-2), 
114.7 [C.(CH3)2], 120.4 (C-5'), 139.8 (C–8'), 149.2 (C–4'), 153.2 (C–2'), 155.5 (C–
6'), 167.4 (C-3") and 170.3 (C-6"); m/z =  407 (M+
 
-1, 2.44%) and 408 (100%). 
ii. 2-[6-(Acetoxyacetylamino)purin-9-yl)-5-acetoxyacetyl 3,4-dihydroxytetrahydro-
furan 3,4-acetonide, 140A light yellow oil (330 mg, 40%). νmax (thin film/cm-1) 3422 
(NH), 2957 (CH), 1725 (CH3C=O) 1610 ( aromatic C=N ) and 1589 (NHC=O); 
δH/ppm (400MHz; CDCl3) 1.39 and 1.62 (6H, 2 × s, 2 × CH3), 2.11 (3H, s, 7'''-H), 
2.22 (3H, s, 5'''–H), 4.34 (1H, dd, J = 11.7 and 6.1 Hz, 1"–Ha), 4.48 (4H, m, 4–H, 1"–
Hb and 4"-H), 5.04 (1H, dd, J = 6.3 and 3.4 Hz, 5–H), 5.30 (2H, d, J = 3.0 Hz, 2'''–
H), 5.43 (1H, dd, J = 6.3 and 2.11 Hz, 3–H), 6.15 (1H, d, J = 2.1 Hz, 2–H), 8.20 (1H, 
s, 2'–H), 8.66 (1H, s, 8'–H) and 9.40 (1H, s, NH); δC/ppm (100MHz; CDCl3) 20.4 (C-
7"), 20.6 (C–5'''), 25.3 a nd 27.1 ( 2 × CH3), 60.4 (C-4"), 64.4 ( C–1"), 64.6 (C–2'''),  
81.4 (C–5), 84.1 (C−3), 84.7 (C−4), 91.1 (C–2), 114.9 [(.(CH3)2], 122.0 (C–5'), 142.7 
(C–8'), 148.7 (C–4'), 150.7 (C–2'), 152.3 (C–6'), 167.3 (C–1''' and C-3"), 170.3 (C–
4''') and 170.3 (C-6"); m/z =  507 (M+
 
, 17.32%) and 157 (100%).  
2-(6-Aminopurin-9-yl)-5-[(2-chloroacetoxy)methyl]-3,4-dihydroxytetrahydro-
furan 3,4-acetonide 141 and 2-[6-(2-chloroacetamido)purin-9-yl]-5-[(2-chloro-
acetoxy)-methyl] 3,4-dihydroxytetrahydrofuran 3,4-acetonide 141A                       
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A mixture of adenosine 3',4'-acetonide 127 (0.50 g, 1.6 m mol) in chloroacetyl 
chloride (1.4 mL, 1.8 mmol) was stirred under argon. The crude ester crystallized out 
within 0.5 h. T he excess acid chloride was evaporated in vacuo and the residue was 
dissolved in CHCl3 (2 × 50 mL). This solution was washed sequentially with satd. aq. 
NaHCO3 (2 × 100 mL) and brine (2 × 100 mL). The aqueous washings were extracted 
with CHCl3 and the organic layers combined and dried (anhydr. MgSO4). 
Evaporation of the solvent in vacuo afforded the pure 2-(6-aminopurin-9-yl)-5-[(2-
chloroacetoxy)methyl]-3,4-dihydroxytetrahydrofuran 3,4-acetonide 141 as light 
yellow crystals, (0.59 g, 94% ), m.p.  150 -151°C. νmax (solid deposit/cm
-1) 3398 
(NH2), 1738 (C=O); δH/ppm (400MHz; CDCl3) 1.38 and 1.59 (6H, 2 × s, 2 × CH3), 
4.00 (2H, s, 4"-H), 4.34 (1H, dd, J = 13.0 and 7.6 Hz, 1"-CHa), 4.48 (2H, m, 1"-CHb 
and 4-H), 5.08 (1H, dd, J = 6.3 and 3.2 Hz, 5-H), 5.46 (1H, dd, J = 6.3 and 1.9 Hz, 3-
H), 6.09 (1H, d, J = 1.9 Hz, 2-H), 6.14 (2H, s, NH2), 7.88 (1H, s, 8'-H) and 8.32 (1H, 
s, 2'-H); δC/ppm (100MHz; CDCl3) 25.3 and 27.1 (2 × CH3), 40.5 (C-4"), 65.4 (C-
1"), 81.5 ( C-5), 84.1 ( C-3), 84.6 ( C-4), 90.9 ( C-2), 114.7 [C.(CH3)2], 120.3 (C-5'), 
139.8 (C-8'), 149.1 (C-4'), 153.1 (C-2'), 155.7 (C-6') and 166.8 (C=O); m/z =  384.22 
(M+
 
+1, 9%) and 346 (100%).   
In a separate reaction the acetonide 127 was treated with the same reagent following 
the procedure above. Work up afforded (i) 141 and (ii) 2-[6-(2-chloroacetamido)-
purin-1-yl]-5-[(2-chloroacetoxy)methyl]-3,4-dihydroxytetrahydrofuran 3,4-acetonide 
141A as a yellow oil.       
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ii 2[6-(2-chloroacetamido) purin-9-yl]-5-[(2-chloroacetoxy)methyl] 3,4-dihydroxy 
tetra-hydrofuran 3,4-acetonide 141A as light yellow crystals. νmax (solid deposit/cm-1)  
(NH), (C=O); δH/ppm (400MHz; CDCl3) 1.39 and 1.62 (6H, 2 ×  s, 2 ×  CH3), 4.01 
(2H, s, 4"-CH2),  4.45 (4H, m, 1''-CH2, 4-H and NH), 4.68 (1H, s, 2'''-CH2), 5.06 (1H, 
dd, J = 6.2 and 3.4 Hz, 5-H),  5.45 (1H, dd, J = 6.2 and 1.9 Hz, 3-H), 6.18 (1H, d, J = 
1.9 Hz, 2-H), 8.25 (1H, s, 2'-H) and 8.72 ( 1H, s, 8'-H); δC/ppm (100MHz; CDCl3) 
25.3 and 27.1 (2 × CH3), 40.5 (C-4"), 44.6 (C-2'''), 65.3 (C-1"), 81.3 (C-5), 84.1 (C-
3), 84.6 (C-4), 91.1 (C-2), 115.0 [C.(CH3)2
 
], 122.5 (C-5'), 142.8 (C-8'), 148.5 (C-4'), 
152.4 (C-2'), 166.0 (C-6'), 166.8 (NH-C=O) and 166.83 (O-C=O).  
5-[(Acryloyloxy)methyl]-2-(6-aminopurin-9-yl)-3,4-dihydroxytetrahydrofuran 
3,4-acetonide 143   
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To a stirred solution of adenosine 3',4'-acetonide 127 (1.0 g, 3.3 mmol) in THF (30 
mL) under nitrogen was added NaH (60% dispersion in mineral oil; 0.15 g, 3.3 mmol) 
in small portions to permit controlled evolution of hydrogen. Acryloyl chloride (0.27 
mL, 3.3 mmol) was then added with a septum and the resulting solution was refluxed 
for ca. 5h. The reaction was quenched by the addition of water (50 mL). The solvent 
was evaporated in vacuo and the aqueous residue extracted with CH2Cl2 (2 × 50 mL). 
The organic extract was washed sequentially with satd. aq. NaHCO3 (2 × 100 m L) 
and brine (2 × 100 mL). The aqueous washings were extracted with CH2Cl2 and the 
organic layers combined and dried (anhydr. MgSO4). Evaporation of the solvent in 
vacuo afforded a pale yellow residue. Column chromatography on silica [elution with 
EtOH-EtOAc (1:20)] afforded 5-[(acryloyloxy)methyl]-2-(6-aminopurin-9-yl)-3,4-
dihydroxytetrahydrofuran3,4-acetonide 143 as a light brown solid (49 mg, 4.1%), 
m.p. 188-192°C. (Found: M+, 361.137825. C16H19N5O5 requires: M
+, 361.138619); 
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νmax (thin film/cm
-1)  3413 (NH2) and 1714 (C=O); δH/ppm (400MHz; CDCl3) 1.39 
and 1.61 (6H, 2 × s, 2 × CH3), 4.30 (1H, dd, J = 11.8 and 6.0 Hz, 1"-Ha), 4.44 (1H, 
dd, J = 11.9 and 4.5 Hz, 1"-Hb), 4.50 (1H, d, J = 1.1 Hz, 4-H), 5.08 (1H, dd, J = 6.3 
and 3.4 Hz, 5-H), 5.48 (1H, dd, J = 6.3 and 2.0 Hz, 3-H), 5.80 (1H, dd, J = 10.5 and 
0.8 Hz, 5"-HE), 5.87 (2H, s, NH2), 6.02 (1H, dd, J = 17.3 and 10.4 Hz, 4"-H), 6.10 
(1H, d, J = 1.9 Hz, 2-H),  6.36 (1H, dd, J = 17.3 and 0.9 Hz, 5"-HZ), 7.87 (1H, s, 8'-
H) and 8.33 (1H, s, 2'-H); δC/ppm (100MHz; CDCl3) 25.4 and 27.1 (2 × CH3), 64.0 
(C-1"), 81.7 (C-5), 84.2 (C-3), 85.0 (C-4), 91.0 (C-2), 114.6 [C.(CH3)2
 
], 120.3 (C-5'), 
127.6 (C-4"), 131.6 (C-5"), 139.7 (C-8'), 149.2 (C-4'), 153.2 (C-2'), 155.6 (C-6') and 
165.5 (C=O). 
4-Bromomethyl-2,2-dimethyl-[1,3]dioxolane 145  
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A solution of 3-bromo-1,2-proanediol (0.50 mL, 5.7 m mol) and p-toluenesulphonic 
acid (4.1 g, 24 mmol) in acetone (600 mL) was stirred at room temperature overnight. 
The reaction was quenched with aqueous Na2CO3 (10%, 210 mL). The solvent was 
removed in vacuo and the aqueous residue extracted with CH2Cl2 (3 × 250 mL). The 
combined organic extracts were dried (anhydr. MgSO4) and evaporated in vacuo to 
afford 4-bromomethyl-2,2-dimethyl-[1,3]dioxolane 145 as a yellow oil (730 mg, 
66%). δH/ppm (400MHz; CDCl3) 1.34 and 1.43 (6H, 2 × s, 2 × CH3), 3.30 (1H, dd, J 
= 9.9 and 8.3 Hz, CHa), 3.42 (1H, dd, J = 10.0 and 4.7 Hz, CHb), 3.86 (1H, dd, J = 
8.7 and 5.2 Hz, 5-Ha), 4.12 (1H, dd, J = 8.7 and 6.1 Hz, 5-Hb)  and 4.33 (1H, ddd, J = 
11.0, 8.2 and 5.4 Hz, 4-H); δC/ppm (100MHz; CDCl3) 25.4 and 27.0 (2 × CH3), 32.7 
(CH2
 
), 63.3 (C-5), 75.3 (C-4) and 110.3 (C-2).  
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(3,4,5,6-Tetraacetoxy 2-acetoxymethyl)pyran 148         
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A mixture of zinc chloride (0.5 g, 3.7 mmol) in acetic anhydride (13 mL, 13.0 mmol) 
was heated for ca. 10 minutes. D-glucose (2.5 g, 1.4 mmol) was then added slowly a 
little at a time to control the evolution of hydrogen. The mixture was then heated 
without reflux for ca. 1 h. Ice-water (125 mL) was added with gentle stirring to 
quench the reaction in a period of ca. 30 minutes. Further stirring was done for 30 
minutes by which time the crude product had started crystallizing out of solution. The 
crude product mixture was allowed to stand at 0ºC for 24 h and the white solid filtered 
off and recrystallised from methanol to afford pure pentaacetylated α–D-
glucopyranose 148 as a white crystalline solid (4.7 g, 87%), m.p. 84-86°C (lit.181 110-
111°C). νmax (solid deposit/cm
-1) 1750 (C=O); δH/ppm (400MHz; CDCl3) 2.01 (9H, 
series of singlets, 3 × CH3), 2.08 (3H, s, 2-CH3), 2.16 (3H, s, 6-CH3), 4.09 (2H, m, 
CHa and 2-H,), 4.25 (1H, dd, J = 12.5 and 4.1 Hz, CHb), 5.11 (2H, m, 3-H and 5-H), 
5.45 (1H, t, J = 9.9 Hz, 4-H) and 6.31 (1H, d, J = 3.7 Hz, 6-H); δC/ppm (100MHz; 
CDCl3) 20.4, 20.5, 20.6, 20.7 and 20.9 (series of singlets, 5 × CH3), 61.5 (CH2), 67.9 
(C-3), 69.2 (C-5), 69.8 (C-2 and C-4), 89.1 (C-6), 168.7 (6-C =O), 169.4, 169.6 and 
170.2 (3 × C =O), and 170.6 (2-C=O); m/z = 390 (M+
 
, 0.03%) and 98 (100%).                 
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3,4,5-Triacetoxy-6-acetoxymethyl-2-(6-aminopurin-9-yl)pyran 149                 
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Adenine 61 (0.5 g, 3.7 mmol) and acetylated glucose 148 (1.4 g, 3.5 m mol) were 
placed in a 100 mL dried 3-neck flask equipped with a reflux condenser. Acetonitrile 
(20 mL) was added through a septum and the reaction mixture stirred. Tin 
tetrachloride (1.0 mL, 9.3 mmol) was then added and the reaction mixture refluxed 
under argon for ca. 6 h. The reaction was quenched with satd. NaHCO3 (50 mL). The 
solvent was evaporated in vacuo and the aqueous residue extracted with EtOAc (2 × 
25 mL). The organic extract was washed sequentially with satd. aq. NaHCO3 (2 × 50 
mL) and brine (2 × 50 mL). The aqueous washings were extracted with EtOAc and 
the organic layers combined and dried (anhydr. MgSO4). Evaporation of the solvent 
in vacuo afforded a pale yellow residue. Column chromatography on silica [elution 
with EtOH-CHCl3 (1:19)] afforded 2-[(6-aminopurin-9-yl)-6-acetoxymethyl-3,4,5-
triacetoxy)] pyran 149 as yellow crystals (510 mg, 30%), m.p. 63-65°C. (Found: M+, 
465.14892. C19H23N5O9 requires: M
+, 465.41498);  νmax (solid deposit/cm
-1)   3339  
(NH2) and 1744 ( C=O); δH/ppm (400MHz; CDCl3) 2.00 – 2.08 (12H, series of 
singlets, 4 × CH3), 4.02 (1H, ddd, J = 10.1, 4.8 and  2.1 Hz, 6-H), 4.14 (1H, dd, J = 
12.6 and 2.1 Hz, CHa),   4.29 (1H, dd, J = 12.6 and 4.9 Hz, CHb) 5.27 (1H, t, J = 9.8 
Hz, 5-H), 5.44 (1H, t, J = 9.5 Hz, 4-H),    5.58 ( 1H, t, J = 9.5 Hz, 3-H), 5.76 (1H, s, 
NH2), 5.88 (1H, d, J = 9.5 Hz, 2-H), 8.00 (1H, s, 8'-H) and 8.36 (1H, s, 2'-H); δC/ppm 
(100MHz; CDCl3) 20.1, 20.5, 20.6 and 20.7 (series of singlets, 5 × CH3), 61.6 (CH2
 
), 
67.9 (C-5), 70.4 (C-3), 72.9 (C-4), 75.1 (C-6), 80.3 (C-2), 119.2 (C-5'), 138.3 (C-8'), 
150.7 (C-4'), 153.4 (C-2'), 155.4 (C-6'), 169.0 (3-C=O), 169.4(5-C=O), 169.8(4-C=O) 
and 170.5 (6-C=O).  
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6-(N-Allylamino)purine 150 and 9-Allyl-[6-amino(N-allylamino)] purine 150A  
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NaH (60% dispersion in mineral oil; 100 mg, 4.0 mmol) was added in small portions 
permit controlled evolution of hydrogen, to a stirred solution of adenine 61 (300 mg, 
2.2 mmol) in dry DMF (20 mL) under nitrogen at 0ºC. Allyl bromide (230 µL, 2.7 
mmol) was then added with through a septum and the resulting solution refluxed for 
ca. 6 h. The reaction was quenched by the addition of water (25 mL). The solvent was 
evaporated in vacuo and the aqueous residue extracted with CHCl3 (2 × 25 mL). The 
combined organic extracts were washed sequentially with satd. NaHCO3 (2 × 50 mL), 
water (2 × 50 mL) and brine (2 × 50 mL). The aqueous washings were extracted with 
CHCl3 and the organic layers combined and dried (anhydr. MgSO4
 
). The solvent was 
evaporated in vacuo and the residue chromatographed on s ilica [column 
chromatography; elution with EtOH-EtOAc (1:20)] to afford two fractions.  
(i) 6-(N-allylamino)purine 150 as a yellow solid (45 mg, 12%), m.p. 165-167°C. 
(Found: M+, 175.085842. C8H9N5 requires: M
+, 175.085795); νmax (solid deposit/cm
-
1) 3382 (NH);  δH/ppm (400MHz; CDCl3) 4.91 (2H, d, J = 5.8 Hz, 1'-H), 5.25 (1H, d, 
J = 17.1 Hz, 3'-Ha, CH=CHZ), 5.35 (1H, d, J = 10.2 Hz, 3'-Hb CH=CHE), 6.07 (1H, 
tdd, J = 16.1, 10.4 and  5.8 Hz, 2'-H), 8.43 (1H, s, 8-H), 8.70 (1H, s, 2-H), 10.01 (1H, 
d, J = 10.0 Hz, 6-NH) and 11.12 (  1 H , d, J = 9.4 Hz, 1-NH); δC/ppm (100MHz; 
CDCl3
 
) 46.1 (C-1'), 119.6 (C-3'), 120.4 (C-5), 131.2 (C-2'), 144.2 (C-8), 149.3 (C-4), 
151.9 (C-6) and 152.5 (C-2).  
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(ii) 9-allyl-[6-amino(N-allylamino)] purine 150A as a yellow solid (8.0 mg, 2.0%),  
m.p. 103-105°C. (Found:  M+, 215.118412. C 11H13N5 requires: M
+, 215.117096); 
νmax (thin film/cm
-1) 3383 (NH); δH/ppm (400MHz; CDCl3) 4.80 (4H, d, J = 5.27 Hz, 
1'-CH2 and 1"-CH2), 5.19 (2H, m, 3"-H), 5.30 (1H, m, 3'-H), 6.02 (2H,  m, 2'-H and 
2"-H), 7.77 (1H, s, 2-H) and 8.40 (1H, s, 8-H); δC/ppm (100MHz; CDCl3
 
) 45.7 (C-1' 
and C-1"), 116.4 (C-3'), 118.9 (C-3"), 119.6 (C-5), 131.9 (C-2"), 134.3 (C-2'), 139.7 
(C-2), 152.5 (C-4), 153.2 (C-2) and 154.7 (C-6).     
4-(Tetrahydropyran-2-yloxy)-1H-pyrazolo[3,4]pyrimidine 157 
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A stirred mixture of allopurinol (1.0 g, 7.4 mmol) in 50 mL reagent grade DMF (50 
mL) was heated to ca. 75 ºC to dissolve the substrate. To the resulting solution was 
added dihydropyran (20 mL) followed by the addition of para-toluene sulphonic acid 
[16 mg in benzene (4 mL) i.e. 0.4% p-TSA in dry benzene]. The reaction mixture was 
stirred for 24 h. at room temperature. The reaction was quenched with a 4% pyridine 
in benzene solution (0.5 mL) at end of which the solvent was evaporated in vacuo at 
40ºC and the crude product dissolved in petroleum ether (100 mL) and allowed to 
crystallize overnight at 0ºC.  Recrystallisation from EtOAc-acetone afforded 4-
(tetrahydropyran-2-yloxy)-1H-pyrazolo[3,4]pyrimidine 157 as white crystals, (0.40 g, 
25%); m.p. 190-193°C (lit.184 200-201°C). νmax (solid deposit/cm
-1) 3403 ( NH); 
δH/ppm (400MHz; CDCl3) 1.62 (1H, dd, J = 7.0 and 4.6 Hz, 4'-CHa), 1.77 (2H, m, 4'-
CHb and 5'-CHa), 1.94 (1H, dd, J = 12.8 and 2.7 Hz, 3'-CHa), 2.13 (1H, m, 5'-CHb), 
2.55 (1H,  m, 3'-CHb), 3.76 (1H, dt, J = 11.4, 11.3 and 2.5 Hz, 6'-CHa), 4.12 (1H, dd, 
J = 7.6 and 6.0 Hz, 6'-CHb), 5.89 (1H, dd, J = 10.2 and 2.5 Hz, 2'-H), 8.03 (1H, s, 7-
H), 8.15 (1H, s, 2-H) and 12.22 (1H, s, NH); δC/ppm (100MHz; CDCl3) 22.7 (C-5'), 
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24.8 (C-4'), 29.4 (C-3'), 68.3 (C-6'), 83.0 (C-2'), 106.5 (C-4), 135.4 (C-7), 146.4 (C-2), 
152.4 (C-6) and  159.9 (C-5).  
 
1-Allyl-4-(tetrahydropyran-2-yloxy)-1H-pyrazolo[3,4]pyrimidine 158  
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To a stirred solution of protected allopurinol 157 (200 mg, 0.91 mmol) in dry THF (50 
mL) under nitrogen was added NaH (60% dispersion in mineral oil; 40 mg, 0.91 
mmol) in small portions to permit controlled evolution of hydrogen. Allyl bromide 
(80 µL, 0.91 mmol) was then added through a septum and the resulting solution was 
refluxed for ca. 6h. The reaction was quenched by the addition of water (50 mL). The 
solvent was evaporated in vacuo and the aqueous residue extracted with CH2Cl2 (2 × 
50 mL). The combined organic extracts were washed sequentially with water (2 × 100 
mL) and brine (2 × 100 mL). The aqueous washings were extracted with CH2Cl2 and 
the organic layers combined and dried (anhydr. MgSO4). Evaporation of the solvent 
in vacuo afforded 1-allyl-4-(tetrahydropyran-2-yloxy)-1H-pyrazolo[3,4-d]pyrimidine 
158 as a pale yellow solid (210 mg, 87%), m.p. 60-62°C. (Found: M+, 260.12774. 
C13H16N4O2 requires: M
+, 260.29174); δH/ppm (400MHz; CDCl3) 1.61 (1H, m, 4'-
CHa), 1.75 (2H, m, 4'-CHb and 5'-CHa), 1.93 (1H, m, 3'-CHa), 2.13 (1H, m, 5'-CHb), 
2.54 (1H,  m, 3'-CHb), 3.75 (1H, dt, J = 11.4 and 2.5 Hz, 6'-CHa), 4.10 (1H, m, 6'-
CHb), 4.61 (2H, m, 3"-CH2), 5.21 (1H, d, J = 17.1 Hz, CH2-CH=CHZ), 5.28 (1H, dd, 
J = 10.3 and 0.8 Hz, CH2-CH=CHE), 5.83 (1H, dd, J = 10.3 and 2.6 Hz, 2'-H), 5.94 
(1H, tdd, J = 16.1, 10.4 and  5.7 Hz, 2"-H), 7.94 (1H, s, 7-H) and 8.12 (1H, s, 2-H). 
δC/ppm (100MHz; CDCl3) 22.7 (C-5'), 24.9 (C-4'), 29.3 (C-3'), 47.8 (C-3"), 68.2 (C-
6'), 82.9 ( C-2'), 106.3 ( C-8), 118.9 ( C-1"), 132.1 (C-2"), 135.8 ( C-7), 149.0 (C-2), 
151.7 (C-6) and 156.8 (C-5).  
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Tert-Butyl 3-(5-bromo-2-hydroxyphenyl)-3-hydroxy-2-methylene propanoate 
165a 
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 To a solution of tert-butyl acrylate 164 (3.2 mL, 22 m mol) in CHCl3 (3 mL) was 
added 1,4-Diazabicyclo[2.2.2]octane (DABCO) (1.3 g, 12 mmol). The solution was 
stirred for ca. 5 mins. 5-bromo-2-hydroxybenzaldehyde 163 (3.0 g, 15 mmol) was 
then added and the reaction mixture stirred for ca. 4 days. The resultant viscous 
yellow material was eluted through silica with acetone. The solvent was taken 
evaporated in vacuo and the residue recrystallised from CHCl3 to obtain 2-[(5-Bromo-
2-hydroxyphenyl) hydroxymethyl] acrylic acid tert-butyl ester 165a as a w hite 
powder (4.3 g, 88%), m.p. 185-187ºC (lit.185 186-188°C); νmax (solid deposit/cm
-1) 
3294 OH, 1684 C=O, δH/ppm (400MHz; DMSO-d6) 1.32 (9H, s, But), 5.59-5.36 (1H, 
br s, CH-OH), 5.65 (1H, dd, J = 5.2 and 3.6 Hz, 3-Ha), 5.66 (1H, s, CH), 6.05 (1H, s, 
3-Hb), 6.75 (1H, d, J = 8.33 Hz, 4'-H), 7.21 (2H, m, 3'-H and  6'-H) and 9.81–9.53 
(1H, b, 2' -OH); δC (100MHz; DMSO-d6) 27.4 C(CH3)3, 64.5 ( C-HOH), 80.0 
C(CH3)3
 
, 109.5 (C-2'), 117.0 (C-4'), 122.8 (C-3), 129.7 (C-6'), 130.3 (C-5'), 131.8 (C-
3'), 144.8 (C-2), 153.7 (C-1') and 164.8 (C=O).  
Tert-Butyl 3-hydroxy-3-(2-hydroxyphenyl)-2-methylene propanoate 165b and 
tert-butyl 2-H-chromene-2-carboxylate 166b 
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A solution of tert-butyl acrylate 164 (5.5 mL, 38 m mol) and 1,4-Diazabicyclo-
[2.2.2]octane (DABCO) (2.2 g, 20 mmol) in CHCl3
 
 (3 mL) was stirred for ca. 5 mins. 
Salicylaldehyde 163b (2.6 mL, 25 m mol) was then added and the reaction mixture 
stirred for ca. 3 weeks. The solvent was evaporated in vacuo and the reddish residue 
chromatographed [gravity chromatography; elution with hexane:EtOAc = 7:1] to 
afford two products.   
i. Tert-butyl 3-hydroxy-3-(2-hydroxyphenyl)-2-methylene propanoate 165b as a white 
powder (0.25 g, 4.1%), m.p. 107-111°C (lit. 108-110ºC); (Found: [M-1]+, 
231.101945. C14H16O3 requires: M
+, 232.109945); νmax (solid deposit/cm
-1) 3414 
(OH) and 1687 ( C=O); δH/ppm (400MHz; CDCl3), 1.50 (9H, s, Bu
t), 4.36 (1H, d, J = 
3.9 Hz, 3-OH), 5.49 (1H, s, 3"-Ha), 5.69 (1H, d, J = 3.3 Hz, 3-H), 6.23 (1H, s, 3"-Hb),  
6.83 (1H, t, J = 7.4 Hz, 5'-H), 6.90 (1H, d, J = 8.0 Hz, 3'-H), 6.96 (1H, dd, J = 7.6 
and 1.5 Hz, 6'-H), 7.20 (1H, m, 4'-H) and 8.14 (1H, s, 2'-OH); δC (100MHz; CDCl3) 
28.0 C(CH3)3, 73.6 ( C-3), 82.6 C(CH3)3
 
, 117.5 ( C-3'), 119.8 (C-5'), 124.1 (C-1'), 
126.9 (C-3'), 127.8 (C-6'), 129.5 (C-4'), 140.8 (C-2), 155.9 (C-2') and 166.7 (C=O).  
ii. Tert-Butyl 2-H-chromene-3-carboxylate 166b   
 
Tert-Butyl 2-H-chromene-3-carboxylate 166b (21 mg, 0.37%) as a yellow oil, νmax 
(thin film/cm-1) 1699 (C=O); δH/ppm (400MHz; CDCl3), 1.52 (9H, s, Bu
t), 4.94 (2H, 
s, 2-H), 6.82 (1H, d, J = 8.1 Hz, 5-H), 6.90 (1H, t, J = 7.4 Hz, 6-H), 7.11 (1H, d, J = 
7.4 Hz, 8-H), 7.20 (1H, m, 7-H), and 7.32 (1H, s, 4-H); δC (100MHz; CDCl3) 28.1 (3 
× C(CH3)3, 64.6 (C-2), 81.2 C(CH3)3
 
, 116.0 (C-5), 121.1 (C-10), 121.6 (C-6), 124.2 
(C-3), 128.7 (C-8), 131.5 (C-7), 132.5 (C-4), 155.0 (C-9) and 163.8 (C=O). 
Tert-butyl 6-bromo-2H-chromene-3-carboxylate 166A  
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NaH (60% dispersion in mineral oil; 0.03 g, 0.61 mmol) added in small portions, to 
permit controlled evolution of hydrogen, to a stirred solution of 3-aminobenzonitrile 
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173 (72 mg, 0.61 mmol) in dry THF (10 mL) under nitrogen at 0°C. The resulting 
solution was refluxed for 1 h  and then allowed to cool. Tert-butyl 3-(5-bromo-2-
hydroxyphenyl)-3-hydroxy-2-methylene propanoate 165A (200 mg, 0.61 mmol) was 
added and the mixture refluxed for ca. 6 h. The reaction was quenched by the addition 
of water (15 mL). The solvent was evaporated in vacuo and the aqueous residue was 
extracted with EtOAc (2 × 30 m L). The combined organic extracts were washed 
sequentially with water (2 × 60 mL) and brine (2 × 60 mL). The aqueous washings 
were extracted with EtOAc and the organic layers combined and dried (anhydr. 
MgSO4). Flash chromatography [on silica gel; elution with hexane-EtOAc (8:2)] 
afforded tert-butyl 6-bromo-2H-chromene-3-carboxylate 166a, as a yellow oil, (47 
mg, 25%). (Found: M+, 310.020638. C14H15
79BrO3 requires: M
+, 310.185966);  νmax 
(solid deposit/cm-1) 1703 (C=O); δH/ppm (400MHz; CDCl3), 1.52 (9H, s, Bu
t), 4.94 
(2H, d, J = 1.3 Hz, 2-H), 6.71 (1H, d, J = 8.6 Hz, 7-H), 7.23 (2H, m, 5-H and 8-H) 
and 7.27 (1H, dd, J = 8.6 and 2.4 Hz, 4-H); δC (100MHz; CDCl3) 28.1 C(CH3)3, 64.8 
(C-2), 81.6 C(CH3)3
 
, 113.5 (C-6), 117.8 (C-7), 122.9 (C-10), 125.5 (C-3), 130.9 (C-
5), 131.1 (C-8), 134.0 (C-4), 154.0 (C-9) and 163.4 (C=O).  
6-Bromo-3-(chloromethyl)chromen-2-one 167, 6-Bromo-3-(acetoxymethyl)cou-
marin 168 and 6-Bromo-3-(hydroxymethyl)coumarin 169                  
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A mixture of tert-butyl 3-(5-bromo-2-hydroxyphenyl)-3-hydroxy-2-methylene 
propanoate (2.0 g, 6.1 m mol), conc. HCl (10 mL, 32%) and glacial acetic acid (10 
mL) was boiled under reflux for 2.5 h. T he reaction mixture was allowed to cool to 
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room temperature. Ice water (40 mL) was then added and the reaction mixture stirred 
for 30 mins. The product mixture was allowed to stand at 0ºC for 24 h and the pink 
solid was filtered off and chromatographed [flash chromatography; elution with 
hex:EtOAc=7:3] to afford 3 products. 
i. 6-Bromo-3-(chloromethyl)chromen-2-one 167 as a white powder (0.52 g, 31%), 
m.p. 102-104°C. (Found: M+, 178.064011. C10H10O3 requires: M
+, 178.062994); νmax 
(solid deposit/cm-1) 1724 C=O, δH/ppm (400MHz; CDCl3), 4.53 (2H, s, CH2), 7.23 
(1H, d, J = 8.8 Hz, 7-H), 7.62 (1H, dd, J = 8.8 and 2.3 Hz, 8-H), 7.65 (1H, d, J = 2.3 
Hz, 5-H) and 7.80 (1H, s, 4-H); δC (100MHz; CDCl3) 40.8 (CH2
 
), 117.3 (C-6), 118.4 
(C-7), 120.3 (C-10), 126.3 (C-3), 130.3 (C-5), 134.7 (C-8), 139.5 (C-4), 152.3 (C-9) 
and 159.4 (C=O). 
ii. 6-Bromo-3-(acetoxymethyl)coumarin 168 as a white powder (33 mg, 1.8%), m.p. 
119-121ºC. (Found: M+, 297.966202. C12H9BrO4 requires: M
+, 298.114208); νmax 
(solid deposit/cm-1) 1720 (C=O), δH/ppm (400MHz; CDCl3) 2.16 (3H, s, CH3), 5.06 
(1H, d, J = 1.1 Hz, CH2), 7.22 (1H, d, J = 8.7 Hz, 7-H), 7.61 (1H, dd, 8.7 and 2.3 Hz, 
8-H) and 7.64 (2H, m, 5-H and 4-H); δC (100MHz; CDCl3) 20.8 (CH3), 60.9 (CH2), 
117.2 (C-6), 118.4 (C-7), 120.3 (C-10), 125.0 (C-3), 130.2 (C-5), 134.5 (C-8), 138.9 
(C-4), 152.3 (C-9), 159.4 (2-C=O) and (CH3
  
C=O). 
iii. 6-Bromo-3-(hydroxymethyl)coumarin 169 as a white powder (0.11 g, 7.3%), m.p. 
147-149°C. (Found: M+, 253.959816. C 10H7
79BrO3 requires: M
+, 254.079497); νmax 
(solid deposit/cm-1) 3409 (OH) and 1632 (C=O); δH/ppm (400MHz; DMSO-d6) 4.36 
(1H, d,  J = 5.4 Hz, CH2), 5.52 (1H, dt, J = 5.3 and 1.3 Hz, OH), 7.37 (1H, d, J = 8.8 
Hz, 7-H), 7.71 (1H, dd, 8.8 and 2.3 Hz, 8-H), 7.94 (1H, d, J = 1.1 Hz, 4-H) and 8.05 
(1H, d, J = 2.2 Hz, 5-H); δC (100MHz; DMSO-d6) 58.1 (CH2
 
), 116.1 (C-6), 118.2 
(C-7), 121.0 (C-10), 130.1 (C-5), 130.5 (C-3), 133.3 (C-8), 135.6 (C-4), 151.3 (C-9) 
and 159.1 (C=O).  
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1-(6-Bromo-3-methyl-2H-chromen-2-one)-6-(tetrahydropyran-2-
yloxy)pyrazolo[3,4-d] pyrimidine 170A                
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Method 1  
 
To a stirred solution of protected allopurinol 157 (120 mg, 0.55 mmol) in dry THF (10 
mL) under nitrogen was added NaH (60% dispersion in mineral oil; 24 mg, 0.99 
mmol) in small portions to permit controlled evolution of hydrogen. The resulting 
solution was refluxed for 1 h a nd then cooled to room temperature before adding of  
6-bromo-3-(chloromethyl)chromen-2-one 167 (150 mg, 0.55 m mol). The reaction 
mixture was refluxed for ca. 6 h a t the end of which water (30 mL) was added to 
quench the reaction. The organic solvent was evaporated in vacuo and the aqueous 
residue extracted with CH2Cl2 (2 × 30 mL). The combined organic extracts were 
washed sequentially with water (2 × 60 m L) and brine (2 ×60 mL). The aqueous 
washings were extracted with CH2Cl2 and the organic layers combined and dried 
(anhydr. MgSO4). Evaporation of the solvent in vacuo afforded pale yellow solid that 
was chromatographed [flash chromatography; elution with hexane-EtOAc (1:1)] to 
afford 1-(6-Bromo-3-methyl-2H-chromen-2-one)-4-(tetrahydropyran-2-yloxy)pyraz-
olo[3,4] pyrimidine 170A as a white powder (77 mg, 31%), m.p. 210-212°C. (Found: 
M+, 458.041200. C20H17
81BrN4O4 requires: M
+, 458.290594); νmax (solid deposit/cm
-
1) 1720 (C=O); δH/ppm (400MHz; CDCl3) 1.60 (1H, m, 4''-Ha), 1.73 (2H, m, 4''-Hb 
and 5''-Ha), 1.90 (1H, m, 3''-Ha), 2.11 (1H, m, 5''-Hb), 2.50 (1H,  m, 3''-Hb), 3.75 (1H, 
m, 6''-Ha), 4.10 (1H, m, 6''-Hb), 5.02 (1H, s, CH2), 5.83 (1H, dd, J = 10.4 and 2.5 Hz, 
2''-H), 7.19 (1H, d, J = 8.8 Hz, 8-H), 7.60 (1H, dd, J = 8.8 and 2.3 Hz, 7-H),  7.66 
(1H, d, J = 2.3 Hz, 5-H), 8.00 (1H, s, 3'-H), 8.08 (1H, s, 2'-H) and 8.42 (1H, s, 4-H). 
δC/ppm (100MHz; CDCl3) 22.7 (C-5''), 24.8 (C-4''), 29.3 (C-3''), 45.7 (CH2), 68.3 (C-
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6''), 82.8 ( C-2''), 106.1 ( C-3), 117.4 ( C-6), 118.3 ( C-8), 120.2 ( C-5'), 123.0 (C-10), 
130.7 (C-5), 135.0 (C-7), 135.6 (C-2'), 143.2 (C-7'), 150.0 (C-4), 151.7 (C-6'), 152.4 
(C-9), 157.3 (C-4') and 160.7 (C=O).      
 
Method 2   
 
In another reaction 157 was reacted with 165A using the same procedure to afford 
170A in 14% yield.  
 
1-(3-methyl-2H-chromen-2-one)-6-(tetrahydropyran-2-yloxy)pyrazolo[3,4-d] 
pyrimidine 170B  
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To a stirred solution of protected allopurinol 157 (110 mg, 0.49 mmol) in dry THF (10 
mL) under nitrogen was added NaH (60% dispersion in mineral oil; 21 mg, 0.88 
mmol) in small portions to permit controlled evolution of hydrogen. The resulting 
solution was refluxed for 1 h a nd then cooled to room temperature before adding of  
tert-butyl 3-hydroxy-3-(2-hydroxyphenyl)-2-methylene propanoate 165B (120 mg, 
0.49 mmol). The reaction mixture was refluxed for ca. 6h. Water (30 mL) was added 
to quench the reaction. The organic solvent was evaporated in vacuo and the aqueous 
residue extracted with CH2Cl2 (2 × 30 mL). The combined organic extracts were 
washed sequentially with water (2 × 60 m L) and brine (2 × 60 m L). The aqueous 
washings were extracted with CH2Cl2 and the organic layers combined and dried 
(anhydr. MgSO4). Evaporation of the solvent in vacuo afforded pale yellow solid that 
was chromatographed [flash chromatography; elution with hexane-EtOAc (3:7)] to 
afford   1-(2H-chromen-3-carbonyl)-4-(tetrahydropyran-2-yloxy)pyrazolo[3,4] pyrim-
idine 170B as a white powder (45 mg, 24%), m.p. 210-212°C. (Found: M+, 
_________________________________________________________  Experimental 
 173 
378.132008. C20H18N4O4 requires: M
+, 378.382244); νmax (solid deposit/cm
-1) 1698 
(C=O); δH/ppm (600MHz; CDCl3) 1.59 (1H, m, 4''-Ha), 1.74 (2H, m, 4''-Hb and 5''-
Ha), 1.90 (1H, m, 3''-Ha), 2.11 (1H, m, 5''-Hb), 2.51 (1H,  m, 3''-Hb), 3.74 (1H, m, 6''-
Ha), 4.10 (1H, m, 6''-Hb), 5.03 (2H, s, CH2), 5.84 (1H, dd, J = 10.4 and 2.4 Hz, 2''-H), 
7.29 (2H, m, 6-H and  8-H), 7.52 (2H, m, 5-H and 7-H), 8.07-8.09 (2H, 2 × s , 2'-H 
and 7'-H) and 8.46 (1H, s, 4-H). δC/ppm (150MHz; CDCl3) 22.7 (C-5''), 24.8 (C-4''), 
29.4 (C-3''), 45.7 (CH2
 
), 68.3 (C-6''), 82.8 (C-2''), 106.2 (C-3), 116.6 (C-6), 118.7 (C-
7), 121.9 ( C-10), 124.8 (C-8), 128.5 ( C-5'), 132.3 (C-5), 135.6 ( C-4), 144.5 (C-7'), 
150.2 (C-2'), 151.8 (C-4'), 153.7 (C-9), 157.4 (C-6') and 161.4 (C=O).  
N-Allyl-3-cyanoaniline 177 and N,N-Diallyallyl-3-cyanoaniline 177A  
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To a stirred solution of 3-aminobenzonitrile 173 (0.50 g ,4.2 mmol) in dry THF (42 
mL) under nitrogen was added NaH (60% dispersion in mineral oil; 0.10 g, 4.2 mmol) 
in small portions to permit controlled evolution of hydrogen. Allyl bromide (0.37 mL, 
4. 2 mmol) was then added through a septum and the resulting solution was refluxed 
for ca. 48 h. The reaction was quenched by the addition of water (45 mL). The solvent 
was evaporated in vacuo and the aqueous residue extracted with EtOAc (2 × 90 mL). 
The combined organic extracts were washed sequentially with water (2 × 180 mL) 
and brine (2 × 180 mL). The aqueous washings were extracted with EtOAc and the 
organic layers combined and dried (anhydr. MgSO4). Radial chromatography [on 
silica gel; elution with hexane-EtOAc (4:1)] afforded N-Allyl-3-cyanoaniline 177 as a 
yellow oil (300 mg, 45%). (Found: M+, 158.085475. C10H10N2 requires: M
+, 
158.200253); νmax (thin film/cm
-1) 3391 (NH) 2228 (CN); δH/ppm (400MHz; CDCl3) 
3.76 (2H, m, 1'-CH2), 4.13 ( 1H, s, NH), 5.18 (1H, ddd, J = 10.3, 2.8 and 1.4 H z, 
CH=CHE), 5.26 (1H, ddd, J = 17.2, 3.1 and 1.6 Hz, CH=CHZ), 5.89 (1H, tdd, J = 
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17.1, 10.4 and 5.2 Hz, 2'-H), 6.78 (2H, m, 4-H and 6-H), 6.92 (1H, m, 2-H) and 7.19 
(1H, m, 5-H); δC/ppm (100MHz; CDCl3
In a separate reaction 3-aminobenzonitrile 173 (1.0 g, 8.5 m mol) in THF (20 mL) 
under nitrogen was NaH (60% dispersion in mineral oil; 370 mg, 15 mmol) and allyl 
bromide (0.74 mL, 8.5 mmol). Radial chromatography [on silica gel; elution with 
hexane-EtOAc (4:1)] afforded (i) N-Allyl-(3-cyano)aniline 177 as a yellow oil (410 
mg, 32%) and  
) 45.9 (C-1'), 112.7 (CN), 114.9 (C-6), 116.6 
(C-3'), 117.3 (C-4), 119.4 (C-3), 120.6 (C-2), 129.7 (C-5), 134.1 (C-2') and 148.2 (C-
1).  
(ii) N,N-Diallyallyl-3-cyanoaniline 177A as yellow oil. (130 mg, 7.6%). (Found: [M-
1]+, 197.107123. C 13H14N2 requires: M
+, 198.115699); νmax (thin film/cm
-1) 2228 
(CN); δH/ppm (400MHz; CDCl3) 3.92 (4H, m, 1'-CH2 and 1"-CH2), 5.16 (4H, m, 3'-
CH2 and 3"-CH2), 5.81 (2H, m, 2'-H and 2"-H), 6.85 (2H, m, 4-H and 6-H), 6.91 (1H, 
d, J = 7.36 Hz, 2-H) and 7.22 (1H, m, 5-H); δC/ppm (100MHz; CDCl3
 
) 52.7 (C-1' 
and C-1"), 112.7 (CN), 114.9 (C-4 or C-6), 116.2 (C-4 or C-6), 116.4 (C-3' and C-3"), 
119.4 (C-2), 119.7 (C-3), 129.6 (C-5), 132.6 (C-2' and C-2"), and 148.6 (C-1).  
2-Chloro-N-(3-cyanophenyl)acetamide 181      
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A mixture of 3-aminobenzonitrile (0.50g, 4.2 m mol) 173 and chloroacetyl chloride 
(3.3 mL, 42 mmol) was stirred under argon at room temperature for ca. 4 days. Excess 
chloroacetyl chloride was evaporated in vacuo and the residue dissolved in EtOAc (50 
mL). The solution was washed sequentially with satd. aq. NaHCO3 (2 × 50 mL) and 
brine (2 × 50 mL). The aqueous washings were extracted with EtOAc and the organic 
layers were combined and dried (anhydr. MgSO4). The solvent was evaporated in 
vacuo to afford 2-chloro-N-(3-cyanophenyl)acetamide 181 as light brown flakes (0.79 
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g, 95%), m.p. 141–144 ºC (lit.1 144–146 ºC) (Found: M+, 194.02431.  Calc. for 
C9H7ClN2O M
+ , 194.02469); νmax (solid deposit/cm
-1) 3451 (NH), 2232 (C≡N) and 
1676 (NHC=O);  δH/ppm  (400MHz; CDCl3) 4.20 (2H, s, CH2), 7.45 (1H, d, J = 1.0 
Hz, 4'-H), 7.46 (1H, m, 6'-H), 7.73 (1H, m, 5'-H), 7.98 (1H, s, 2'-H) and 8.35 (1H, s, 
NH);  δC (100MHz; CDCl3) 42.7 ( CH2), 113.3 (C-3'), 118.1 ( C-1'), 123.1 (C-2'), 
124.1 (C-5'), 128.6 (C-6'), 130.0 (C-4'), 137.5 (C≡N) and 164.1(C=O). 
 
  
Diethyl [(3-cyanophenyl)carbamoyl]methyl phosphonate 182                
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2-Chloro-N-(3-cyanophenyl)acetamide 181 (1.0 g, 5.1 mmol) was placed in an oven- 
dried round bottomed flask equipped with a reflux condenser. Triethyl phosphite (4.4 
mL, 26 mmol) was added under nitrogen through a septum. The resulting mixture was 
refluxed until the substrate 181 was shown by TLC to have been completely 
consumed (ca. 5.5h). The cooled mixture was then stirred with hexane (20 mL) for ca. 
10 minutes followed by decantation of the hexane layer to remove the excess 
phosphite. This procedure was repeated twice. The crude solid was transferred to a 
Buchner funnel and washed with more hexane to afford diethyl [(3-
cyanophenyl)carbamoyl]methyl phosphonate 182 as a cream powder (1.3 g, 84%), 
m.p. 119-125ºC (Found: M+, 296.09163. C 13H17N2O4P requires: M
+, 296.09260); 
νmax (solid deposit/cm
-1) 3423 (NH),  2231 (C≡N), 1685 (C=O), 1220 (P=O) and 1024 
(P−O−C2H5);  δH/ppm (400MHz; CDCl3) 1.39 (6H, t, J = 7.1 Hz, 2 ×  CH3), 3.09 
(2H, d, JP–H = 21.6 Hz, CH2P), 4.22 (4H,  p, J = 7.1 Hz, 2 × CH3CH2
                                                 
1http://www.acros.com/DesktopModules/Acros_Search_Results/Acros_Search_Results.aspx?search_ty
pe=CatalogSearch&SearchString=BTB02751 
), 7.21 (2H, m, 
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4'-H and 5'-H), 7.52 (1H, td, J = 6.9 and 2.3 Hz, 6'-H), 7.87 (1H, s, 2'-H) and 9.92 
(1H, s, NH); δC (100MHz; CDCl3)  16.3 (d, JP–C =24.8 Hz, 2 × CH3), 36.3 (d, JP–C = 
129.6 Hz, CH2P), 63.3 (d, JP–C = 26.8 Hz, 2 × CH2CH3), 112.6 (C-1'), 118.4 (C-3'), 
122.4 (C-2'), 123.2 (C-6'), 127.3 (C-5'), 129.5 (C-4'), 138.9 (C≡N) and 162.6 (C=O, d, 
JP−C =  4.5,);  δP/ppm  (162 MHz; CDCl3
 
) 18.3 (P=O).  
2-Acetoxy-N-(3-cyanophenyl)acetamide 184 
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NaH (60% dispersion in mineral oil; 0.17 g , 8.1 mmol) in small portions to permit 
controlled evolution of hydrogen, to a stirred solution of 3-aminobenzonitrile 176 
(0.50 g, 4.2 mmol) in dry THF (43 mL) under nitrogen at 0ºC. Acetoxyacetyl chloride 
(0.50 mL, 4.2 m mol) was then added through a septum and the resulting solution 
refluxed and monitored for ca. 5 h during which time the reaction was monitored for 
the disappearance of the substrate 173. The reaction was quenched by the addition of 
water (40 mL). The solvent was evaporated in vacuo and the aqueous residue 
extracted with CH2Cl2 (2 × 40 mL). The combined organic extracts were washed 
sequentially with 10% aq. NaHCO3 (2 × 80 mL), water (2 × 80 mL) and brine (2 × 80 
mL). The aqueous washings were extracted with CH2Cl2 and the organic layers 
combined and dried (anhydr. MgSO4). Evaporation of the solvent in vacuo afforded 
2-acetoxy-N-(3-cyanophenyl)acetamide 184 as light yellow crystals (0.78 g, 85%), 
m.p. 96-100°C. (Found M+, 218.06803, C11H10N2O3 requires M
+, 218.20920), νmax 
(solid deposit/cm-1) 3344 ( NHC=O), 2230 ( CN) and 1735 ( CH3C=O); δH/ppm 
(400MHz;CDCl3) 2.20 (3H, s, CH3), 4.68 (2H, s, C-2), 7.40 (2H, m, 5'-H and 6'-H),  
7.74 (1H, td, J = 7.6 and 2.0 H z, 4'-H) and 7.94 (1H, s, 2'-H); δC/ppm (100MHz; 
CDCl3) 20.6 (CH3), 63.0 (C-2), 112.7 (C-3'), 118.3 (C-1'), 123.2 (C-2'), 124.3 (C-4'), 
128.1 (C-5'), 129.9 (C-6'), 137.7 (C≡N), 165.6 (NHC=O) and 169.6 (CH3C=O); m/z =  
217.10 (M+-1, 4%) and 294.12 (100%). 
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2,3,4,5,6-Pentaacetyl-N-(3-cyanophenyl)gluconamide 186       
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To a solution of 3-aminobenzonitrile (0.10 g, 0.85 mmol) in pyridine (2 mL) was 
added NaH (60%  dispersion in mineral oil; 0.035 g, 0.85 mmol) in small portions to 
permit controlled evolution of hydrogen. 2,3,4,5,6-pentaacetylgluconoyl chloride 131 
(0.36 g, 0.85 mmol) was then added and the reaction mixture stirred at room 
temperature for 2.5 days. The solvent was evaporated in vacuo and the residue 
dissolved in EtOAc (30 mL). The solution was washed with water (2 × 30 mL) and 
brine (2 × 30 mL), dried (anhydr. MgSO4) and evaporated in vacuo to afford a yellow 
residue, chromatography [radial chromatography; elution with hexane-EtOAc (1:1)] 
of which afforded 2,3,4,5,6-pentaacetyl-N-(3-cyanophenyl)-gluconamide 186 as 
yellow crystals (180 mg, 41%), m.p. 103-105ºC. (Found: M+, 506.15293. 
C23H26N2O11 requires: M
+, 506.46033);  νmax (solid deposit/cm
-1) 3431 (NH), 2231 
(CN), 1747 (CH3C=O) and 1600 (NHC=O); δH/ppm (400MHz; CDCl3) 2.05-2.11 
(12H, series of singlets, 4 × OAc), 2.23 (3H, s, CH3, 6-OAc), 4.12 (1H, dd, J = 12.5 
and 5.3 Hz, 6-Ha), 4.36 (1H, dd, J = 12.5 and 3.2 Hz, 6-Hb), 5.05 (1H, ddd, J = 6.6, 
5.3 and 3.2 Hz, 5-H), 5.28 (1H, d, J = 5.9 Hz, 2-H), 5.47 (1H, dd, J = 6.7 and 4.6 Hz, 
4-H), 5.72 (1H, dd, J = 5.81 and 4.58 Hz, 3-H), 7.41 (2H, m, 4'-H and 6'-H), 7.72 
(1H, m, 5'-H), 7.89 (1H, s, 2'-H) and 8.23 (1H, s, NH); δC/ppm (100MHz; CDCl3) 
20.4, 20.6, 20.67, 20.70 and 20.73 (5 × CH3), 61.8 (C-6), 68.6 (C-3), 68.9 (C-5), 69.1 
(C-4), 71.6 (C-2), 113.1 (C-3'), 118.2 (C-1'), 123.1 (C-2'), 124.2 (C-5'), 128.4 (C-6') 
130.0 (C-4') 137.7 (C-7'), 164.6 (NH-C=O), 169.4 (2-C=O), 169.9 (3-C=O), 170.0 (5-
C=O), 170.3 (4-C=O) and 170.9 (6-C=O); m/z =  507.07 (M+
 
+1, 100%).  
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3-(Allyloxy)phenol 188 
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NaH (60% dispersion in mineral oil; 0.36 g, 9.1 mmol) was added in small portions to 
permit controlled evolution of hydrogen, to a stirred solution of 3-aminophenol (1.0 g, 
9.1 mmol) in dry THF (20 mL) under nitrogen at 0ºC. Allyl bromide (0.8 mL, 9.1 
mmol) was then added with through a septum and the resulting solution refluxed for 
ca. 6 h. The reaction was quenched by the addition of water (50 mL). The solvent was 
evaporated in vacuo and the aqueous residue extracted with EtOAc (2 × 50 mL). The 
combined organic extracts were washed sequentially with water (2 × 100 mL) and 
brine (2 × 100 m L). The aqueous washings were extracted with EtOAc and the 
organic layers combined and dried (anhydr. MgSO4). The solvent was evaporated in 
vacuo and the residue chromatographed [radial chromatography; elution with hexane-
EtOAc (7:3)] to afford 3-(allyloxy)phenol 188 as a reddish brown oil (0.38 g, 28%). 
(Found: M+, 150.067020. C9H10O2 requires: M
+, 150.068080); νmax (thin film/cm
-1) 
(OH); δH/ppm (400MHz; CDCl3) 4.50 (2H, dt, J = 5.2 and 1.5 Hz, 1'-CH2), 5.28 (1H, 
qd, J = 10.5 and 1.4 Hz, CH=CHE), 5.40 (2H, m, HC=CHZ and OH), 6.04 (1H, m, 2'-
H), 6.43 (2H, m, 2-H and 6-H), 6.52 (1H, ddd, J = 8.3, 2.2 and 1.1 Hz, 4-H) and 7.12  
(1H, t, J = 8.5, 5-H); δC/ppm (100MHz; CDCl3
 
) 68.9 (C-1'), 102.4 (C-2), 107.3 (C-4), 
108.0 (C-6), 117.8 (C-3'), 130.2 (C-5), 133.1 (C-2'), 156.6 (C-1) and  159.8 (C-3).  
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1,3-Bis(chloroacetoxy)phenol  189A  
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NaH (60% dispersion in mineral oil; 0.22 g, 9.1 mmol) was added in small portions to 
permit controlled evolution of hydrogen, to a stirred solution of resorcinol 187 (1.0 g, 
9.1 mmol) in dry THF (20 mL) under nitrogen at 0 ºC . Chloroacetyl chloride (0.71 
mL, 9.1 mmol) was then added through a septum and the resulting solution refluxed 
for ca. 6 h. The reaction was quenched by the addition of water (20 mL). The solvent 
was evaporated in vacuo and the aqueous residue extracted with EtOAc (2 × 40 mL). 
The combined organic extracts were washed sequentially with water (2 × 80 mL) and 
brine (2 × 80 mL). The aqueous washings were extracted with EtOAc and the organic 
layers combined and dried (anhydr. MgSO4). The solvent was evaporated in vacuo 
and the residue chromatographed [radial chromatography; elution with hexane-EtOAc 
(6:4)] to afford 1,3-(bischloroacetoxy)phenol 189A as a yellow oil. (570 mg, 24%), 
(Found: M+, 261.978798  C10H8
35Cl2O4 requires: M
+,  262.106210) ; νmax (thin 
film/cm-1)  1776 (C=O); δH/ppm (400MHz; CDCl3)  4.27 (4H, s, 2'-H and 2"-H), 7.03 
(1H, t, J = 2.2 Hz, 2-H), 7.06 (1H, d, J = 2.3 Hz, 4-H or 6-H), 7.08 (1H, d, J = 2.15 
Hz, 4-H or 6-H) and 7.41 (1H, t, J = 8.2 Hz, 5-H); δC/ppm (100MHz; CDCl3
 
)  40.7 
(C-2' and C-2"), 114.7 (C-2), 119.1 (C-4 and C-6), 130.1 (C-5), 150.7 (C-3 and C-1) 
and 165.3 (C-1' and C-1").   
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Resorcinol bis [(acetyloxy)acetate] 190A    
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NaH (60% dispersion in mineral oil; 48 mg, 2.0 mmol) was added in small portions to 
permit controlled evolution of hydrogen, to a stirred solution of resorcinol 187 (220 
mg, 2.0 m mol) in dry THF (15 mL) under nitrogen at 0ºC. Acetoxyacetyl chloride 
(0.22 mL, 2.0 m mol) was then added through a septum and the resulting solution 
refluxed for ca. 5 h dur ing which time the reaction was monitored for the 
disappearance of the substrate resorcinol 187. The reaction was quenched by the 
addition of water (20 mL). The solvent was evaporated in vacuo and the aqueous 
residue extracted with EtOAc (2 × 20 mL). The combined organic extracts were 
washed sequentially with water (2 × 40 m L) and brine (2 × 40 m L). The aqueous 
washings were extracted with EtOAc and the organic layers combined and dried 
(anhydr. MgSO4). Evaporation of the solvent in vacuo and chromatography of the 
residue [column chromatography with EtOH:CHCl3:hexane = 0.5:1.5:2.5] afforded 
resorcinol bis[(acetyloxy)acetate] 190A as a yellow oil (25 mg, 40%). (Found M+, 
310.067879, C14H14O8 requires 310.068868); νmax (solid deposit) 1746 δH/ppm 
(400MHz; CDCl3) 2.18 (6H, 2 × s, 2× CH3), 4.81 (4H, 2 × s, 2 × CH2), 6.96 (1H, t, J 
= 2.2 Hz, 2-H), 7.03 (2H, dd, J = 8.2 and 2.2 Hz, 4-H and 6-H) and 7.38 (1H, t, J = 
8.2 Hz, 5-H); δC/ppm (100MHz; CDCl3)  20.4 (2 × CH3), 60.7 (2 × CH2), 115.0 (C-
2), 119.2 (C-4 and C-6), 129.9 (C-5), 150.4 (C-1 and C-3), 167.8 (2 × CH2C=O) and 
170.3 (2 × CH3
 
C=O).   
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2,3,4,5,6-Pentaacetyl-O-(3-hydroxyphenyl)gluconate 191 
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To a solution of resorcinol (200 mg, 0.91 mmol) in pyridine (2 mL) was added NaH 
(60%  di spersion in mineral oil; 41 mg, 1.7 mmol) in small portions to permit 
controlled evolution of hydrogen. 2,3,4,5,6-pentaacetylgluconoyl chloride 131 (400 
mg, 0.94 mmol) was then added and the reaction mixture stirred at room temperature 
for ca. 2.5 days. The solvent was taken off in vacuo and the residue dissolved in 
EtOAc (2 × 25 mL). This solution was washed with water (2 × 50 mL) and brine (2 × 
50 mL). The organic layer was then dried (anhydr. MgSO4) and the solvent 
evaporated in vacuo to afford a reddish brown oil, flash chromatography [on silica 
gel; elution with EtOH:CHCl3:hexane (0.5:1.5:2.5)] of which afforded 2,3,4,5,6-
pentaacetyl-O-(3-hydroxyphenyl)-gluconate 191 as a yellow oil, (64 mg, 14%). 
(Found: M+, 498.137550,  C22H26O13 requires: M
+, 498.434913); νmax (thin film/cm
-
1) 3419 (OH) and 1747 (C=O); δH/ppm (400MHz; CDCl3) 2.08 ( 12H, series of 
singlets, 4 × OAc), 2.22 (3H, s, CH3, 6-OAc), 4.16 (1H, dd, J = 12.2 and 5.3 Hz, 6-
Ha), 4.32 (1H, dd, J = 12.3 and 4.0 Hz, 6-Hb), 5.14 (1H, m, 5-H), (1H, d, J = 3.53 Hz, 
2-H), 5.58 (1H, dd, J = 6.7 and 4.6 Hz, 4-H), 5.74 (1H, t, J = 4.10 Hz, 3-H), 6.59 (1H, 
t, J = 2.0 Hz, 2'-H), 6.65 (1H, dd, J = 8.0 and 1.8 Hz, 4'-H), 6.71 (1H, dd, J = 8.2 and 
1.8 Hz, 6'-H) and 7.20 (1H, t, J = 8.2 Hz, 5'-H); δC/ppm (100MHz; CDCl3
 
) 20.4, 
20.45, 20.6, 20.68 and 20.8 (5 × OAc), 61.6 (C-6), 68.3 (C-5), 68.4 (C-3), 69.2 (C-4), 
70.8 (C-2), 108.8 (C-2'), 113.2 (C-4'), 113.7 (C-4'), 130.2 (C-5'), 150.8 (C-1'), 156.7 
(C-3'), 165.4 (1'-C=O), 169.7 (5-C=O), 169.8 (3-C=O), 169.9 (4-C=O), 170.1 ( 2-
C=O) and 170.6 (6-C=O).  
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Resorcinol monoacrylate 192 and resorcinol diacrylate 192A  
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NaH (60% dispersion in mineral oil; 400 mg, 9.1 mmol) was added in small portions 
permit controlled evolution of hydrogen, to a stirred solution of resorcinol 187 (1.0 g, 
9.1 mmol) in dry THF (20 mL) under nitrogen at 0ºC. Acryloyl chloride (0.74 mL, 9.1 
mmol) was then added with through a septum and the resulting solution refluxed for 
ca. 6 h. The reaction was quenched by the addition of water (25 mL). The solvent was 
evaporated in vacuo and the aqueous residue extracted with EtOAc (2 × 25 mL). The 
combined organic extracts were washed sequentially with water (2 × 50 mL) and 
brine (2 × 50 mL). The aqueous washings were extracted with EtOAc and the organic 
layers combined and dried (anhydr. MgSO4
 
). The solvent was evaporated in vacuo 
and the residue chromatographed [preparative TLC; elution with hexane-EtOAc (1:1)] 
to afford two fractions.  
(i) Resorcinol monoacrylate 192 as a yellow oil (120 mg, 8%). (Found: M+, 
164.046723. C9H8O3 requires: M
+, 164.047344); νmax (thin film/cm
-1)  3393 (OH) 
1721 (C=O); δH/ppm (400MHz; CDCl3) 5.68 (1H, s, OH), 6.02 (1H, d, J = 10.5 Hz, 
CH=CHE), 6.31 ( 1H, dd, J = 17.3 and 10.5 Hz, 2'-H), 6.60 (1H, m, 2-H and 
CH=CHZ), 6.66 (1H, d, J = 2.2 Hz, 4-H),  6.68 ( 1 H, d, J = 2.1 Hz, 6-H) and 7.21 
(1H, t, J = 8.2 Hz, 5-H); δC/ppm (100MHz; CDCl3
 
) 109.1 (C-2), 113.2 (C-6), 113.5 
(C-4), 127.8 (C-2'), 130.1 (C-5), 133.0 (C-3'), 151.3 (C-1), 156.6 (C-3) and 164.8 
(C=O).  
(ii) Resorcinol diacrylate 192A as a yellow oil (260 mg, 13%). (Found: M+, 
218.058102. C12H10O4 requires: M
+, 218.057909.); νmax (thin film/cm
-1) 1743 (C=O); 
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δH/ppm (400MHz; CDCl3) 6.01 (1H, 2 ×  dd, J = 10.4 and 0.8 Hz, 2 × CH=CHE), 
6.30 (1H, dd, J = 17.3 and 10.4 Hz, 2'-H and 2"-H), 6.60 (2H, 2 × dd, J = 17.3 and 0.8 
Hz, 2 × CH=CHZ), 7.01 (1H, m, 2-H), 7.03 (1H, d, J = 2.1 Hz, 4-H), 7.05 (1H, d, J = 
2.1 Hz, 6-H) and 7.39 (1H, t, J = 8.1 Hz, 5-H); δC/ppm (100MHz; CDCl3
 
) 115.4 (C-
2), 119.0 (C-4 and C-6), 127.6 (C-2' and C-2"), 129.7 (C-5), 132.9 (C-3' and C-3"), 
150.9 (C-1 and C-3) and 164.1 (2 × C=O). 
N-Allyl-(3-hydroxy)aniline 194, N-Allyl-3-(allyloxy)aniline 194A and N,N-diallyl-
3-hydroxyaniline 194B 
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To a stirred solution of 3-aminophenol 193 (3.0 g, 28 m mol) in dry THF (30 mL) 
under nitrogen was added NaH (60% dispersion in mineral oil; 1.1 g, 28  mmol) in 
small portions to permit controlled evolution of hydrogen. Allyl bromide (2.4 mL, 28 
mmol) was then added through a septum and the resulting solution was refluxed for 
ca. 4.5 h. The reaction was quenched by the addition of water (50 mL). The solvent 
was evaporated in vacuo and the aqueous residue extracted with EtOAc (2 × 50 mL). 
The combined organic extracts were washed sequentially with water (2 × 100 mL) 
and brine (2 × 100 mL). The aqueous washings were extracted with EtOAc and the 
organic layers combined and dried (anhydr. MgSO4
 
). Flash chromatography [on silica 
gel; elution with hexane-EtOAc (8:2)] afforded 3 fractions.  
(i) N-Allyl-(3-hydroxy)aniline 194 a dark brown oil (680 mg, 17%). (Found M+, 
149.083104. C9H11NO requires 149.084064); νmax (thin film/cm
-1) 3388 (NH); 
δH/ppm (400MHz; CDCl3) 3.70 (2H, dt, J = 5.4 and 1.6 Hz, 1'-CH2), 5.16 (1H, qd, J 
= 10.3 and 1.40 Hz, CH=CHE), 5.26 (1H, qd, J = 17.2 and 1.6 Hz, CH=CHZ), 5.92 
(1H, m, 2'-H), 6.10 (1H, t, J = 2.3 Hz, 2-H), 6.20 (1H, dd, J = 8.0 and 2.3 Hz, 6-H), 
6.23 (1H, dd, J = 8.1 and 2.1 Hz, 4-H) and 7.02 (1H, t, J =  8.0 Hz, 5-H); δC/ppm 
_________________________________________________________  Experimental 
 184 
(100MHz; CDCl3
 
)  46.6 (C-1'), 100.3 (C-2), 105.0 (C-6), 106.2 (C-4), 116.4 (C-3'), 
130.1 (C-5), 135.1 (C-2'), 149.4 (C-1) and 156.6 (C-3). 
(ii) N-Allyl-3-(allyloxy)aniline 194A a dark brown oil (270 mg, 5.2%). (Found M+, 
189.115840. C12H15NO requires 189.115364); νmax (thin film/cm
-1) 3406 ( NH2); 
δH/ppm (400MHz; CDCl3)  3.77 (2H, dt, J = 5.4 and 1.6 Hz, 1'-CH2), 4.51 (2H, td, J 
= 5.3 and 1.5 Hz, 1"-CH2),  5.18 (1H, m, 3'-Ha), 5.30 (2H, m, 3'-Hb and 3"-Ha),  5.42 
(1H, m, 3"-Hb), 5.97 (1H, m, 2'-H), 6.07 (1H, m, 2"-H), 6.23 (1H, t, J = 2.3 Hz, 2-H),  
6.26 ( 1 H, dd, J = 8.0 and 2.2 Hz, 6-H), 6.31 (1H, dd, J = 8.1 and 2.3 Hz, 4-H)  and 
7.08 (1H, t, J = 8.1 Hz, 5-H); δC/ppm (100MHz; CDCl3
 
)  46.5 ( C-1'), 68.6 (C-1"),  
99.7 (C-2), 103.4 (C-4), 106.3 (C-6), 116.1 (C-3'), 117.3 (C-3"), 129.8 (C-5), 133.5 
(C-2"), 135.3 (C-2'), 149.4 (C-1) and 159.8 (C-3). 
(iii) N,N-Diallyl-3-(hydroxy)aniline 194B as a dark brown oil (830 mg, 16%). (Found 
M+, 189.114166. C 12H15NO requires 189.115364); νmax (thin film/cm
-1) 3363 (NH); 
δH/ppm (400MHz; CDCl3) 3.89 (4H, m, 1'-CH2 and 1"-CH2), 5.18 (4H, m, 3'-CH2 
and 3"-CH2), 5.85 (2H, m, 2'-H and 2"-H), 6.19 (1H, m, 6-H), 6.22 (1H, s, 2-H), 6.32 
(1H, m, 4-H), and 7.06 (1H, t, J = 8.1 Hz, 5-H); δC/ppm (100MHz; CDCl3
 
)  52.7 (C-
1' and C-1"), 99.6 (C-2), 103.5 (C-6), 105.3 (C-4), 116.0 (C-3' and C-3"), 129.9 (C-5), 
133.8 (C-2' and C-2"), 150.2 (C-1) and 156.4 (C-3).  
2-Chloro-N-(3-hydroxyphenyl)acetamide 195       
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To a stirred solution of 3-aminophenol (3.0 g, 28 mmol) in THF (30 mL) under 
nitrogen was added NaH (60%  di spersion in mineral oil; 1.2 g , 50 mmol) in small 
portions to permit controlled evolution of hydrogen. Chloroacetyl chloride (2.2 mL, 
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28 mmol) was then added through a septum and the resulting solution was stirred for 
ca. 6 h. The solvent was evaporated in vacuo and the residue dissolved in EtOAc (2 x 
50 mL). The organic extract was washed sequentially with satd. aq. NaHCO3 (2 × 100 
mL), water (2 x 100 m L) and brine (2 × 100 mL). The aqueous washings were 
extracted with EtOAc and the combined organic solutions were (anhydr. MgSO4). 
Evaporation of the solvent in vacuo afforded 2-chloro-N-(3-hydroxyphenyl)acetamide 
195 as a grey solid (3.9 g, 76%) m.p. 119-120°C. νmax (solid deposit/cm
-1)  3360 (OH) 
and 1642 (CO); δH/ppm (400MHz; DMSO-d6) 4.22 (2H, s, CH2), 6.48 (1H, dd, J = 
8.0 and 2.0 Hz, 6'-H), 6.94 (1H, d, J = 8.5 Hz, 4'-H), 7.09 (1H, t, J = 8.1 Hz, 5'-H), 
7.17 (1H, t, J = 2.0 Hz, 2'-H), 9.48 (1H, s, OH) and 10.18 (1H, s, NH); δC/ppm 
(100MHz; DMSO-d6) 43.6 (CH2
                                                                                         
), 106.3 (C-2'), 110.0 (C-6'), 110.9 (C-4'), 129.5 (C-
5'), 139.5 (C-1'), 157.6 (C-3') and 164.4 (C=O).    
[(3-Hydroxyphenyl)carbamoyl)methyl]phosphonate 196  
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To 2-Chloro-N-(3-hydroxyphenyl)-acetamide 195 (500 mg, 30 m mol) in an oven-
dried round bottomed flask equipped with a reflux condenser was added triethyl 
phosphite (2.6 mL,  15 mmol) under nitrogen through a septum. The resulting mixture 
was refluxed for ca. 9 h during which time the reaction was monitored by TLC. The 
cooled mixture was then stirred with hexane (20 mL) for ca. 10 minutes followed by 
decantation of the hexane layer to remove the excess phosphite; this was repeated 
twice. Evaporation of the solvent in vacuo afforded [(3-hydroxyphenyl)-
carbamoyl)methyl]phosphonate 196 as white crystals (370 mg, 48%), m.p. 115-
117°C. (Found: M+, 287.093363. C12H18NO5P requires: M
+, 287.092261); νmax (solid 
deposit/cm-1) 3263 ( OH), 1667 ( C=O), 1230 ( P=O) and 1024 ( O=P−O−C 2H5);  
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δH/ppm (400MHz; CDCl3) 1.32 (6H, t, J = 6.8 Hz, 2 × CH3), 3.05 (2H, d, JP–H = 21.1 
Hz, 1-CH2), 4.17 (4H, p, JP–H = 7.1 Hz, 2 × CH3CH2),  6.60 (1H, d, J = 8.0 Hz, 4'-
H), 6.80 (1H, d, J = 7.9 Hz, 6'-H), 7.09 (1H, t, J = 8.0 Hz, 5'-H), 7.46 (1H, s, 2'-H), 
7.99 (1H, s, OH) and 8.96 (1H, s, NH); δC (100MHz; CDCl3)  16.3 (2C, d, JP–C = 6.0 
Hz, 2 × CH3), 36.4 (1C, d, JP–C = 130.4 Hz, 1-CH2), 63.3 (2C, d, JP–C = 6.6 Hz, 2 × 
CH2), 107.3 (C-2'), 111.1 (C-6'), 112.1 (C-4'), 129.8 (C-5'), 138.5 (C-1'), 157.3 (C-3') 
and 162.7 (1C, d, JP−C = 4.1 Hz, C=O);  δP/ppm  (162 MHz; CDCl3
 
) 24.2 (P=O).  
2-Acetoxy-N-(3-hydroxyphenyl)acetamide 197                 
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NaH (60% dispersion in mineral oil; 60 mg, 2.5 mmol) was added in small portions to 
a stirred solution of 3-aminophenol (150 mg, 1.4 mmol) in dry THF (10 mL) under 
nitrogen at 0ºC, to permit controlled evolution of hydrogen. Acetoxyacetyl chloride 
(160 µL, 2.5 m mol) was then added through a septum and the resulting solution 
refluxed for ca. 5.0 h. The reaction was quenched by the addition of water (20 mL). 
The solvent was evaporated in vacuo and the aqueous residue was extracted with 
EtOAc (2 × 40 mL). The combined organic extracts were washed sequentially with 
water (2 × 80 mL) and brine (2 × 80 mL). The aqueous washings were extracted with 
EtOAc and the organic layers combined and dried (anhydr. MgSO4). Evaporation of 
the solvent in vacuo and chromatography of the residue [column chromatography with 
EtOH:CHCl3:hex= (0.5:1.5:2.5)] afforded 2-acetoxy-N-(3-hydroxyphenyl)acetamide 
197 as a grey powder (70 mg, 24%), m.p. 154-156°C. (Found M+, 209.068446, 
C10H11NO4 requires 209.068808), νmax (solid deposit/cm
-1)  3424 ( OH),  173 4 
(CH3C=O), 1678 (NHC=O); δH/ppm (400MHz; DMSO-d6) 2.11 (3H, s, CH3), 4.61 
(2H, s, CH2), 6.46 (1H, dd, J = 7.9 and 2.2 Hz, 6'-H),  6.93 (1H, d, J = 8.3 Hz, 4'-H), 
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7.07 (1H, t, J = 8.06 Hz, 5'-H), 7.13 (1H, t, J = 2.0 Hz, 2'-H), 9.39 (1H, br s, OH) and 
9.92 (1H, s, NH); δC/ppm (100MHz; DMSO-d6) 20.4 (CH3), 62.5 (CH2), 106.3 (C-
2'), 109.9 (C-4'), 110.5 (C-6'), 129.3 (C-5'), 139.3 (C-1'), 157.5 (C-3'), 165.2 (C-1) and 
169.9 (CH3
 
C=O).  
2,3,4,5,6-Pentaacetyl-N-(3-hydroxyphenyl)-gluconamide 198   
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To a solution of 3-aminophenol (0.10 g, 0.92 mmol) in pyridine (2 mL) was added 
NaH (60%  dispersion in mineral oil; 0.041 g, 0.92 mmol) in small portions to permit 
controlled evolution of hydrogen. 2,3,4,5,6-pentaacetylgluconoyl chloride 131 (0.40 
g, 0.92 mmol) was then added and the reaction mixture stirred at room temperature 
for ca. 2.5 days. The solvent was taken off in vacuo and the residue dissolved in 
EtOAc (30 mL). This solution was washed with water (2 × 30 mL) and brine (2 × 30 
mL). The organic layer was then dried (anhydr. MgSO4) and the solvent was 
evaporated in vacuo to afford a reddish brown oil, flash chromatography [on silica 
gel; elution with hexane-EtOAc (4:6)] of which afforded 2,3,4,5,6-pentaacetyl-N-(3-
hydroxyphenyl)-gluconamide 198 as a reddish brown oil, (93 mg, 20%). (Found: M+, 
497.15132. C22H27NO12 requires: M
+, 497.45019); νmax (solid deposit/cm
-1) 3427 
(OH), 1740 (CH3C=O) and 1605 (NHC=O); δH/ppm (400MHz; CDCl3) 2.06 (12H, 
series of singlets, 4 × OAc), 2.22 (3H, s, CH3, 6-OAc), 4.12 (1H, dd, J = 12.4 and 5.5 
Hz, 6-Ha), 4.34 (1H, dd, J = 12.4 and 3.3 Hz, 6-Hb), 5.06 (1H, dt, J = 6.0, 5.8 and 3.4 
Hz, 5-H), 5.34 (1H, d, J = 5.4 Hz, 2-H), 5.47 (1H, dd, J = 6.5 and 4.7 Hz, 4-H), 5.70 
(1H, t, J = 5.00 Hz, 3-H), 6.63 (1H, dd, J = 8.1 and 2.0 Hz, 4'-H),  6.81 (1H, dd, J = 
8.0 and 1.1 Hz, 6'-H), 7.13 (1H, t, J = 8.1 Hz, 5'-H), 7.33 (1H, s, 2'-H) and 8.10 (1H, 
s, NH); δC/ppm (100MHz; CDCl3) 20.4, 20.6, 20.66 and 20.72 (5 × OAc), 61.7 (C-6), 
68.9 (C-3), 69.0 (C-5), 69.2 (C-4), 71.8 (C-2), 107.4 (C-2'), 111.6 (C-6'), 112.4 (C-4'), 
130.0 (C-5'), 137.6 (C-3'), 156.9 (C-1'), 164.6 (NH-C=O), 169.6 (5-C=O), 169.9 (3-
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C=O), 170.0 (2-C=O), 170.3 (4-C=O) and 170.9 (6-C=O); m/z = 496.11 (M+
 
-1, 28 %) 
and 412.25 (100%).  
N-(3-Hydroxyphenyl) acryloyl amine 199 and 3-(acryloylamino)phenyl acrylate 
199A  
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To a stirred solution of 3-aminophenol (0.50 mg, 4.6 m mol) in dry THF (15 mL) 
under nitrogen was added NaH (60% dispersion in mineral oil; 0.11 g, 4.6 mmol) in 
small portions to permit controlled evolution of hydrogen. Acryloyl chloride (0.37 
mL, 4.6 mmol) was then added through a septum and the resulting solution was 
refluxed for ca. 6 h. The reaction was quenched by the addition of water (20 mL). The 
solvent was evaporated in vacuo and the aqueous residue extracted with EtOAc (2 × 
40 mL). The combined organic extracts were washed sequentially with water (2 × 80 
mL) and brine (2 × 80 mL). The aqueous washings were extracted with EtOAc and 
the organic layers combined and dried (anhydr. MgSO4
  
). Preparative thin layer 
chromatography [on silica gel; elution with hexane-EtOAc (4:6)] afforded two 
fractions.   
(i) N-(3-hydroxyphenyl)acryloyl amine 199 as a yellow oil, (5.4 mg, 0.72%). (Found: 
M+, 163.076095. C9H9NO2 requires: M
+, 163.063329); νmax (thin film/cm
-1) 3419 
(OH) 1667 (C=O); δH/ppm (400MHz; CDCl3) 6.01 (1H, d, J = 10.5 Hz, 3'-Ha), 6.30 
(1H, dd, J = 17.3 and 10.5 Hz, 2'-H), 6.60 (1H, d, J = 17.3 Hz, 3'-Hb), 6.89 (1H, d, J 
= 7.0 Hz), 7.34 ( 2H, m, 5-H and 6-H) and 7.50 (1H, s, 2-H); δC/ppm (150MHz; 
CDCl3) 113.5 (C-2), 117.1 (C-6), 17.6 (C-4), 127.8 (C-2'), 129.7 (C-5), 132.9 (C-3'), 
138.5 (C-1), 150.9 (C-3) 164.6 and 167.7 (H-N-C=O).  
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(ii) 3-(Acryloylamino)phenyl acrylate 199A as yellow oil, (12 mg, 1.2%). (Found: 
M+, 217.072324. C12H11NO3 requires: M
+, 217.073893); νmax (thin film/cm
-1) 
1731(C=O) and 1663 (NHC=O); δH/ppm (400MHz; CDCl3) 5.70 (1H, d, J = 10.2 Hz, 
3"-Ha), 6.03 (1H, d, J = 10.4 Hz, 3'-Ha),  6.16 (1H, dd, J = 16.8 and 10.3 Hz, 2"-H), 
6.32 (2H, m, 2'-H and 3"-Hb), 6.60 (1H, d, J = 17.3 Hz, 3'-Hb), 6.82 (1H, d, J = 7.09 
Hz, 6-H), 7.24 (2H, m, 4-H and 5-H), 7.58 (1H, s, 2-H) and 7.95 (1H, s, NH); δC/ppm 
(100MHz; CDCl3
 
) 113.5 (C-2), 117.2 (C-4), 117.3 (C-6), 127.7 (C-2'), 127.9 (C-3"), 
129.6 (C-5),130.9 (C-1),133.1 (C-3'), 139.1 ( C-3), 150.7 ( C-1), 163.7 (C=O) and 
165.0 (NHC=O).  
N-Allyl-3-(hydroxymethyl) aniline 201, N-allyl-3-[(allyloxy)methyl] aniline 201A, 
N,N-diallyl-3-(hydroxymethyl)aniline 201B and 3-[Allyloxy)methyl]aniline 201C   
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To a stirred solution of 3-aminobenzyl alcohol 200 (1.0 g, 8.1 mmol) in dry THF (41 
mL) under nitrogen was added NaH (60% dispersion in mineral oil; 0.30 g, 8.1 mmol) 
in small portions to permit controlled evolution of hydrogen. Allyl bromide (0.80 mL, 
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8.1 mmol) was then added through a septum and the resulting solution was refluxed 
for ca. 6h. The reaction was quenched by the addition of water (50 mL). The solvent 
was evaporated in vacuo and the aqueous residue extracted with EtOAc (2 × 50 mL). 
The combined organic extracts were washed sequentially with water (2 × 100 mL) 
and brine (2 × 100 mL). The aqueous washings were extracted with EtOAc and the 
organic layers combined and dried (anhydr. MgSO4
 
). Flash chromatography [on silica 
gel; elution with hexane-EtOAc (7:3)] afforded four fractions.   
i. N-Allyl-3-(hydroxymethyl) aniline 201 a reddish brown oil (130 mg, 10%). (Found 
M+, 163.098763. C 10H13NO requires 163.099714); νmax (thin film/cm
-1) 3347 ( OH 
and NH); δH/ppm (400MHz; CDCl3) 3.76 (2H, td, J = 5.4 and 1.6 Hz, 1'-CH2), 4.58 
(2H, s, 7-CH2), 5.16 (1H, ddd, J = 10.3, 3.0 and 1.5 Hz, CH=CHE), 5.28 (1H, ddd, J 
= 17.2, 3.3 and 1.6 Hz, CH=CHZ), 5.95 (1H, m, 2'-H),  6.54 (1H, dd, J = 8.0 and 2.2 
Hz, 6-H), 6.62 (1H, s, 2-H), 6.68 (1H, d, J = 7.47 Hz, 4-H) and 7.15 (1H, t, J = 7.8 
Hz, 5-H); δC/ppm (100MHz; CDCl3
 
) 46.5 (C-1'), 65.6 ( C-7), 111.4 (C-2), 112.2 (C-
6), 116.0 (C-4), 116.2 (C-3'), 129.4 (C-5), 135.3 (C-2'), 142.1 (C-1) and 148.3 (C-3).     
ii. N-Allyl-3-[(allyloxy)methyl] aniline 201A as reddish brown oil (140 mg, 8.5%). 
(Found: M+, 203.130341. C13H17NO requires: M
+, 203.131014); νmax (thin film/cm
-1) 
3393 (NH); δH/ppm (400MHz; CDCl3) 3.78 (2H, td, J = 5.4 and 1.5 Hz, 1'-CH2), 
4.02 (1H, td, J = 5.6 and 1.4 Hz, 3-H), 4.46 (2H, s, CH2), 5.18 (1H,  m, 3'-H), 5.29 
(2H, qdd, J = 17.2, 9.8 and 1.6 Hz, 3"-H), 5.96 (2H,  m, 2"-H and 2'-H), 6.55 (1H, dd, 
J = 8.0 and 2.3 Hz, 6-H), 6.64 (1H, s, 2-H), 6.68 (1H, d, J = 7.5 Hz, 4-H), 7.14 (1H, 
dd, J = 9.6 and 5.9 Hz, 5-H). δC/ppm (100MHz; CDCl3) 46.5 (C-1'), 71.0 (C-1"), 72.3 
(CH2
 
), 112.15 (C-2), 112.20 (C-6), 116.2 (C-3'), 116.91 (C-3"), 116.93 (C-4), 129.2 
(C-5), 134.8 (C-2"), 135.3 (C-2'), 139.4 (C-3) and 148.2 (C-1).        
iii. N,N-bis allyl-3-(hydroxymethyl) aniline 201B as a reddish brown oil, (82 mg, 
6.2%). (Found: M+, 203.131507. C10H17NO requires: M
+, 203.131014); νmax (thin 
film/cm-1) 3360 (OH) and (NH); δH/ppm (400MHz; CDCl3) 3.93 (4H, m, 1'-H and 1"-
H), 4.60 (2H, s, CH2), 5.17 (4H,  m, 3'-H and 3"-H), 5.86 (2H, tdd, J = 17.1, 10.1 and 
4.9 Hz, 2'-H and 2"-H), 6.63 (1H, dd, J = 8.3 and  2.5 Hz, 6-H), 6.67 (1H, d, J = 7.4 
Hz, 4-H),  6.71 (1H, d, J = 1.1 Hz, 2-H) and 7.18 (1H, t, J =  7.9 Hz, 5-H); δC/ppm 
(100MHz; CDCl3) 52.7 (C-1' and C-1"), 65.9 (CH2), 110.8 (C-2), 111.7 (C-6), 114.9 
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(C-4), 116.0 ( C-3' and C-3"), 129.3 ( C-5), 133.8 (C-2' and C-2"), 141.9 (C-3) and 
148.9 (C-1). 
 
iv. 3-[(allyloxy)methyl]aniline 201C as a reddish brown oil (140 mg, 11%). (Found: 
M+, 163.099525. C 10H13NO requires: M
+, 163.099714); νmax (thin film/cm
-1) 3356 
(NH2); δH/ppm (400MHz; CDCl3) 3.50 (2H, b, NH2), 4.02 (2H, td, J = 5.6 and 1.2 
Hz, 1'-CH2), 4.44 (2H, s, 7-CH2), 5.20 (1H, dd, J = 10.4 and 1.3 Hz, CH2−CH=CHE), 
5.30 (1H, qd, J = 17.2 and 1.5 Hz, CH2-CH=CHZ), 5.95 (1H, tdd, J = 17.2, 10.5 and 
5.6 Hz, 2'-H), 6.60 (1H, dd, J = 7.9 and 1.7 Hz, 6-H), 6.69 (1H, s, 2-H), 6.72 (1H, d, J 
= 7.2Hz, 4-H) and 7.11 (1H, dd, J = 9.6 and 5.8 Hz, 5-H); δC/ppm (100MHz; CDCl3
 
) 
71.0 (C-1'), 72.1 (C-7), 114.2 (C-2), 114.3 (C-6), 117.0 (C-3'), 117.9 (C-4), 129.2 (C-
5), 134.8 (C-2'), 139.5 (C-3) and 146.5 (C-1).  
2-Chloro-N-[3-(hydroxymethyl)phenyl]acetamide 202 and 3-(Chloroacetamido)-
benzyl chloroacetate 202A 
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 NaH (60% dispersion in mineral oil; 0.20 g, 8.1 mmol) was added in small portions 
to permit controlled evolution of hydrogen, to a stirred solution of 3-aminobenzyl 
alcohol 200 (1.0 g, 8.1 mmol) in dry THF (20 mL) under nitrogen at 0°C. 
Chloroacetyl chloride (0.64 mL, 8.1 mmol) was then added through a septum and the 
resulting solution refluxed for ca. 8h. The reaction was quenched by the addition of 
water (30 mL). The solvent was evaporated in vacuo and the aqueous residue was 
extracted with EtOAc (2 × 30 mL). The combined organic extracts were washed 
sequentially with water (2 × 60 mL) and brine (2 × 60 mL). The aqueous washings 
were extracted with EtOAc and the organic layers combined and dried (anhydr. 
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MgSO4
 
). The solvent was evaporated in vacuo and the residue was chromatographed 
[Column   chromatography; elution with hexane-EtOAc (1:1)] to afford two products: 
i. 2-Chloro-N-[3-(hydroxymethyl)phenyl]acetamide 202 as a light brown solid (0.60 
g, 37%) m.p. 88-90°C. (Found: M+, 199.03915. C9H10NO2
35Cl  requires: M
+, 
199.15044); νmax (solid deposit/cm
-1) 3378 ( OH), 1681 ( C=O) and 1615 (NHCO); 
δH/ppm (400MHz; DMSO-d6) 4.23 (2H, s,  1"-H), 4.48 (2H, d, J = 5.2 Hz, CH2Cl), 
5.17 (1H, d, J = 5.0 Hz, OH), 7.03 (1H, d, J = 7.3 Hz, 6'-H),  7.27 (1H, t, J = 7.7 Hz, 
5'-H), 7.47 (1H, d, J = 7.8 Hz, 4'-H), 7.56 ( 1H, s, 2'-H) and 10.23 (1H, s, NH) ; 
δC/ppm (100MHz; DMSO-d6) 43.4 (CH2OH), 62.6 (CH2Cl), 117.3 (C-2'), 117.6 (C-
4'), 121.7 (C-6'), 128.3 (C-5'), 138.2 (C-1'), 143.2 (C-3') and  164.4 (C=O); m/z = 199 
(M+
 
, 10%) and 198 (100%).  
ii. 3-(Chloroacetamido)-benzyl chloroacetate 202A as a yellow solid (0.41 g, 18%), 
m.p. 84-86°C. (Found: M+, 275.01078. C11H11NO3
35Cl2  requires: M
+, 275.14811); 
νmax (solid deposit/cm
-1) 3411 (NH), 1747 (O.C=O), 1664 (C=O) and 1617 (NHC=O); 
δH/ppm (400MHz; CDCl3) 4.10 (2H, s, 2-CH2), 4.18 (2H, s, 2"-CH2), 5.19 (2H, s, 7'-
H), 7.17 (1H, d, J = 7.6 Hz, 4'-H), 7.36 (1H, t, J = 7.9 Hz, 5'-H), 7.52 (1H, d, J = 8.14 
Hz, 6'-H), 7.60 (1H, s, 2'-H) and 8.28 (1H, s, NH); δC/ppm (100MHz; CDCl3) 40.8 
(C-2), 42.8 (C-2"), 67.4 (C-7'), 119.9 (C-6'), 120.2 (C-2'), 125.0 (C-4'), 129.5 (C-5'), 
136.1 (C-1'), 137.0 (C-3'), 163.9 (C-1") and 167.1 (C-1); m/z = 274.12 (M+
 
-1, 50%) 
and 314.02 (100%).  
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Diethyl {[3-(hydroxymethyl)phenyl]carbamoyl}methyl] phosphonate 203    
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Triethyl phosphite (1.6 mL, 9.3 mmol) was added under nitrogen through a septum to 
2-chloro-N-(3-hydroxymethylphenyl)acetamide 202 (150 mg, 0.75 mmol) in an oven- 
dried round bottomed flask equipped with a reflux condenser. The resulting mixture 
was refluxed for ca. 5.5h during which time the reaction was monitored by TLC. The 
cooled mixture was then stirred with hexane (20 mL) for ca. 10 minutes followed by 
decantation of the hexane layer to remove the excess phosphite; this was repeated 
twice. The residual brown oil that was chromatographed [column chromatogragpy; 
elution with EtOAc:EtOH = 20:1] to afford diethyl {[3-
(hydroxymethyl)phenyl]carbamoyl}methyl] phosphonate 203 as a light yellow oil (77 
mg, 34%). (Found: M+, 301.10706. C13H20NO2P requires: M
+, 301.27591); νmax (thin 
film/cm-1) 3400 (OH), 1670 NHC=O (1613), 1232 (P=O) and 1023 (O=P−O−C 2H5);  
δH/ppm (400MHz; CDCl3) 1.35 (6H, t, J = 7.1 Hz, 2 × CH3), 1.78 (1H, br s, OH), 
3.04 (2H, d, JP–H = 21.1 Hz, CH2P), 4.18 (4H, m, 2 × CH3CH2), 4.57 (2H, s, 7-H), 
6.98 (1H, d, J = 7.5 Hz, 6-H), 7.18 (1H, t, J = 7.8 Hz, 5-H), 7.39 (1H, s, 2-H), 7.43 
(1H, d, J = 8.1 Hz, 4-H) and 9.27 (1H, s, NH); δC (100MHz; CDCl3)  16.3 (2C, d, JP–
C = 6.1 Hz, 2 × CH3), 36.3 (d, JP–C = 129.9 Hz, CH2P), 63.1 (d, JP–C = 6.5 Hz, 2 × 
CH2CH3),  64.8 (C-7), 118.1 (C-2), 118.7 (C-4), 122.6 (C-6), 128.9 (C-5), 138.1 (C-
1), 141.9 (C-3) and 162.3 (C=O, d, JP−C =  3.9) ;  δP/ppm  (162 MHz; CDCl3
 
) 23.5 
(P=O).  
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N-Acryoyl-3-(hydroxymethyl)aniline 204 and 3-acrylamidobenzyl acrylate 204A   
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To a stirred solution of 3-aminobenzyl alcohol 200 (0.50 g, 4.1 mmol) in dry THF (20 
mL) under nitrogen was added NaH (60% dispersion in mineral oil; 0.098 g, 4.1 
mmol) in small portions to permit controlled evolution of hydrogen. Acryloyl chloride 
(0.33 mL, 4.1 mmol) was then added through a septum and the resulting solution was 
refluxed for ca. 6 h. The reaction was quenched by the addition of water (30 mL). The 
solvent was evaporated in vacuo and the aqueous residue extracted with EtOAc (2 × 
30 mL). The combined organic extracts were washed sequentially with water (2 × 60 
mL) and brine (2 × 60 mL). The aqueous washings were extracted with EtOAc and 
the organic layers combined and dried (anhydr. MgSO4
  
). Preparative thin layer 
chromatography [on silica gel; elution with hexane-EtOAc (4:6)] afforded two 
fractions.   
(i) N-Acryoyl-3-(hydroxymethyl)aniline 204 as a yellow oil, (7.2 mg, 1%). Found: M+, 
177.078091. C10H11NO2 requires: M
+, 177.078979); νmax (thin film/cm
-1)  3296 (OH) 
and 1711 (C=O); δH/ppm (600MHz; CDCl3) 5.17 (1H, s, 7-CH2), 5.85 (1H, d, J = 
10.5 Hz, 3'-Ha), 6.16 (1H, dd, J = 17.3 Hz and 10.5 Hz, 2'-H), .45 (1H, d, J = 17.3 
Hz, 3'-Hb), 7.14 (1H, d, J = 7.7 Hz, 4-H), 7.32 (1H, t, J = 7.8 Hz, 5-H), 49 (1H, d, J = 
7.7 Hz, 6-H) and 7.56 (1H, s, 2-H); δC/ppm (150MHz; CDCl3
 
) 66.0 (C-7), 119.6 (C-
2), 119.9 ( C-6), 124.3 (C-4), 128.2 ( C-2'), 129.5 (C-5), 131.3 (C-3'), 137.0 (C-1), 
137.7 (C-3) and 167.7 (C=O).  
(ii) 3-acrylamidobenzyl acrylate 204A as a yellow oil, (0.019, 2%). (Found: M+, 
231.088347. C13H13NO3 requires: M
+, 231.089543); νmax (thin film/cm
-1) 1713 
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(C=O) and 1665 NHC=O; δH/ppm (400MHz; CDCl3) 5.18 (1H, s, 7-CH2) , 5.78 (1H, 
dd, J = 10.2 and 1.1 Hz, 3"-Ha), 5.85 (1H,  dd, J = 10.4 and 1.3 Hz, 3'-Hb), 6.20 (2H, 
m, 2'-H and 2"-H), 6.42 (1H, dd, J = 5.2 and 1.2 Hz, 3"-Hb), 6.46 (1H, dd, J = 5.7 
and 1.1 Hz, 3'-Hb), 7.14 (1H, d, J = 7.5 Hz, 6-H), 7.33 (1H, t, J = 7.8 Hz, 5-H), 7.55 
(1H, d, J = 6.8 Hz, 4-H) and 7.61 (1H, s, 2-H); δC/ppm (100MHz; CDCl3) 66.0 (7-
CH2
 
), 119.8 (C-4), 124.2 (C-6), 128.2 (C-2' and C-2"), 129.3 (C-5), 131.3 (C-3' and 
C-3"), 136.9 (C-1 and C-3) and 166.0 (2 × C=O).  
2-Acetoxy-N-[(3-hydroxymethyl)phenyl]-acetamide 205 
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NaH (60% dispersion in mineral oil; 0.33 g, 8.1 mmol) was added in small portions to 
a stirred solution of 3-aminobenzyl alcohol (1.0 g, 8.1 m mol) in dry THF (20 mL) 
under nitrogen at 0 ºC , to permit controlled evolution of hydrogen. Acetoxyacetyl 
chloride (0.90 mL, 8.1 mmol) was then added through a septum and the resulting 
solution refluxed for ca. 5.0 h. The reaction was quenched by the addition of satd. aq. 
NaHCO3 (50 mL). The solvent was evaporated in vacuo and the aqueous residue was 
extracted with EtOAc (2 × 50 mL). The combined organic extracts were washed 
sequentially with water (2 × 100 mL) and brine (2 × 100 mL). The aqueous washings 
were extracted with EtOAc and the organic layers combined and dried (anhydr. 
MgSO4). Evaporation of the solvent in vacuo and chromatography of the residue 
[radial chromatography with hexane-EtOAc (1:9)] to afforded 2-acetoxy-N-[(3-
hydroxymethyl)phenyl]-acetamide 205 as a light yellow oil (0.26 g, 14%). (Found M+, 
223.08369, C11H13NO4 requires 223.22569), νmax (solid deposit/cm
-1) 3354 (OH), 
1741 (CH3C=O), 1678 (NHC=O); δH/ppm (400MHz; CDCl3) 2.19 (3H, s, CH3), 4.62 
(2H, s, CH2OH),  4.63 (2H, s, CH2), 5.28 (1H, s, OH), 7.09 (1H, d, J = 7.6 Hz, 4'-H),  
7.27 (1H, t, J = 7.8 Hz, 5'-H), 7.43 (1H, d, J = 8.40 Hz, 6'-H), 7.47 (1H, s, 2'-H) and 
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8.04 (1H, s, NH); δC/ppm (100MHz; CDCl3) 20.7 (CH3), 63.2 ( C-2), 64.7 ( CH2), 
118.7 (C-2'), 119.4 (C-6'), 123.4 (C-4'), 129.2 (C-5'), 136.9 (C-1'), 142.1 (C-3'), 165.3 
(C-1) and 169.6 (CH3C=O); m/z = 224.13 (M+
 
+1, 35%) and 206.21 (100%).  
2,3,4,5,6-Pentaacetyl-N-[3-(hydroxymethylphenyl)]-gluconamide 206       
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To a solution of 3-aminobenzyl alcohol 200 (100 mg, 0.81 m mol) pyridine (2 mL) 
was added NaH (60% dispersion in mineral oil; 37 m g, 0.81 m mol) was added in 
small portions to permit controlled evolution of hydrogen. 2,3,4,5,6-
pentaacetoxyhexanoyl chloride 131 (350 mg, 0.81 m mol) was then added and the 
reaction mixture stirred at room temperature for 2.5 days. The solvent was evaporated 
in vacuo and the residue dissolved in EtOAc (30 mL). This solution was washed with 
satd. aq. NaHCO3 (2 × 30 mL) and brine (2 × 30 mL). The organic layer was then 
dried (anhydr. MgSO4) and the solvent was evaporated in vacuo to afford a reddish 
brown oil of which flash chromatography [on silica gel; elution with hexane-EtOAc 
(4:6)] afforded 2,3,4,5,6-pentaacetyl-N-[3-(hydroxymethylphenyl)]-gluconamide  206 
as a light brown oil, (58 mg, 14%). (Found: M+, 511.16685. C23H29NO12 requires: 
M+, 511.47681) νmax (solid deposit/cm
-1)  3413  (OH), 1747 ( CH3C=O) and 1602 
(NHC=O); δH/ppm (400MHz; CDCl3) 2.06 (12H, series of singlets, 4 ×  OAc), 2.23 
(3H, s, 6-OAc), 4.11 (1H, dd, J = 12.4 and 5.5 Hz, 6-Ha), 4.31 (1H, dd, J = 12.3 and 
3.5 Hz, 1-Hb), 4.63 (1H, s, CH2), 5.06 (1H, dt, J =5.7, 5.6 and 3.8 Hz, 5-H), 5.34 (1H, 
d, J = 5.7 Hz, 2-H), 5.48 (1H, dd, J = 6.7 and 4.5 Hz, 4-H), 5.70 (1H, m, 3-H), 7.10 
(1H, d, J = 7.7 Hz, 6'-H), 7.25 (1H, s, OH), 7.29 (1H,  m, 5'-H), 7.40 (1H, d, J = 8.2 
Hz, 4'-H), 7.47 (1H, s, 2'-H) and 8.07 (1H, s, NH); δC/ppm (100MHz; CDCl3) 20.4, 
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20.6, and 20.7 (5 × OAc), 61.6 (C-6), 64.8 (C-7'), 68.7 (C-3), 68.8 (C-5), 69.1 (C-4), 
71.8 (C-2), 118.5 (C-2'), 119.3 (C-4'), 123.4 (C-6'), 129.2 (C-5'), 136.9 (C-1'), 142.1 
(C-3'), 164.3 ( NH-C=O), 169.4 ( 3-C=O), 169.8 ( 2-C=O), 169.9 ( 5-C=O), 170.1 ( 4-
C=O) and 170.7 (6-C=O).  
 
Allyl (3-hydroxy)benzoate 208 and allyl 3-(allyloxy)benzoate 208A  
OH
O
O1
2
3
4
5
6
1'
2'
3'
O
O
O
1
2
3
4
5
6 1''
2''
3''
1'
2'
3'
 
To a stirred solution of 3-hydroxybenzoic acid 207 (0.50 g , 3.6 mmol) in dry DMF 
(36 mL) under nitrogen was added NaH (60% dispersion in mineral oil; 170 mg, 7.2 
mmol) in small portions to permit controlled evolution of hydrogen. Allyl bromide 
(0.34 mL, 4.0 mmol) was then added through a septum and the resulting solution was 
refluxed for ca. 48 h. The reaction was quenched by the addition of water (40 mL). 
The solvent was evaporated in vacuo and the aqueous residue extracted with EtOAc 
(2 × 80 mL). The combined organic extracts were washed sequentially with water (2 
× 160 mL) and brine (2 × 160 mL). The aqueous washings were extracted with EtOAc 
and the organic layers combined and dried (anhydr. MgSO4
 
). Radial chromatography 
[on silica gel; elution with hexane-EtOAc (4:1)] afforded two fractions.  
(i) Allyl 3-hydroxybenzoate 208 as a yellow oil that crystallized at 0°C. (330 mg, 
52%), m.p. 43-45°C. (Found: M+, 178.064011. C13H14O3  requires: M
+, 178.062994); 
νmax (thin film/cm
-1) 3410 (OH) and 1693 (CO); δH/ppm (400MHz; CDCl3) 4.82 (2H, 
td, J = 5.6 and 1.3 Hz, 1'-CH2), 5.28 (1H, dd, J = 10.5 and 1.24 Hz, CH=CHE) 5.40 
(1H, ddd, J = 17.2, 2.9 and 1.43 Hz, CH=CHZ), 5.84 (1H, br s, OH), 6.02 (1H, tdd, J 
= 16.1, 10.6 and 5.6 Hz, 2'-H), 7.07 (1H, ddd, J = 8.1, 2.6 and 0.9 Hz, 4-H), 7.31 (1H, 
t, J = 7.9 Hz, 5-H) and 7.61 (2H, m, 2-H and 6-H); δC/ppm (100MHz; CDCl3) 65.8 
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(C-1'), 116.4 (C-2), 118.4 (C-3'), 120.4 (C-4), 122.0 (C-6), 129.7 (C-5), 131.4 (C-2'), 
131.9 (C-1), 155.9 (C-3) and 166.4 (C=O). 
 
(ii) Allyl 3-(allyloxy)benzoate 208A as light yellow oil (150 mg, 19%). (Found: M+, 
218.093606. C13H14NO3 requires: M
+, 218.094294); νmax (thin film/cm
-1) 1691 (CO); 
δH/ppm (400MHz; CDCl3) 4.58 (2H, d, J = 5.3 Hz, 1'-CH2), 4.81 (2H, d, J = 5.6 Hz, 
1"-CH2), 5.35 (4H, m, 3'-Ha and 3"-Ha), 6.04 (2H, m, 2'-H and 2"-H), 7.11 (1H, dd, J 
= 8.2 and 2.0 Hz, 4-H), 7.33 (1H, t, J = 8.0 Hz, 5-H), 7.59 (1H, s, 2-H), 7.65 (1H, d, J 
= 7.7 Hz, 6-H); δC/ppm (100MHz; CDCl3
   
) 65.6 ( C-1"), 69.0 (C-1'), 115.1 (C-2), 
117.9 (C-3"), 118.2 (C-3'), 120.2 (C-4), 122.2 (C-6), 129.4 (C-5), 131.5 (C-1), 132.2 
(C-2"), 132.9 (C-2'), 158.6 (C-3) and 166.1 (C=O).  
In a separate reaction 3-hydroxybenzoic acid 207 (2.0 g, 14 mmol) in DMF (60 mL) 
under nitrogen was treated with NaH (60% dispersion in mineral oil; 360 m g, 150 
mmol) and allyl bromide (1.2 mL, 15 mmol). Radial chromatography [on silica gel; 
elution with hexane-EtOAc (4:1)] afforded only allyl 3-hydroxybenzoate 208 (1.2 g, 
45 %).  
 
3-(Allylamino)benzoic acid 210 and Allyl 3-(N-allylamino)benzoate 210A   
NH2
O
O
1
2
3
4
5
6
1'
2'
3'
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O
O
H
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4
5
6 1''
2''
3''
1'
2'
3'
 
 
To a stirred solution of 3-aminobenzoic acid 209 (500 mg , 3.7 mmol) in dry DMF 
(36 mL) under nitrogen was added NaH (60% dispersion in mineral oil; 9.7 mg, 4.1 
mmol) in small portions to permit controlled evolution of hydrogen. Allyl bromide 
(0.32 mL,  3.7 mmol) was then added through a septum and the resulting solution was 
refluxed for ca. 48 h. The reaction was quenched by the addition of water (40 mL). 
The solvent was evaporated in vacuo and the aqueous residue extracted with EtOAc 
_________________________________________________________  Experimental 
 199 
(2 × 80 mL). The combined organic extracts were washed sequentially with water (2 
× 160 mL) and brine (2 × 160 mL). The aqueous washings were extracted with EtOAc 
and the organic layers combined and dried (anhydr. MgSO4
 
). Radial chromatography 
[on silica gel; elution with hexane-EtOAc (4:1)] afforded. 
 (i) 3-(Allylamino)benzoic acid 210 as a r eddish brown oil (160 mg, 25%). (Found: 
M+, 177.077749. C 10H11NO2 requires: M
+, 177.200260); νmax (thin film/cm
-1) 3436 
(NH) and 1710 (CO); δH/ppm (400MHz; CDCl3 3.76 (1H, d, J = 5.2 Hz, 1'-CH2), 
5.19 (1H, dd, J = 10.3 and 1.3 H z, CH=CHE) 5.26 (1H, dd, J = 17.2 and 1.4 H z, 
CH=CHZ), 5.89 (1H, tdd, J = 17.1, 10.4 and  5.2 Hz, 2'-H), 6.78 (2H, m, 2-H and 4-
H), 6.93 (1H, d, J = 7.4 Hz, 6-H) and 7.20 (1H, m, 5-H); δC/ppm (100MHz; CDCl3
 
) 
46.0 (C-1'), 112.9 ( C-3), 115.0 ( C-4), 116.8 ( C-3'), 117.3 ( C-2), 119.4 ( C-1), 120.8 
(C-6), 129.8 (C-5), 134.2 (C-2') and 148.2 (C=O). 
In a separate reaction 3-aminobenzoic acid 209 (1.0 g, 7.3 mmol) in DMF (20 mL) 
under nitrogen was treated NaH (60% dispersion in mineral oil; 320mg, 13 mmol) and 
allyl bromide (0.63 mL, 7.3 mmol). Two fractions were obtained.  
(i) 210 (220 mg, 17%) and           
(ii) Allyl 3-(N-allylamino)benzoate 210A as a yellow oil (160 mg, 10%). (Found: M+, 
217.109334. C13H15NO2 requires: M
+, 217.264231); νmax (thin film/cm
-1) 3391 (OH) 
and 1711 (CO); δH/ppm (400MHz; CDCl3) 3.80 (2H, td, J = 5.3 and 1.5 Hz, 1'-CH2), 
3.94 (1H, b s, NH), 4.79 (2H, td, J = 5.6 and 1.4 Hz, 1"-CH2), 5.17 (1H, dd, J = 10.3 
and 1.4 Hz, 3'-Ha), 5.27 (2H,  m,, 3'-Hb and 3"-Ha), 5.40 (1H, m, 3"-Hb), 5.94 (1H, 
tdd, J = 17.1, 10.5 and 5.3 Hz, 2'-H), 6.02 (1H, ddd, J = 22.8, 10.8 and 5.6 Hz, 2"-H), 
6.79 (1H, dd, J = 7.8 and 2.2 Hz, 4-H), 7.22 (1H, t, J = 7.9, 5-H), 7.30 (1H, s, 2-H) 
and 7.40 (1H, d, J = 7.7 Hz, 6-H); δC/ppm (100MHz; CDCl3) 46.4 (C-1'), 65.4 (C-
1"), 113.6 ( C-2), 116.5 (C-3'), 117.8 ( C-4), 118.0 (C-3"), 118.7 (C-6), 129.1 (C-5), 
131.0 (C-1), 132.3 (C-2"), 134.9 (C-2'), 150.0 (C-3) and 166.6 (C=O).  
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